Skip to content
FrontierPicks

Dossiers · 929 published · 917 with a kill line · 8 archetypes · 40 themes

Thesis. Kill line. Catalyst. Per ticker.

Each dossier compresses thirty days of news, four quarters of earnings transcripts, and narrative-cluster classification into one read: thesis, kill line, archetype, conviction, catalyst calendar. Generated by a frontier model, dated, and graded against the line it published.

Watch lists

Conviction mix

  1. Supreme 17 · 2%
  2. High 49 · 5%
  3. Medium 330 · 36%
  4. Low 522 · 56%
  5. None 11 · 1%

Archetype mix

  1. Compounder 128 · 14%
  2. Cyclical recovery 121 · 13%
  3. Theme leader 63 · 7%
  4. Special situation 256 · 28%
  5. Earnings inflection 226 · 25%
  6. Retail squeeze 52 · 6%
  7. Defensive 72 · 8%

Freshness · last analysed

  1. ≤ 7 days 740 · 80%
  2. ≤ 30 days 189 · 20%

conviction highmediumlownone

929 shown

No dossiers match your filters.

Held

28
AMD Advanced Micro Devices, Inc. fresh MEDIUM Advanced Micro Devices’ Helios thesis depends on an operating OpenAI deployment in the fourth quarter of 2026. September 9 analyst target changes extend favorable coverage, but delayed activation or a weekly close below $456 would… Cyclical recovery · Mega-cap AI platforms catalyst · HPE Hewlett Packard Enterprise Company fresh MEDIUM Hewlett Packard Enterprise's AI and networking earnings upgrade has stronger price support at the 2026-09-09 close of $58.90. Confirmation requires a weekly close above $54.44 after the 2026-09-30 Networking Investor Day with the fiscal… Special situation · AI datacenter infrastructure catalyst · HUM Humana Inc. fresh MEDIUM Humana's Medicare Advantage margin reset supports continuation above the $409.42 adjusted reference high before a daily close below $383. Bernstein maintained its $425 analyst target on 2026-09-09, while October Star Ratings leave the 2028… Compounder · Managed care & health services catalyst · IRDM Iridium Communications Inc fresh MEDIUM Iridium Communications’ merger-discount thesis depends on Rocket Lab completing the acquisition announced on 2026-06-29. The 2026-09-24 vote tests shareholder approval; completion before a weekly close below $43.50 settles the published… Earnings inflection · Space economy catalyst · JBHT J.B. Hunt Transport Services, Inc. fresh MEDIUM J.B. Hunt’s freight recovery requires stronger intermodal pricing and continued profit growth at the estimated 2026-10-15 report. Confirmation requires fuel-excluded pricing growth above Q2’s 1% year-over-year increase and rising… Compounder · Freight & logistics · Cyclical industrials catalyst · MRCY Mercury Systems Inc fresh MEDIUM Defense-electronics turnaround still re-rating on record bookings and a promised FCF turn, but the stock has given back ~20% from its $128.45 ATH and now chops near the analyst median (~$103) into a binary ~Aug 10-18 Q4/full-year print.… Special situation · Defense & aerospace catalyst · MU Micron Technology, Inc. fresh MEDIUM Micron Technology's contracted memory revenue supports a durability thesis tested by its 2026-09-30 results against June's $50.0 billion ±$1.0 billion revenue guidance and approximately 86% adjusted gross margin. A weekly close below $958… Cyclical recovery · AI chips & memory catalyst · NTAP NetApp, Inc. fresh MEDIUM NetApp's AI storage expansion must meet its September guidance before a weekly close below $164 breaks the recovery thesis. Fiscal-Q2 revenue of at least $2.025 billion and non-GAAP gross margin of at least 67.0%, with the September 2… Special situation · AI datacenter infrastructure catalyst · OKTA Okta, Inc. fresh MEDIUM Identity-security re-rating in its second, sell-side-led leg; the upgrade wave is still building nearly two months post-print — Wells Fargo lifted its target to $150 from $100 on 2026-07-20, collapsing the low-end dispersion. Cyber theme… Defensive · Cybersecurity catalyst · OSCR Oscar Health, Inc. fresh MEDIUM Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the… Earnings inflection · Managed care & health services catalyst · RXO RXO, Inc. fresh MEDIUM Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to… Compounder · Freight & logistics · Cyclical industrials catalyst · SIMO Silicon Motion Technology Corporation fresh MEDIUM Silicon Motion's storage-controller expansion needs third-quarter 2026 revenue of at least $519 million to validate the recovery before a weekly close below $230 breaks it. Its September 9 certification adds no revenue guidance; reported… Cyclical recovery · AI chips & memory catalyst · TXG 10x Genomics, Inc. fresh MEDIUM 10x Genomics' Atera launch and Parse patent verdict support a recovery thesis tested by a weekly close above $65.12 before a weekly close below $58.57. The September 9 daily close of $67.29 advances that test, while shipment execution and… Special situation · Medtech & diagnostics catalyst · XMTR Xometry, Inc. fresh MEDIUM Xometry's AI manufacturing thesis depends on marketplace growth delivering its August 4 profit guidance. Third-quarter revenue of at least $234 million and adjusted EBITDA of at least $16 million, with the annual growth outlook maintained,… Theme leader · AI datacenter infrastructure catalyst · ARCB ArcBest Corporation fresh LOW ArcBest’s cost reductions must preserve margins: Q3 2026 recurring savings and an adjusted Asset-Based operating ratio at or below Q2’s 90.8% would confirm the case. A weekly close below $134.45 invalidates the price-supported thesis first. Special situation · Freight & logistics · Cyclical industrials catalyst · ATEX Anterix Inc. fresh LOW Anterix's spectrum-conversion thesis requires another utility agreement with disclosed payments before a weekly close below $85.31 invalidates it. The 2026-09-09 daily close of $83.93 is below that reference but does not itself establish a… Defensive · Industrial power & grid catalyst · CNC Centene Corporation fresh LOW Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a… Earnings inflection · Managed care & health services catalyst · DAVE Dave Inc. fresh LOW Dave Inc.'s growth-and-credit-quality story supports a recovery case, completed by a weekly close above the September 3 reference close of $390.86 before a weekly close below $358 invalidates it. The September 9, 2026 close of $361.88… Compounder · Fintech & consumer credit catalyst · DELL Dell Technologies Inc. fresh LOW Dell Technologies’ AI-server backlog must convert into roughly $19 billion of next-quarter revenue while ISG operating margin holds at least 15.0%. The next quarterly results test those September 1, 2026 benchmarks; management’s margin… Cyclical recovery · AI datacenter infrastructure catalyst · HNGE Hinge Health, Inc. fresh LOW Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating… Compounder · Managed care & health services analysed · LSTR Landstar System, Inc. fresh LOW Landstar System's truckload repricing needs to produce further earnings improvement. The 2026-10-27 results confirm the case if truck revenue per load grows year over year and earnings per share exceed Q2's $1.44 before a weekly close… Defensive · Freight & logistics catalyst · MRVL Marvell Technology, Inc. fresh LOW Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction — chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the… Cyclical recovery · Mega-cap AI platforms catalyst · SEZL Sezzle Inc. fresh LOW Sezzle's recovery thesis is that profitable growth can repair its post-earnings price structure. A daily close above the 2026-08-17 recovery level of $129.87 would establish the case before a weekly close below $114 invalidates it; the… Compounder · Fintech & consumer credit catalyst · SNX TD SYNNEX Corporation fresh LOW TD SYNNEX's Hyve business links AI hardware demand to earnings; the 2026-09-24 results test whether growth exceeds guidance. The case requires revenue above $19.0 billion and non-GAAP EPS above $4.75 before a weekly close below $255… Theme leader · AI datacenter infrastructure catalyst · STX Seagate Technology Holdings PLC fresh LOW Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two… Cyclical recovery · AI chips & memory catalyst · UMC United Microelectronic Corp. fresh LOW Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) — late-stage distribution behaviour. The 2026-07-29 Q2… Special situation · Semi foundry & equipment catalyst · WDC Western Digital Corporation fresh LOW The 29% bounce off the 2026-07-28 low stalled: WDC closed $527.22 on 2026-08-03, −3.23% on a day its sector rose 0.58%, back under a rising 50-day at $562.65. Consensus (~$3.69B / $3.31–$3.35) still sits above the company's own $3.65B… Cyclical recovery · AI chips & memory analysed · XPO XPO, Inc. fresh LOW XPO, Inc.'s shipment-growth story requires continued volume growth and a third-quarter adjusted LTL operating ratio below 81% at the confirmed 2026-10-29 results. A weekly close below $185 invalidates the price case first; the 2026-09-09… Compounder · Freight & logistics · Cyclical industrials catalyst ·

Watchlist

243
APGE Apogee Therapeutics, Inc. SUPREME The all-cash takeout settled: the AbbVie merger became effective 2026-09-03 at $135.11 per share (~$10.9B equity value), trading was halted after the 2026-09-02 close of $135.07 and Nasdaq suspended the stock 2026-09-04. The leg terminated… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · ATAI AtaiBeckley Inc. SUPREME All named antitrust gates are retired: HSR expired 2026-08-28, the UK CMA had no further questions on 2026-08-21, Germany cleared 2026-07-30, and the ACCC's 14-day waiting period runs to 10:00 a.m. ET on 2026-09-10. Only the 2026-09-08… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · DSGR Distribution Solutions Group, Inc. SUPREME DSGR trades $0.34 under the $35.00 all-cash price LKCM Headwater agreed on 2026-07-16 to pay for the ~21% of the company it does not already own; the 2026-09-01 PREM14A and SC 13E-3 filings started the clock, leaving only HSR and a… Earnings inflection · M&A & special situations · Industrial power & grid analysed · ATKR Atkore Inc. HIGH Eight days to the HSR gate: notifications filed 2026-08-14 put the initial waiting period's expiry at 2026-09-14, and EDGAR still shows no definitive proxy as of 2026-09-06 — the 2026-08-28 PREM14A leaves meeting date, record date and… Earnings inflection · Industrial power & grid · M&A & special situations catalyst · BWMN Bowman Consulting Group Ltd. HIGH Bowman Consulting Group’s $43.00 cash acquisition makes merger completion the central thesis. The case resolves with payment of the announced consideration before a daily close below $40.50; the 2026-09-13 go-shop deadline narrows… Earnings inflection · Cyclical industrials catalyst · CXW CoreCivic, Inc. HIGH DHS is buying CoreCivic's detention real estate outright — $2.2B gross for four facilities, about $307k/bed — while CoreCivic keeps operating them; proceeds funded $608.5M of debt repayment and a $500M buyback expansion (2026-08-05… Compounder · Travel & leisure · Managed care & health services analysed · DCTH Delcath Systems, Inc. HIGH Self-funded liver-directed procedure ramp — Q2 revenue $29.133M, 90% gross margin, FY26 guide $104–108M — is now trading on calendar rather than data: the public record ends at the 2026-08-31 conference release, the 2026-09-04 close of… Defensive · Oncology & immunology catalyst · FSM Fortuna Mining Corp. HIGH Gold rebounded 2% to $4,478 on 2026-09-03 after an ADP count of 38,000 August private jobs cut September hike odds, and FSM took the whole move to $12.66 — 7.3% off its $13.66 high — having held $12.26 through the prior week's slide to… Compounder · Critical materials & rare earths catalyst · GEO The GEO Group, Inc. HIGH Federal detention-capacity narrative is converting to signed revenue: five-year ICE contracts effective 2026-07-09 (Big Horn, 1,188 beds, ~$85M/yr) and 2026-08-01 (Rivers, 1,320 beds, ~$80M/yr), with FY26 GAAP EPS guided up to $1.27–$1.32… Compounder · Travel & leisure · Managed care & health services catalyst · HAE Haemonetics Corporation HIGH The CSL option is now priced by the sell side and still unpriced by the company: six analyst actions since 2026-08-07 took the top of the range to Raymond James' $125 on 2026-09-03, yet the 2026-09-04 close of $102.92 sits 5.4% under the… Special situation · Medtech & diagnostics analysed · HALO Halozyme Therapeutics, Inc. HIGH Royalty-compounding re-rating: the 2026-08-06 Q2 print beat at $481.0M vs $407.5M consensus and lifted the FY26 non-GAAP EPS guide to $8.65–9.00 from $7.75–8.25, and the stock closed 2026-09-04 at $110.19, 0.5% off its 52-week high. The… Cyclical recovery · Precision biotech & therapeutics · AI enterprise software catalyst · HZO MarineMax, Inc. HIGH Deal pin rather than a growth story: the $53.00 all-cash Safe Harbor/Blackstone Infrastructure take-private signed 2026-08-09 leaves $0.89 to terms at the 2026-09-02 close of $52.11. The gap widened from $0.80 on 2026-08-21 while no… Earnings inflection · Consumer discretionary rotation catalyst · IAG IAMGold Corporation HIGH The margin leg's revenue side firmed: spot gold was quoted $4,489.80/oz on 2026-09-03, above the $4,384/oz IAMGOLD realized in Q2, so the spread no longer needs new metal highs — only the Côté ramp pulling AISC back from $2,271/oz toward… Compounder · Critical materials & rare earths · Crypto exchanges & financials catalyst · IOVA Iovance Biotherapeutics, Inc. HIGH Amtagvi's commercial ramp inflected on the 2026-08-06 print — approximately $99.3M revenue, 56% gross margin, and FY2026 guidance of $350–370M pulled under review for an upward revision management said lands in Q3. The narrative is… Compounder · Oncology & immunology catalyst · LFST LifeStance Health Group, Inc. HIGH Margin-inflection pivot is now being repriced by the calendar rather than by new company data: LifeStance confirmed on 2026-09-01 that its CFO presents at Jefferies on 2026-09-14 and its CEO at Morgan Stanley on 2026-09-15, putting two… Special situation · Managed care & health services · Cyclical industrials catalyst · LPG Dorian Lpg Ltd fresh HIGH Dorian has pre-fixed 99% of September-quarter calendar days above $88,000/day (2026-09-04 release) against a record $75,926 June-quarter TCE, with the Strait of Hormuz at day 188 and Brent near $96. The freight spike is the trade, not a… Compounder · Freight & logistics catalyst · PSNL Personalis, Inc. HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… Earnings inflection · Medtech & diagnostics · Oncology & immunology catalyst · SIBN SI-BONE, Inc. HIGH Momentum reset without a price give-back: since the 2026-08-03 Q2 beat ($56.01M, +15.2% YoY; FY26 floor raised to $231M) price has held the reclaimed $17.05 shelf, closing $19.21 on 2026-08-28 while RSI(14) unwound from 72.0 to 55.1. The… Defensive · Medtech & diagnostics analysed · SSRM SSR Mining Inc. HIGH Post-Çöpler balance-sheet reset — $1,783.0M cash, no long-term debt, a $500M buyback — now trades as a rate-path derivative: the 2026-09-03 close of $38.89 sits 0.8% under the $39.21 52-week high after gold rebounded to ~$4,491/oz. The… Compounder · Critical materials & rare earths catalyst · TVTX Travere Therapeutics, Inc. HIGH The FSGS/IgAN ramp story stalled rather than broke: the 2026-09-04 close of $65.28 sits 3.3% under the 2026-08-27 high of $67.52 with RSI(14) decayed from 65.6 to 56.0 and no published target change since Piper Sandler's $68 on 2026-08-17.… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · UGP Ultrapar Participacoes S.A. fresh HIGH The operating leg has printed and only the undated Ipiranga stake sale is left to underwrite the premium: the 2026-08-28 close of $6.45 sits 2.0% under the $6.58 52-week high with RSI(14) 69.2 after a 30.2% three-month advance built… Special situation · Oil, energy & geopolitical catalyst · VREX Varex Imaging Corporation HIGH Signed all-cash takeout at $18.90 (Teledyne, 2026-08-10); the 2026-09-02 close of $18.47 leaves $0.43 of gross gap, three cents wider than on 2026-08-28. Twenty-four days past signing, EDGAR shows nothing after the 2026-08-18 Form 4 — no… Earnings inflection · Medtech & diagnostics catalyst · AAMI Acadian Asset Management Inc. MEDIUM Pure-play quant manager compounding: AUM $232.7B at 2026-06-30 (+54% YoY), H1 net client inflows $25.7B, ENI operating margin 40.3% vs 30.7%. The re-rating is already aired — Evercore ISI lifted its target to $96 on 2026-08-10 at In Line,… Special situation · Cybersecurity analysed · ABCL AbCellera Biologics Inc. MEDIUM Post-binary shelf intact and unchanged: closes of $11.38 (08-14), $11.35 (08-28) and $11.36 (09-02) against the $9.75 follow-on price, with RSI(14) unwinding 97.4 → 52.9. The 2026-09-09 Cantor Global Healthcare presentation is the only… Earnings inflection · Precision biotech & therapeutics catalyst · ABSI Absci Corporation MEDIUM Single-asset binary: ABS-201's interim hair-growth proof-of-concept is guided to 2H 2026 with no confirmed date, funded by the June 2026 $100M raise that left $201.1M at 2026-06-30 and a runway into H2 2028. Since the 2026-08-11 revenue… Earnings inflection · Binary-catalyst biotech · AI datacenter infrastructure catalyst · ADPT Adaptive Biotechnologies Corporation MEDIUM clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22… Defensive · Precision biotech & therapeutics · Medtech & diagnostics analysed · AGCO AGCO Corporation MEDIUM AGCO Corporation's valuation reflects a 2027 farm-equipment recovery that remains unconfirmed by reported demand. A weekly close above the $139.71 market high recorded as of 2026-09-04 and Q3 results meeting July guidance would confirm the… Compounder · Cyclical industrials catalyst · AGM Federal Agricultural Mortgage Corporation MEDIUM Farm-credit GSE re-rating on infrastructure lending: the 2026-07-30 Q2 print put outstanding volume at $37.2B (+22% YoY) with $13.1B now in infrastructure — power, renewables, broadband, data-center-adjacent — at 18.9% core ROE. The tape… Theme leader · Biofuels & low-carbon fuels · AI datacenter infrastructure catalyst · ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… Earnings inflection · Binary-catalyst biotech catalyst · AMLX Amylyx Pharmaceuticals, Inc. MEDIUM The binary resolved on 2026-08-18 (LUCIDITY: 55% cut in Level 2/3 hypoglycemic events, p=0.000003) and the launch was funded at $35.50 on 2026-08-20 for ~$471.7M net. What is left is the regulatory leg — NDA guided by year-end 2026, with a… Earnings inflection · Precision biotech & therapeutics catalyst · APPN Appian Corporation MEDIUM Second-order agentic-AI re-rating met its first real supply: the 52-week range top moved to $46.06 and the 2026-09-04 close came in at $38.37, down 6.00% on the session, still above the compiled $34.00 average target that stockanalysis.com… Theme leader · AI enterprise software catalyst · AQST Aquestive Therapeutics, Inc. MEDIUM Anaphylm's 2026-01-30 CRL was usability-scoped, and the 2026-08-10 human factors data — median pouch-opening time 3 seconds versus 17 — addresses the named deficiency, with the NDA resubmission guided into Q3 2026, a window closing… Earnings inflection · Precision biotech & therapeutics catalyst · ASMB Assembly Biosciences, Inc. MEDIUM Gilead-validated antiviral: Gilead exercised the HPI license option on 2025-12-22 ($35M net fee, up to $330M milestones), Q2 beat both lines on 2026-08-13, and Assembly's 40% US cost/profit-share opt-in is due by year-end 2026. The… Earnings inflection · Precision biotech & therapeutics analysed · ASST Strive, Inc. fresh MEDIUM Strive, Inc.'s bitcoin-treasury premium thesis depends on increasing bitcoin per diluted common share. A company-reported year-to-date Bitcoin Yield above the 40.8% reading dated 2026-08-28 would confirm the case before a weekly close… Compounder · Crypto exchanges & financials analysed · ASTH Astrana Health Inc. MEDIUM Full-risk value-based-care compounder: the 2026-08-06 Q2 raised FY adjusted EBITDA guidance to $255–280M on 49% revenue growth, but revenue missed at $972.5M vs $985.7M consensus and the shares sit 22.8% under the $49.81 high. Truist $55… Defensive · Managed care & health services analysed · ATRC AtriCure, Inc. fresh MEDIUM The buyer changed: S&P DJI added ATRC to the SmallCap 600 on 2026-09-04, effective before the 2026-09-21 open, and Needham went to $64 from $45 on 2026-09-02 — while the last company number remains the 2026-07-23 Q2 print. The 2026-09-04… Compounder · Medtech & diagnostics analysed · AVAH Aveanna Healthcare Holdings Inc. MEDIUM the last close carried into coverage is $13.58 (2026-09-04) against a $13.82 52-week high — and the leg on offer is a fifth straight FY2026 guide raise at the Q3 print. Between here and then: two conference dates, a ~2026-09-20… Special situation · Managed care & health services catalyst · BAX Baxter International Inc. MEDIUM Legacy medtech turnaround re-rating: the 2026-07-30 Q2 print lifted FY26 organic growth guidance to 2-3% and adjusted EPS to $1.95-$2.15, gapping the shares to a $28.34 52-week high. Six weeks on, the 2026-09-04 close of $25.83 sits 8.9%… Special situation · Medtech & diagnostics · Freight & logistics catalyst · BULL Webull Corporation fresh MEDIUM June dormant-to-leader flip is confirming: the ~$7.52 breakout resolved up on the 2026-07-21 surge, Rosenblatt lifted its target to $13 (2026-07-16), and June ops printed 28.2M users / $800M net deposits. Theme accelerating; read is a… Retail squeeze · Crypto exchanges & financials catalyst · CAI Caris Life Sciences, Inc. MEDIUM Post-2026-08-05 beat-and-raise ($263.7M vs $238.1M est; FY26 guide to $1.030–1.040B) is now consolidating: the 2026-08-28 close of $25.63 is back under the $26.50 median Street target, RSI(14) has cooled from 82.6 to 59.2, and no analyst… Theme leader · Medtech & diagnostics analysed · CDNA CareDx, Inc. MEDIUM Post-LCD repricing extended rather than stalled: the $48.61 shelf broke, a 52-week high of $52.36 printed, and the 2026-08-28 close was $49.79 — all with no company release since 2026-08-07. The 2026-08-30 LCD effective date carries only… Earnings inflection · Medtech & diagnostics analysed · CLDT Chatham Lodging Trust MEDIUM Guidance-raise leg in a small-cap lodging REIT with an AI-adjacent demand pocket: Q2 adjusted FFO $0.48 (+22% YoY) and FY26 AFFO guided to $1.28–$1.34 on 2026-08-04, with four Silicon Valley hotels at 17% of EBITDA printing July RevPAR… Theme leader · Freight & logistics · AI datacenter infrastructure catalyst · CLF Cleveland-Cliffs Inc. MEDIUM Tariff-plus-free-cash-flow leg intact but the tape has stalled: after recovering to $12.42 on 2026-09-02 the stock was quoted at $12.46 on 2026-09-05, above the 11-analyst average target of $11.96, with no company disclosure since the… Special situation · Cyclical industrials · Critical materials & rare earths catalyst · CLYM Climb Bio, Inc. MEDIUM The 2026-09-03 CLYM116 Phase 1 read cleared: a single 320 mg dose suppressed APRIL >90% and IgA/Gd-IgA1 60–75% through 12 weeks, supporting quarterly dosing, and BTIG ($32), B. Riley ($30) and Baird ($25) re-marked within two sessions. The… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology catalyst · CMG Chipotle Mexican Grill, Inc. MEDIUM Outbreak repair has done its work: the 2026-09-02 close of $38.52 has retraced the entire drawdown from the 2026-08-14 close of $33.50, and the CDC count has sat at 431 cases/32 states since its 2026-08-19 update. The marginal bid rotated… Compounder · Consumer discretionary rotation · Freight & logistics analysed · CNH CNH INDUSTRIAL N.V. MEDIUM CNH Industrial's farm-equipment recovery is being priced ahead of earnings after September's analyst upgrades. The next quarterly report tests margin recovery, while a weekly close below $12.50 invalidates the re-rating leg. Compounder · Cyclical industrials catalyst · COIN Coinbase Global, Inc. MEDIUM Two macro prints set the whole September range: a 10.1% surge to $192.70 on 2026-09-03 on Waller's hold signal and bitcoin above $81,000, then roughly 4% back on 09-04 as August payrolls printed +162,000 and hike odds moved to ~50%. The… Compounder · Crypto exchanges & financials · AI datacenter infrastructure catalyst · CRDL Cardiol Therapeutics Inc. Class A MEDIUM Single-asset cardiology micro-cap re-rating on Phase II publication flow and Canaccord's 2026-08-17 Buy reiteration at a $10 target; the shares closed 2026-09-04 at a 52-week high of $2.20, up 103.7% in three months, and the only… Earnings inflection · Precision biotech & therapeutics catalyst · CRM Salesforce, Inc. MEDIUM De-rated Dow software incumbent on two dated legs: the $1.6B VA agentic ELA (2026-07-24) and Reuters' 2026-08-13 report of Silver Lake–Workday take-private talks, which put a private-market floor under mega-cap SaaS. Six target revisions… Special situation · AI enterprise software catalyst · CRWD CrowdStrike Holdings, Inc. MEDIUM Fal.Con (2026-08-31 to 09-03) delivered real product — Falcon Guardian, Falcon IQ, GPT-5.6 Cyber in Falcon, Anthropic marketplace distribution — and nine broker actions through 2026-09-04 including Truist $300, yet CRWD closed $213.10 on… Compounder · Cybersecurity · AI enterprise software analysed · CRWV CoreWeave, Inc. MEDIUM Post-print repricing is holding but fading: the 2026-08-12 gap to $107.73 is unfilled after closes of $106.29 and $105.26, RSI 71.1. Q2 printed $128M adjusted operating income against a $30–90M guide, and the $2.6B facility closed… Compounder · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · CVI CVR ENERGY, INC. MEDIUM CVR Energy’s refining thesis is that Hormuz disruption lifts reported margins above second-quarter 2026’s $9.94 per throughput barrel. Third-quarter results test that inference; a weekly close below $39 invalidates the price structure. Compounder · Oil, energy & geopolitical catalyst · CYRX CryoPort, Inc. MEDIUM Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability… Cyclical recovery · Rare disease & gene therapy · Precision biotech & therapeutics analysed · DINO HF Sinclair Corporation fresh MEDIUM Refining-crack plus break-up story now trades above nearly every published mark: the 2026-09-04 close of $105.41 sits 0.7% under the 52-week high with RSI(14) at 70.0 against a sixteen-analyst average target of $83.42. No company-dated… Compounder · Oil, energy & geopolitical catalyst · DK Delek US Holdings, Inc. fresh MEDIUM Record distillate cracks still carry the leg: EIA reported a fourth straight distillate draw (−2.2M bbl, week ended 2026-08-21, released 2026-08-26) with refineries at 97.4%, and the 2026-08-28 close of $72.25 was a 52-week high. But the… Compounder · Oil, energy & geopolitical analysed · EGO Eldorado Gold Corporation MEDIUM The macro leg has partially repaired — Waller's 2026-09-03 remarks cut September hike odds from ~63.3% to 50.3% and gold traded back to $4,488/oz — which leaves the company leg as the open question: Skouries first copper-gold concentrate… Compounder · Critical materials & rare earths catalyst · ETON Eton Pharmaceuticals, Inc. MEDIUM The post-print re-rate topped at an all-time closing high of $64.43 on 2026-08-24 and faded 7.2% to $59.78 by 2026-08-28, with no broker revision since 2026-08-14 and a second Form 4 disposal (director, 2026-08-28) after the CEO's 100,000… Defensive · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · EWTX Edgewise Therapeutics, Inc. MEDIUM Post-divestiture cardiovascular pivot: Servier paid $1.55B upfront (closed 2026-07-10) for the muscular dystrophy franchise, leaving ~$2.01B pro forma cash behind EDG-7500 in hypertrophic cardiomyopathy. The re-rate is already in the tape… Special situation · Precision biotech & therapeutics · Medtech & diagnostics analysed · EXK Endeavour Silver Corp. MEDIUM Operating leverage is the leg: silver $66.25/oz on 2026-09-03 against a $36–38/oz planning deck, with Terronera ramping through Q3. No company disclosure since the 2026-08-24 restart, so the 43.4% three-month advance runs on the metal and… Compounder · Critical materials & rare earths · Housing, homebuilders & proptech catalyst · FA First Advantage Corporation MEDIUM Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first… Special situation · M&A & special situations · Prediction markets & betting catalyst · FBIZ First Business Financial Services, Inc. MEDIUM Post-2026-07-30 re-rating in a micro-cap Wisconsin business bank: Q2 EPS $1.84 vs $1.54 consensus, NIM +22bp to 3.78%, record $19.8M pre-provision earnings, followed by target raises to $74 (KBW), $80 (DA Davidson) and $84 (Piper). Shares… Defensive · Small-cap value rotation · Squeeze & momentum setups catalyst · FDMT 4D Molecular Therapeutics, Inc. MEDIUM Wet-AMD durability re-rating off the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected, n=30) is cooling without news: from the 2026-08-21 close of $15.83 the shares closed $14.67 on 2026-08-28, 12.5%… Earnings inflection · Precision biotech & therapeutics catalyst · FIGS FIGS, Inc. MEDIUM The post-print shelf resolved upward: the 2026-08-28 close of $15.42 sits 8.1% above the 2026-08-07 mark of $14.26 and 9.9% under the $17.12 52-week high, with no company-dated news since the 2026-08-07 target revisions. The re-rating off… Defensive · Consumer discretionary rotation catalyst · FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… Earnings inflection · Binary-catalyst biotech analysed · FROG JFrog Ltd. MEDIUM Software-supply-chain-security plus AI-agent "trust layer" narrative keeps re-rating: the analyst cluster now leads price above $100 (UBS Buy $110 Jul 2, Truist Buy $105 Jul 9), confirming the continuation tell flagged in June.… Theme leader · Cybersecurity · AI enterprise software analysed · FTK Flotek Industries, Inc. MEDIUM Legacy oilfield chemistry re-rating into a power/measurement business: Data Analytics hit 51% of gross profit in Q2 2026, the 2026-08-03 PREPA award adds ~$400M of 10-year expected backlog, and the 2026-08-04 guide went to $340–350M from… Special situation · Cyclical industrials · Oil, energy & geopolitical analysed · FTNT Fortinet, Inc. MEDIUM Q2 (2026-07-29) resolved up — revenue $2.047B vs ~$1.89B, product +52% YoY, FY26 guide raised to $8.020–8.180B — but price has gone nowhere since: $161.95 on 07-31, $160.01 on 08-14, still 4.9% under the $168.29 high. The 44-analyst mean… Theme leader · Cybersecurity · AI datacenter infrastructure analysed · GTLB GitLab Inc. MEDIUM GitLab's consumption pivot got hard numbers on 2026-09-01: revenue $286.3M (+21% YoY), net ARR growth above 40%, dollar-based net retention up to 117%, FY27 guide raised to $1,129–$1,133M — and the shares gapped to a 52-week high of $51.04… Theme leader · AI enterprise software analysed · HBB Hamilton Beach Brands Holding Company MEDIUM Tariff-reversal re-rating that has stopped extending: a $36.5M IEEPA refund lifted Q2 gross margin to 54.3% from 27.5% (print 2026-08-05), but ex-refund margin was 26.1% and FY2026 operating profit is still guided to a high-single-digit… Defensive · Consumer discretionary rotation · Cyclical industrials catalyst · HL Hecla Mining Company MEDIUM Debt-free silver margin with the metal moving again: silver $65.83/oz and gold $4,439.03/oz on 2026-09-03 against Q2 AISC of $6.07/oz ex-Keno and $63.06/oz realized, with the shares closing $21.21 the same day. No company datapoint lands… Compounder · Critical materials & rare earths · Housing, homebuilders & proptech catalyst · HNST The Honest Company, Inc. MEDIUM Margin re-rate broke out rather than faded: the 2026-08-28 close of $5.67 sits 1.6% under a $5.76 52-week high and 12.3% above the 2026-08-21 consolidation low of $5.05, on no company headline since the 2026-08-20 conference notice. Price… Special situation · Consumer discretionary rotation catalyst · HOOD Robinhood Markets, Inc. fresh MEDIUM Robinhood Markets' September repricing now includes prediction-market infrastructure alongside on-chain finance. Stronger August activity and a weekly close above $124.72 would confirm continuation; a weekly close below $107 would… Compounder · Crypto exchanges & financials catalyst · HP Helmerich & Payne, Inc. MEDIUM Land-drilling activity re-rating on a geopolitical crude move: Brent $95.25 on 2026-09-03 (+42% y/y) with the 2026-08-05 fiscal Q3 print delivering $1.034B revenue vs $988.74M consensus, 147 Lower 48 rigs working and a raised Q4 guide of… Cyclical recovery · Oil, energy & geopolitical catalyst · IREN IREN Limited MEDIUM Post-print de-rating has stabilised without reversing: the 2026-09-02 close of $39.60 is still 2.3% under the $40.53 pre-print level, and the four-session bounce came on neocloud sector flow with no IREN disclosure since 2026-08-28. The… Special situation · GPU cloud & neoclouds catalyst · KARO Karooooo Ltd. MEDIUM Record-subscriber-adds story cleared its ceiling: KARO closed $65.48 on 2026-09-04, 2.6% under a new $67.20 high, after breaking the $65.91 shelf founder-CEO Calisto had been selling into — Nothing estimate-moving until the ~2026-10-13 Q2… Compounder · Emerging markets · AI enterprise software catalyst · KRO Kronos Worldwide, Inc. MEDIUM Post-print re-rating extended rather than faded: the 2026-08-28 close of $8.80 sits 1.2% under a new $8.91 52-week high after Deutsche Bank raised its target to $9 from $6 on 2026-08-25 with a Buy — the first published target above the… Defensive · Critical materials & rare earths analysed · KRT Karat Packaging Inc. MEDIUM Tariff-refund re-rating has stalled within 1.4% of the $49.80 52-week high: the 2026-08-28 close of $49.11 leaves Lake Street's $50 as the last published target above the market, RSI(14) has cooled from 78.4 to 58.2 without a lower low,… Defensive · Cyclical industrials · Small-cap value rotation catalyst · LIFE Ethos Technologies Inc. MEDIUM Guidance-durability re-rating broke to new highs — the 2026-09-04 close of $39.85 (+5.67% on the session) versus $34.16 on 2026-08-21, 52-week high $40.97 — with the only dated company event inside 30 days the CEO's 2026-09-09 Goldman… Defensive · Precision biotech & therapeutics · AI datacenter infrastructure catalyst · LMND Lemonade, Inc. MEDIUM The $50 shelf has held six weeks: $53.14 on 2026-09-02, RSI(14) 50.6, three reference closes since 2026-08-21 inside a $0.41 band. The state cadence restarted — Florida car 2026-08-26, Kansas renters 2026-09-01, Missouri car plus… Theme leader · Fintech & consumer credit · AI datacenter infrastructure catalyst · LTH Life Time Group Holdings, Inc. MEDIUM Premium-club compounder re-rating as the 2021-IPO sponsors clear out: comps +9.1% and FY2026 guidance raised on 2026-07-30, then Leonard Green placed 5.1M shares at $43.16 on 2026-08-10 and dropped below 5%. Price now sits on that… Compounder · Oil, energy & geopolitical · Fintech & consumer credit analysed · MANE Veradermics, Incorporated MEDIUM Extended-release oral minoxidil story: Study '302' showed +30.3/+33.0 hairs/cm² vs +7.3 placebo at Month 6 (2026-04-27, p<0.0001), and the confirmatory Study '304' topline guided to 2H26 is the binary. The 2026-09-04 close of $98.51 sits… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · META Meta Platforms, Inc. MEDIUM Two dated numbers landed on 2026-09-02 that the capex-leverage story had been missing: Broadcom's Hock Tan put three MTIA generations and 3GW of Meta deployment on the record through end-2027, and Muse Spark 1.3 shipped as a paid API.… Compounder · Mega-cap AI platforms catalyst · MGNI Magnite, Inc. MEDIUM The August deal-cadence gap closed on 2026-09-03: Magnite's Live Marketplace release named Disney Advertising, 37 media owners and +56% YoY live-sports ad spend (Jan–Jul 2026), and Needham took its target to $30 the same day, with the… Theme leader · AI enterprise software catalyst · MGNX MacroGenics, Inc. MEDIUM MGC026's head-and-neck cohort cleared its pre-specified Stage 1 threshold on 2026-07-23 and the interim Phase 1 data lands as ESMO poster 1020P on 2026-10-23; the name walks in with $327M pro forma cash (2026-06-30) built from the Bora… Earnings inflection · Oncology & immunology · Rare disease & gene therapy analysed · MNKD MannKind Corporation MEDIUM Legacy inhaled-insulin story pivoting: Q2 2026 marketed products grew 111% YoY and now exceed the Tyvaso DPI royalty line, which grew just 4%. INFLO-1 Phase 1b IPF data, guided to Q3 2026, is the next dated event. The narrative is maturing… Special situation · Precision biotech & therapeutics catalyst · MOD Modine Manufacturing Co MEDIUM De-rated datacenter-cooling compounder: Data Centers sales $348.6M (+90% YoY) and the $650M–$680M FY27 EBITDA guide were affirmed 2026-07-29, while the 2026-09-03 close of $186.63 sits 39.2% under the $306.89 high with RSI(14) at 34.1. The… Cyclical recovery · AI datacenter infrastructure · Cybersecurity catalyst · MTW The Manitowoc Company, Inc. MEDIUM Manitowoc's crane-order recovery supports its re-rating if Q3 backlog holds at least $1,050.1 million and raised 2026 profit guidance survives. A weekly close below $18 invalidates the price thesis; the Q3 reporting date remains… Defensive · Cyclical industrials catalyst · NAVN Navan, Inc. MEDIUM Q2 FY2027 prints 2026-09-09 with the first positive non-GAAP operating-income guide ($13.5–14.5M) on the line. Four target raises in 21 days — BofA $26→$34 on 09-02, Morgan Stanley $33 on 09-04 — landed while the shares fell from the… Earnings inflection · AI enterprise software · Travel & leisure catalyst · NIQ NIQ Global Intelligence plc MEDIUM Post-take-private deleveraging re-rate still running after the 2026-08-10 beat-and-raise, now with an OpenAI Deployment Company collaboration (2026-08-25) and targets chasing price — Needham $21 on 08-20, Baird $23 on 08-28. But the… Special situation · AI enterprise software analysed · NSP Insperity, Inc MEDIUM Margin-repair re-rating in a legacy PEO has stalled just under its high: the 2026-09-04 close of $51.96 sits 2.7% below the $53.40 adjusted 52-week high, and the +162,000 August payroll beat did not extend it because professional and… Special situation · Prediction markets & betting catalyst · NVCT Nuvectis Pharma, Inc. MEDIUM Nuvectis re-rated on the 2026-06-22 Haisco ex-China in-license and the 2026-07-23 China approval of oral Factor B inhibitor ciprocopan; Nothing binary lands inside 30 days — only conference slots on 09-11 and 09-14, against RSI 72.3 and a… Defensive · Oncology & immunology · Precision biotech & therapeutics catalyst · OABI OmniAb, Inc. MEDIUM Milestone-flywheel re-rating extended past the 2026-08-22 note: a +8.78% session on 2026-08-24 made a new 52-week closing high, then price eased to $4.47 on 08-28 with RSI(14) cooling from 97.6 to 77.3. The 2026-08-26 release put two dated… Cyclical recovery · Precision biotech & therapeutics catalyst · OMER Omeros Corporation MEDIUM Launch-ramp re-rating has stopped extending and started digesting: the 2026-09-02 close of $18.86 sits 2.4% under the $19.32 52-week high with RSI(14) back to 63.2 from 92.0 on 2026-08-21, and no Omeros disclosure is dated after the… Compounder · Precision biotech & therapeutics catalyst · ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · PBF PBF ENERGY INC. MEDIUM Record diesel cracks ($108.02 intraday, 2026-09-01) met a stalled tape: the adjusted series closed 2026-09-04 at $74.34, 1.5% under its $75.48 high with RSI 48.7, while the >10% holder resumed selling on 2026-09-02 at $76.94–$77.09. A… Compounder · Oil, energy & geopolitical catalyst · PCTY Paylocity Holding Corporation MEDIUM Post-print re-rating leg: the 2026-08-04 Q4 FY26 beat ($1.84 adj. EPS vs $1.61 est.) triggered five price-target raises in 48 hours and a $150.42 close on 2026-08-07, +35.5% over three months. The buy is multiple recovery in mid-cap HCM… Theme leader · AI enterprise software analysed · PGNY Progyny, Inc. MEDIUM The August de-rate stopped without a new bid: the 2026-09-04 close of $25.94 is 1.1% above the 2026-08-21 close of $25.65, while RSI(14) reset from 18.1 to 55.9. The narrative leg has shifted to Progyny Select — Citizens' 2026-09-02 note… Special situation · Managed care & health services catalyst · PLPC Preformed Line Products Company MEDIUM The July rollover read was voided by the 2026-07-29 Q2 print: sales $212.7M vs $193M consensus, EPS $4.49 vs $2.41, and a ~30% one-session repricing to a new all-time closing high of $480.77 (2026-08-11). Grid/AI-power second-order… Theme leader · Industrial power & grid analysed · PLSE Pulse Biosciences, Inc MEDIUM Timeline-compression leg still printing highs on thinning inputs: the 2026-09-02 close of $52.68 is a fresh 52-week high, but RSI(14) fell to 73.2 from 82.5 at the 2026-08-21 high and no company disclosure has landed since the 2026-08-06… Earnings inflection · Medtech & diagnostics catalyst · PMTS CPI Card Group Inc. MEDIUM Levered card manufacturer re-rating on cash generation: Q2 revenue $149.2M (+15%) with net leverage cut to 2.7x from 3.6x and FY free-cash-flow guidance lifted to $45–50M on 2026-08-06. Adjusted EBITDA grew just 7% against that 15% top… Cyclical recovery · Fintech & consumer credit analysed · PRGO PERRIGO COMPANY PLC MEDIUM Store-brand self-care turnaround re-rating off the 2026-08-05 beat — adjusted EPS $0.50 and a reaffirmed core adjusted-EPS guide of $2.25–$2.55 against a $2.07B market cap and $3.3B of debt, with infant-formula and oral-care strategic… Special situation · Consumer discretionary rotation · Cyclical industrials catalyst · PSX Phillips 66 fresh MEDIUM Hormuz-driven refining-margin blowout is the leg: Q2 2026 realized refining margin $24.08/bbl vs $10.11 in Q1, adjusted EPS $9.41 vs $7.44 consensus, plus a $10B buyback expansion (2026-08-05). The narrative is maturing — well known since… Compounder · Oil, energy & geopolitical analysed · PUBM PubMatic, Inc. MEDIUM Growth-inflection re-rating in an independent SSP re-labelled as an AI story is holding but no longer feeding on new headlines. The 2026-08-07 gap to $17.78 has survived fifteen sessions to the 2026-08-28 close of $16.82, two August… Special situation · AI enterprise software catalyst · PYPL PayPal Holdings, Inc. MEDIUM The takeover leg is dead — Advent/Stripe walked on 2026-08-28 and the stock broke 12.71% to $53.66 — leaving a standalone legacy-payments turnaround on the raised FY26 guide (~$5.38 adj EPS, ~$15.6B transaction-margin dollars). The tape… Special situation · Fintech & consumer credit · Cyclical industrials catalyst · QNST QuinStreet, Inc. MEDIUM The 2026-08-06 beat-and-raise stands unrevised while the tape has faded since mid-August: the 2026-09-04 close was $18.73, 14.9% under the $22.02 high, with all six published targets ($21–$24) sitting above it. Northland's 2026-09-01… Cyclical recovery · Fintech & consumer credit · Managed care & health services catalyst · RCMT RCM Technologies, Inc. MEDIUM RCM Technologies’ energy-services re-rating requires continued Engineering growth and stable margins. Q3 revenue above the segment’s $39.5 million Q2 level and consolidated gross margin of at least 25.7% would confirm the case, provided a… Cyclical recovery · Cyclical industrials analysed · RVTY Revvity, Inc. MEDIUM Post-2026-08-04 print, RVTY re-rated on the wet-lab-under-AI story — management's strongest instrument backlog in 3–4 years — plus Diagnostics +11% organic and a signed exit from China immunodiagnostics. KeyBanc took its target to $165 on… Theme leader · Medtech & diagnostics · AI datacenter infrastructure catalyst · SBET SharpLink, Inc. MEDIUM SharpLink's Ether treasury discount is the recovery thesis: The Block reported a 0.84-times net asset value multiple on 2026-09-07. The case plays out if a comparable valuation reaches net asset value before a weekly close below $7.50… Special situation · Crypto exchanges & financials catalyst · SGMT Sagimet Biosciences Inc. Series A MEDIUM IND clearance (2026-08-13) has converted into a schedule: sites identified, CRO engaged, AURORA screening from October 2026, first patient shortly after (2026-08-25). Price closed at the 52-week high of $10.99 on 2026-09-02 with RSI(14)… Defensive · Precision biotech & therapeutics catalyst · SLDB Solid Biosciences Inc. MEDIUM Post-Sarepta DMD vacuum trade still in its waiting phase, with the sell-side moving before the company does: no release since the 2026-08-06 Q2 print, but Truist carried Buy/$20 on 2026-08-21 and Cantor raised to $26 on 2026-08-27. The… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech analysed · SNDK Sandisk Corporation MEDIUM Contracted-revenue re-rating (~$94B of NBM agreements, 2026-08-13) is intact on fundamentals, but the price leg has stalled: the 2026-08-28 close of $1,484.98 sits below the 2026-08-14 close of $1,641.11, and the newest headlines are… Cyclical recovery · AI chips & memory catalyst · SPCX SpaceX (Space Exploration Technologies Corp.) MEDIUM Two target actions (Oppenheimer to $280 from $250, Bernstein SocGen reiterating $248) and a Musk compute headline all landed 2026-09-02, and the stock still closed $140.71, leaving the 2026-08-12 high close of $146.15 untaken for fifteen… Compounder · Space economy · AI datacenter infrastructure catalyst · SPT Sprout Social, Inc MEDIUM Margin-inflection re-rate now trading through its own sell-side band: the 2026-08-28 close of $11.49 sits above the $10.44 compiled consensus target and above four of the five targets raised after the 2026-08-06 print. The last leg came… Special situation · AI enterprise software catalyst · SPXC SPX Technologies, Inc. MEDIUM Q2 beat-and-raise on 2026-07-30 was the strongest print of the cycle — HVAC backlog $919M (+59% organic), 2026 data-center revenue set at $430M, capacity target lifted to $1.1B from $750M — yet the 2026-08-14 close of $217.32 sits 11.8%… Cyclical recovery · Industrial power & grid analysed · SRPT Sarepta Therapeutics, Inc. MEDIUM Post-crisis rare-disease cash engine re-rating: the 2026-08-05 Q2 print showed $945.0M cash (up $197M in the quarter), a stable $230.6M PMO franchise and operating profitability, and the shares have run 44.7% in three months to within 8.0%… Special situation · Precision biotech & therapeutics analysed · STLN Starling Oncology, Inc. MEDIUM Value-based oncology pivot repriced on the 2026-08-06 Q2 print: revenue $161.3M (+34.6% YoY), gross profit +55.2%, first positive adjusted EBITDA (+$229K), FY26 guide raised to $650–670M. The capitated/delegated-risk ramp is the leg, but… Special situation · Managed care & health services · Oncology & immunology analysed · TARS Tarsus Pharmaceuticals, Inc. MEDIUM Tarsus Pharmaceuticals’ eye-care expansion depends on XDEMVY sustaining growth after the Alkeus acquisition. The case requires next-quarter sales above Q2 2026’s $173.9 million and retention or an increase of both boundaries of the… Compounder · Binary-catalyst biotech catalyst · TEAM Atlassian Corporation MEDIUM The "agentic AI kills seat-based software" de-rating just reversed: Q4 FY26 (2026-08-06) put cloud +31% and $6,606M subscription ARR behind the Rovo/MCP agent story, and the stock gapped 30%+ on 2026-08-07 to close $149.07. The… Theme leader · AI enterprise software catalyst · TNET Trinet Group, Inc. MEDIUM Post-print durability leg: after the 2026-07-30 Q2 beat (ICR 86% vs 90%, adj EPS $1.55 vs $0.93) and FY guide raise, TNET closed 2026-08-28 at $70.27, 2.0% under its $71.67 high. UBS lifted its target to $71 on 2026-08-24 but the… Earnings inflection · Managed care & health services catalyst · TSEM Tower Semiconductor Ltd. MEDIUM Picks-and-shovels photonics foundry where the demand chain keeps beating and the equity has only just begun to follow: the line closed $206.81 on 2026-09-02, reclaiming the $200 shelf, hours before Broadcom guided Q4 AI semiconductor… Cyclical recovery · Semi foundry & equipment catalyst · TWLO Twilio Inc. MEDIUM Legacy CPaaS repricing as voice/agentic-AI engagement infrastructure; sell-side re-clustered higher into the print — Cowen $245, Mizuho $240, Citizens $250 (2026-07-17/20) — but the 2026-07-30 Q2 report is now the binary deciding whether… Special situation · AI enterprise software · Cyclical industrials catalyst · TWST Twist Bioscience Corporation MEDIUM Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and… Theme leader · Medtech & diagnostics · AI datacenter infrastructure catalyst · U Unity Software Inc. MEDIUM Post-print re-rating has cooled: the 2026-08-28 close of $43.31 sits below the entire $45–55 target cluster set on 2026-08-07, with RSI(14) back to 51.0 from 91.5 on 2026-08-14. The second leg needs the ~2026-11-05 Q3 print to deliver Grow… Special situation · AI enterprise software · Cyclical industrials analysed · VLO Valero Energy Corporation fresh MEDIUM Refiner crack spreads at a record ~$70/bbl 3-2-1 as a Hormuz/Iran supply shock idles ~10% of global refining; VLO is the pure-play margin leverage and the fundamental leg is accelerating. But sell-side (6 PT raises in 11 days) and CNBC… Compounder · Oil, energy & geopolitical analysed · VST Vistra Corp. MEDIUM The 2026-09-02 close of $143.46 clears the six-session $135.66–$139.81 band on the same day a Form 4 disclosed the CEO buying 6,665 shares for $903,069 at $135.25–$135.99. FERC acceptance of PJM's backstop framework (ER26-3380-000) by… Theme leader · Nuclear & uranium catalyst · VSTM Verastem, Inc. MEDIUM Post-Q2 re-rate extended rather than stalled: $6.89 on 2026-08-21 to $8.02 on 2026-09-02, RSI(14) 71.4, with no new company disclosure located in that window beyond a 2026-09-02 conference notice. The 2026-08-28 Oberland closing date has… Earnings inflection · Oncology & immunology catalyst · XNCR Xencor, Inc. MEDIUM Two overhangs closed in three weeks: the $105M Alexion settlement (2026-07-29) ended the Ultomiris dispute and pushed runway through 2028, and Q2 revenue of $51.2M vs $18.9M consensus (2026-08-05) drew three price-target raises on 08-06.… Earnings inflection · Oncology & immunology analysed · ZLAB Zai Lab Limited MEDIUM Re-rating from China in-licensing platform to global originator on zocilurtatug pelitecan, the internal DLL3 ADC: the 2026-08-03 FDA orphan-drug grant in neuroendocrine carcinomas and Citi's 2026-08-07 raise to $45 extended the leg, and… Earnings inflection · Oncology & immunology analysed · AA Alcoa Corporation LOW The policy-proxy leg now carries an opposing vector: the September US Midwest premium — the benchmark roughly 1.35Mt of Alcoa shipments price against — fell 8.2% to 95 cents a pound on 2026-08-20 on signals Washington will cut Canadian… Compounder · Critical materials & rare earths · Cyclical industrials catalyst · AAOI Applied Optoelectronics, Inc. LOW The 2026-09-02 close of $103.13 leaves the shares below both the $110.21 shelf lost 2026-08-28 and the $104.50 low taken out 2026-09-01, with nothing company-dated before the ~2026-11-05 Q3 print. Against that void sit a 115%–144% Q3… Cyclical recovery · Networking & optical catalyst · AAPL Apple Inc. LOW July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns… Earnings inflection · Mega-cap AI platforms · Managed care & health services catalyst · AEHR Aehr Test Systems LOW Wafer-level burn-in toll on AI silicon: fiscal 2027 guided $130.0–150.0M against $50.0M in fiscal 2026, unamended on the wire as of 2026-09-03. The unwind paused — $80.24 on 2026-09-02 against $76.59 the prior session, RSI(14) 27.3 from… Cyclical recovery · Semi foundry & equipment catalyst · AEIS Advanced Energy Industries, Inc. LOW Datacenter-power picks-and-shovels re-rating is now fully mainstream — Morgan Stanley initiated Overweight $421 (07-22) atop Wells $465 and Susquehanna $535 — yet the stock fell 12.65% on 07-02 and is sitting on its 200-day while analyst… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure catalyst · AESI Atlas Energy Solutions Inc. fresh LOW Frac-sand legacy pivoting to behind-the-meter gas power for AI data centers, but the story is DORMANT and the structure broken: shares fell from $16.73 (6/29) to an $11.96 close (7/24, -8.5%), losing the ~$15 base and $13 shelf on… Special situation · Oil, energy & geopolitical catalyst · AGL agilon health, inc. LOW Value-based-care turnaround is filed, not promised: Q2 (2026-08-05) medical margin $197M vs -$53M a year earlier, FY26 adjusted EBITDA guided $75–$95M. The re-rating leg has stalled anyway — the 2026-09-04 close of $88.50 sits 31.8% under… Special situation · Managed care & health services catalyst · AMPL Amplitude, Inc. LOW The post-print re-rate stalled: AMPL closed $13.02 on 2026-09-04 against the 2026-08-28 52-week high of $14.30, losing the $13.30 breakout shelf and slipping back under the $13.77 mean target, with no dated analyst action since Needham's… Theme leader · AI enterprise software catalyst · AMR Alpha Metallurgical Resources, Inc. LOW Alpha Metallurgical Resources’ coal-supply-shock thesis requires stronger third-quarter realized pricing before August support breaks. Realization above the second quarter’s $118.71 per short ton would confirm transmission; a weekly close… Compounder · Oil, energy & geopolitical catalyst · AMSC American Superconductor Corporation LOW Grid/advanced-conductor supplier to data-center and utility power; backlog still ~+40% YoY (~$280M), but the tape broke after the 2026-05-28 beat-and-soft-guide and a late-June Russell removal piled on passive selling. Below the lost ~$40… Cyclical recovery · Industrial power & grid catalyst · AMZN Amazon.com, Inc. LOW AWS reacceleration is a printed fact — +37% YoY to $42.2B on 2026-07-30 — but the tape has handed the whole move back: record close $284.02 on 2026-08-03, $254.98 on 2026-09-02, RSI(14) 39.9. The new variable is legal rather than… Compounder · Mega-cap AI platforms · AI datacenter infrastructure catalyst · APLD Applied Digital Corporation LOW Contracted-to-energized conversion story (~1,410 MW booked, ~175 MW energized) with no own-name disclosure since 2026-07-27; the $25.56 April base broke on the 2026-08-28 weekly close of $25.34 and the 2026-09-02 close of $24.91 sits… Special situation · GPU cloud & neoclouds analysed · ASML ASML Holding N.V. LOW ASML lost the July–August floor on the 2026-09-01 close of $1,665.14, and the 2026-09-02 close of $1,682.30 left the $1,686.01 shelf unreclaimed. RSI(14) reads 23.8, no broker revision has printed since the 2026-08-11 BofA reiterate at… Cyclical recovery · Semi foundry & equipment catalyst · ASTS AST SpaceMobile, Inc. LOW The 2026-09-02 close of $62.40 reclaimed the $56 shelf breached one session earlier, driven by a Berenberg Buy initiation at $92 and a director's 2026-08-31 open-market purchase of 10,822 shares — neither a company disclosure. Spectrum… Earnings inflection · Space economy catalyst · AU AngloGold Ashanti plc LOW The 2026-09-04 payroll beat resolved against the metal: gold fell to $4,420/oz, the miner group fell 1.9%, and AU closed $109.07 versus the 2026-08-21 high of $123.39. Gold-margin leverage still works against a $2,039/oz Q2 cost line, but… Compounder · Critical materials & rare earths catalyst · AUGO Aura Minerals Inc. LOW Gold/copper producer basing $53–$76 under a broken ~$72 shelf after a ~45% fall from the $110 high. Q2 output slipped 8% QoQ — first sequential drop after a record Q1 — as gold cools to the low-$4,000s and sell-side keeps trimming (JPM to… Compounder · Critical materials & rare earths catalyst · AVGO Broadcom Inc. LOW Broadcom beat and raised on 2026-09-02 — Q3 revenue $29.591B vs $29.362B consensus, AI semis $16.7B (+221%), FY26 AI lifted to $58B, plus a stated ~$115B FY27 / ~$230B FY28 AI roadmap — but Q4 revenue guided $34.8B against $35.03B… Cyclical recovery · AI chips & memory catalyst · AXTI AXT Inc LOW AXTI's contracted-InP leg is intact on paper with no price expression: the 2026-09-02 close of $56.95 reclaimed neither the $58 line lost 09-01 nor April's $64.25 placement shelf lost 08-28, and no AXT release or filing is dated later than… Cyclical recovery · Semi foundry & equipment catalyst · AZZ AZZ Inc. LOW Beat-and-raise fired 2026-07-08 — Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum — but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells… Cyclical recovery · Industrial power & grid catalyst · BBNX Beta Bionics, Inc. LOW The post-2026-07-29 re-acceleration leg has stalled at consensus: $19.42 on 2026-09-04 versus $19.72 on 2026-08-28, RSI(14) cooling 71.7 to 62.7, against a 12-analyst average target of $20.31. Into that stall the CMO and CEO sold on… Earnings inflection · Medtech & diagnostics catalyst · BIDU Baidu, Inc. ADS LOW The last dated event in a flow-mechanical leg lands 2026-09-07: southbound Stock Connect eligibility for the Hong Kong counters that turned dual-primary on 2026-09-01. The ADR closed $95.58 on 2026-09-03, -41.2% from the $162.52 high, with… Special situation · EV & autonomous mobility · Mega-cap AI platforms catalyst · BLMN Bloomin' Brands, Inc. LOW The 2026-08-05 margin-repair re-rating has broken on the tape: after Friday closes of $10.55 and $10.58, the week to 2026-09-04 closed $9.79, back inside the guidance-raise gap and through the $9.90 pivot. No analyst action since… Special situation · Consumer discretionary rotation catalyst · BLSH Bullish fresh LOW Bullish's regulatory repricing thesis requires successful CLARITY Act cloture followed by a weekly close above $37.10 before a weekly close below $31. The September 15, 2026 milestone is motion ripening, while the September 9 close of… Earnings inflection · Crypto exchanges & financials catalyst · BMEA Biomea Fusion, Inc. LOW Icovamenib's beta-cell-preservation story got a dated readout when COVALENT-211 completed enrollment on 2026-08-24, but the same release pushed 26-week topline to Q1 2027 — against $35.2M cash at 2026-06-30, runway into Q2 2027 and… Earnings inflection · Precision biotech & therapeutics analysed · BMNR BitMine Immersion Technologies, Inc. fresh LOW Premium-to-NAV funding engine is closed; the 2026-08-10 release shows capital flipping from coin to float — 7,391 ETH bought for $14.3M (smallest week of 2026) against 3.0M shares retired, with cash down to $104M from $173M. The narrative… Compounder · Crypto exchanges & financials catalyst · BTCS BTCS Inc. LOW BTCS Inc.’s Ethereum recovery thesis requires stronger DeFi earnings without renewed borrowing. The next Q3 disclosure must show gross profit above Q2 2026’s $1.5 million and debt no higher than June’s $50.4 million before a weekly close… Compounder · Crypto exchanges & financials catalyst · BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… Earnings inflection · Crypto exchanges & financials · AI datacenter infrastructure catalyst · CADL Candel Therapeutics, Inc. LOW Pre-BLA re-rating is cooling rather than breaking: shares quoted $12.78 on 2026-09-05 against the $13.75 52-week high and the 2026-08-28 close of $13.07, with no company data since the 8/13 Q2 print. Three CEO firesides (09-09, 09-10,… Earnings inflection · Oncology & immunology catalyst · CCJ Cameco Corporation LOW Nuclear-uranium theme maturing and CCJ's structure has broken twice into improving news: mkt cap $44.79B (06-29) → ~$39.9B (07-25), ~$88, ~35% off the $135.24 high, absorbing a $17.5B federal AP1000 program and NJ's $24B plan. Barclays cut… Theme leader · Nuclear & uranium catalyst · CDE Coeur Mining, Inc. LOW Coeur's repair leg has not started: the NYSE Arca Gold Miners Index rose 33% in August (Bloomberg, 2026-09-01) while CDE closed 2026-09-04 at $21.24, where it sat on 2026-08-28. Record Q2 cash ($387.5M FCF, $347.0M net cash) is offset by… Compounder · Critical materials & rare earths catalyst · CEG Constellation Energy Corporation LOW CEG closed $290.04 on 2026-09-02, roughly +3.5% on the day and the first close above the $281–$282.50 band that had capped every attempt since the shelf broke 2026-07-19 (failed touches $282.50 on 08-14, $282.41 on 08-27). RSI(14) 59.8.… Theme leader · Nuclear & uranium catalyst · CIEN Ciena Corporation LOW The 1.6T WaveLogic demand cycle is intact at the order book, but the trade has broken: $627.00 (06-02) to ~$370 (07-18) is a ~41% de-rating, and the $455–$467 shelf that framed the prior read is gone. Multiple compression from 54x forward,… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · CRCL Circle Internet Group, Inc. fresh LOW Circle Internet Group's Arc-led infrastructure breakout failed when its 2026-09-09 close of $92.99 breached the published $95 boundary. The scheduled 2026-09-16 public launch still tests delivery, while any recovery case requires renewed… Earnings inflection · Crypto exchanges & financials catalyst · CRCT Cricut, Inc. LOW Hardware-to-platform crossover still holds the 2026-08-05 gap: Platform revenue $85.0M now exceeds Products $71.3M, but Q2's 74.5% gross margin carried $26.7M of one-time credits against a ~58.9% ex-item rate. Goldman Sachs began coverage… Special situation · Consumer discretionary rotation · Bitcoin miners analysed · CRSR Corsair Gaming, Inc. LOW The recovery leg off the 2026-08-21 close of $10.93 carried CRSR to $12.00 on 2026-08-28 without any company disclosure: the margin-mix story (33.2% Q2 gross margin, peripherals +13% YoY at 44.9%) is fully published, Goldman's 2026-08-19… Special situation · Consumer discretionary rotation · AI chips & memory analysed · DDOG Datadog, Inc. LOW June's sell-side upgrade wave has exhausted and the first cut printed — Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the… Theme leader · AI enterprise software · GPU cloud & neoclouds catalyst · DPRO Draganfly Inc. LOW US drone-onshoring policy is doing the re-rating: the 2026-08-13 tariff proclamation and the 2026-09-01 FAA Section 44807 heavy-lift exemption carried price from a 50-day average of $4.67 to a $6.12 close on 2026-09-04, while filed Q2… Retail squeeze · Space economy analysed · DTIL Precision BioSciences, Inc. LOW First clinical evidence that a gene editor removes hepatitis-B cccDNA (EASL late-breaker, 2026-05-27, <1% remaining in one biopsy) is the whole story; the shares closed $7.47 on 2026-09-04, 19.5% under the $9.28 52-week high, with no… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · EDIT Editas Medicine, Inc. LOW Legacy pivot on one asset: after halting ex vivo reni-cel in December 2024, Editas is EDIT-401 — an in vivo LNP editor for HeFH showing ~90%+ NHP reductions in LDL-C, Lp(a) and ApoB, with an Australian CTN submitted in August 2026 and four… Special situation · Rare disease & gene therapy · Oncology & immunology analysed · EMBC Embecta Corp. LOW The post-collapse levered-stub re-rating extended to a 2026-09-02 close of $5.69 while the short base shrank to 5.44M shares (9.94% of float) from 6.68M on 2026-08-21 — the covering fuel is thinning as price trades above the highest of… Special situation · Medtech & diagnostics catalyst · EOLS Evolus, Inc. LOW Margin-inflection re-rating has run to a new 52-week high — the 2026-09-04 close of $9.30 is +39.2% over three months with RSI(14) at 80.6 — on no company news since the 2026-08-05 Q2 print. Defensive · Precision biotech & therapeutics · Medtech & diagnostics catalyst · ESTC Elastic N.V. LOW AI-retrieval-layer narrative accelerating: Q4 FY26 total RPO $1.98B grew 28% YoY against revenue +16%, and the 2026-07-30 OpenAI partnership re-rated the name 56.8% in three months. The 2026-08-27 Q1 FY27 print is the binary — company… Theme leader · Cybersecurity analysed · EVC Entravision Communication LOW Smadex AI-DSP re-rate broke to a new 52-week high of $13.48 with no dated company news since 2026-07-12 — an anticipatory leg into the 2026-08-10 Q2 print, the binary on whether Q1's +204% ATS growth and ~22% EBIT margin held.… Special situation · AI enterprise software · Cyclical industrials catalyst · FLEX Flex Ltd. LOW AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1… Special situation · AI datacenter infrastructure · Industrial power & grid analysed · FLY Firefly Aerospace Inc. LOW Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the… Defensive · Space economy · Defense & aerospace catalyst · FWDI Forward Industries, Inc. LOW Forward Industries' Solana treasury re-rating requires growing tokens per share and a verified recovery to net asset value. Updated disclosure must show fully diluted mNAV at or above 1.0x and SOL per share of at least 0.0754 before a… Special situation · Crypto exchanges & financials catalyst · GOOG Alphabet Inc. LOW Cloud backlog conversion is still the leg — $514B and Cloud +82% at the 2026-07-22 print — but the 2026-09-02 clean sweep (AdX divestiture denied, Gemini 3.8 Flash shipped, Berkshire's $36.6B stake on CNBC) bought only a 1.6%… Compounder · Mega-cap AI platforms · EV & autonomous mobility catalyst · HIMS Hims & Hers Health, Inc. LOW GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1,… Retail squeeze · Managed care & health services · Precision biotech & therapeutics analysed · HTFL Heartflow, Inc. LOW The post-Q2 re-rating is intact but the marginal bid now pays above the whole published target band: the 2026-09-02 close of $50.00 sits above the $45 top target set on 2026-08-14, RSI(14) is 88.0, and four insider sale filings landed… Compounder · Medtech & diagnostics catalyst · ILMN Illumina, Inc. LOW Momentum has outrun the information set: a 52-week high of $227.69 then a fade to the 2026-08-28 close of $215.59, RSI(14) 69.2, with no company-dated input since the 2026-07-30 beat-and-raise and none scheduled before the Q3 print… Special situation · Medtech & diagnostics · Oncology & immunology catalyst · IMMX Immix Biopharma, Inc. LOW Single-asset CAR-T regulatory story now inside its own event window: the 95% CR (19/20) from 2026-05-21 is the bar the late-September NEXICART-2 update must clear on a bigger denominator. The 2026-09-02 close of $13.96 is 3.5% under the… Earnings inflection · Oncology & immunology catalyst · IMRN Immuron Limited LOW Immuron’s consumer-health expansion needs a dated US PROIBS launch and disclosed commercial terms to validate its September repricing. The 2026-09-04 agreement supplies neither; a weekly close below $1.65 or an annual report without those… Retail squeeze · Binary-catalyst biotech catalyst · INBX Inhibrx Biosciences, Inc. fresh LOW Inhibrx Biosciences’ advance prices HexAgon clinical success and a Phase 3 start within the guided quarter. The 2026-09-08 results and September start confirmation test that case; a weekly close below $104 or reported primary-endpoint… Earnings inflection · Oncology & immunology analysed · IONQ IonQ, Inc. LOW The missing forward number is the story: no Q3 range and a $280–290M FY guide that excludes SkyWater have left IonQ unbenchmarked since 2026-08-05, and the 2026-09-08 NYSE Investor Day is the dated venue where combined guidance is… Earnings inflection · Quantum computing catalyst · KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… Earnings inflection · Oncology & immunology catalyst · LITE Lumentum Holdings Inc. LOW Two initiations in two sessions — Evercore ISI $1,100 on 08-31, Deutsche Bank $1,200 on 09-01 — and the tape closed 2026-09-02 at $870.58, still under the $885 weekly-close level and below the 08-31 close of $914.76. The $40 fiscal-2028… Cyclical recovery · Networking & optical catalyst · LUNR Intuitive Machines, Inc. LOW The June 30 NASA Moon BASE award ($148.3M Nova-C) bought exactly one green session before the stock broke: seven straight down days into 2026-07-13 for -24.5%, -36.5% on the month, $13.80 on 2026-07-18 versus a $38.55 May high. A live… Retail squeeze · Space economy · AI datacenter infrastructure catalyst · MAN ManpowerGroup LOW Cyclical staffing inflection confirmed by the 2026-08-07 10-Q, but sell-side marks stopped moving 2026-07-20 and the next company binary is ~2026-10-15. Retail squeeze · Cyclical industrials · Prediction markets & betting catalyst · MPC Marathon Petroleum Corporation LOW Record refining cracks are already in the tape: Q2 R&M margin $36.33/bbl vs $17.58 YoY and a 29% EPS beat on 2026-08-04, yet the stock closed 2026-08-07 at $298.20 — RSI 37.3, 6.7% under the $319.76 high — while six desks raised targets… Compounder · Oil, energy & geopolitical catalyst · MRNA Moderna, Inc. LOW The INTerpath-001 platform-validation leg is intact, but the company monetised it first: $2.6B of upsized 0.00% converts priced 2026-08-28 at a $210.58 conversion price, six sessions after the 177.0% print, with the shares at $137.99 and… Compounder · Binary-catalyst biotech analysed · MRVI Maravai LifeSciences Holdings, Inc. LOW The Moderna read-through leg has round-tripped most of its gain: after gapping +25.78% on 2026-08-19 and printing an $8.87 intraday high on 2026-08-25, MRVI closed $7.32 on 2026-09-04, 18.7% below the $9.00 series high, leaving the $7.24… Cyclical recovery · Precision biotech & therapeutics · Freight & logistics catalyst · MSFT Microsoft Corporation LOW AI-capex derating still in control and now colliding with a hostile print tape: Alphabet lost ~$294B on 2026-07-24 punished purely for AI spend, Tesla/Intel/Google all sold post-earnings, and MSFT reports Q4 FY26 on 2026-07-29 AMC below… Compounder · Mega-cap AI platforms · AI datacenter infrastructure catalyst · MSTR Strategy Inc fresh LOW Strategy Inc.'s bitcoin accumulation thesis needs successive purchase disclosures and STRC recovering its $100 stated amount. Those milestones must arrive before a weekly close below $123 invalidates the price structure. Compounder · Crypto exchanges & financials catalyst · MTRN Materion Corporation LOW Beryllium critical-materials scarcity narrative still building, but the parabola cracked: a new ATH of $298.76 in early July gave way to a 5.6% reversal on 2026-07-07 to $247.20, now ~$258 and still ~9% above KeyBanc's $237 top target. The… Compounder · Critical materials & rare earths · Defense & aerospace catalyst · NET Cloudflare, Inc. LOW The post-Q2 re-rating is fully unwound: the 2026-09-02 close of $272.74 is 17.6% under the $330.83 high with RSI(14) at 31.7, and the three-month price change is +1.5%, erasing the summer advance with no company-dated news behind it since… Cyclical recovery · AI enterprise software · AI datacenter infrastructure catalyst · NKE Nike, Inc. LOW The $39 level the prior note flagged is behind price: NIKE closed 2026-09-02 at $38.24, under the 2026-08-17 close of $39.09 that coverage called a 12-year low, and JPMorgan cut FY2027 EPS to $1.55 vs $1.72 consensus on 2026-08-31. The… Special situation · Consumer discretionary rotation catalyst · NNE Nano Nuclear Energy Inc. LOW Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78… Compounder · Nuclear & uranium catalyst · NUTX Nutex Health Inc. LOW Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950… Retail squeeze · Managed care & health services · Squeeze & momentum setups catalyst · NVAX Novavax, Inc. LOW Novavax's Matrix-M royalty re-rating needs company-confirmed Sanofi trial timing at the 2026-09-09–2026-09-10 conferences. The near-term case fails if both pass without that timing or a weekly close falls below $9.00. Earnings inflection · Binary-catalyst biotech catalyst · OKLO Oklo Inc. LOW Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary. Earnings inflection · Nuclear & uranium catalyst · OMDA Omada Health, Inc. LOW The post-print leg is fully retraced — $22.77 on 2026-09-04 versus $23.89 on 2026-08-21 and the $26.78 52-week high — leaving price under the mid-July pre-beat shelf despite eight sell-side target actions between 2026-08-03 and 2026-08-31.… Compounder · Managed care & health services · AI enterprise software catalyst · OPEN Opendoor Technologies Inc LOW Early-July retail squeeze is broken: OPEN lost the $4.88 insider shelf and $4.50 base, fell ~12% to $3.88 on 2026-07-24 on a technical breakdown plus fresh housing weakness, into an Aug 4 Q2 print. A rolled-over meme trading into an… Retail squeeze · Consumer discretionary rotation · Housing, homebuilders & proptech catalyst · OPRT Oportun Financial Corporation LOW Margin repair at a non-prime lender is intact on the numbers but the post-Q2 bid has drained: after the 2026-08-05 beat (adj EPS $0.42 vs $0.33, adj EBITDA $49M vs a $34–$39M guide), the stock peaked at $8.09 on 2026-08-07 and closed $7.36… Special situation · Fintech & consumer credit analysed · PANL Pangaea Logistics Solutions Ltd. fresh LOW Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the… Earnings inflection · Freight & logistics analysed · PATH UiPath, Inc. LOW Legacy RPA vendor re-cast as the orchestration layer for enterprise AI agents; the last leg to a 2026-08-28 close of $18.15 came from Salesforce's 2026-08-26 beat-and-raise lifting all software, not from any UiPath datapoint, leaving price… Special situation · AI enterprise software analysed · PAYC Paycom Software, Inc. LOW Operating-leverage re-rating on a de-rated HCM name printed a new 52-week high at $238.53 (2026-08-28) after JP Morgan raised its target to $264 on 2026-08-25 while keeping Neutral — the fifth raise without a stance change. RSI(14) fell to… Special situation · AI enterprise software catalyst · PAYS Paysign, Inc. LOW The momentum leg has broken while the fundamental leg stays untested: the shares gave back 11.4% from the $14.14 high to a 2026-09-02 close of $12.53, RSI(14) 44.2 from 96.7 on 2026-08-21, after the 2026-08-26–27 Midwest IDEAS appearance… Defensive · Fintech & consumer credit · Managed care & health services catalyst · PL Planet Labs PBC LOW The 9/2 close of $19.99 reclaimed the $19.83 July range top and held about 4% above the $19.16 range low with RSI(14) at 13.2, but everything still rests on the 9/3 Q2 FY27 print against a $102–107M guide unrevised since 6/4. Options… Earnings inflection · Space economy catalyst · PLTR Palantir Technologies Inc. LOW The narrative on offer is government-AI production revenue compounding — the 2026-09-01 TITAN award put $127M into Palantir USG — The tape answered with closes of $179.92 (-3.47%) and $169.46 (-5.81%), losing the $179–$180.18 shelf and the… Compounder · AI enterprise software catalyst · POWL Powell Industries, Inc. LOW Record orders $934M and a 3.0x book-to-bill lifted backlog to $2.4B (+69% YoY) at the 2026-08-03 print, yet shares fell 13.4% the next pre-market on a second straight EPS/revenue miss and closed 2026-08-14 at $213.48, -33.7% off the high.… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure catalyst · PTEN Patterson-UTI Energy, Inc. fresh LOW Rig-reactivation cyclical is basing, not broken: June averaged 95 US rigs (vs ~90 Q2 guide), the July EIA STEO lifted 2026 Henry Hub to $3.67, gas rigs turned up 122→126, and Piper upgraded to Overweight 07-14. Price bottomed $8.57 (07-01)… Special situation · Oil, energy & geopolitical catalyst · PTRN Pattern Group Inc. Series A LOW Fundamentals still compounding — Q2 revenue $876.8M +47%, NRR 129%, FY guide raised to $3.42–3.46B — while the tape drifted from $23.16 post-print to $20.20 on 2026-09-04, closing on the $19.00 shelf where June's secondary cleared 9.2M… Cyclical recovery · Managed care & health services · Consumer discretionary rotation catalyst · QBTS D-Wave Quantum Inc. LOW Three named enterprise agreements (AT&T 07-27, Verafin 08-03, DOCOMO 08-18) never held a bid; after the 2026-08-25 CFO notice and a 2026-09-01 Pomerantz investigation announcement the shares closed 2026-09-02 at $16.49, just above the… Retail squeeze · Quantum computing catalyst · QLYS Qualys, Inc. LOW The digestion read is on its own line: the 2026-09-04 close of $171.65 sits 0.9% above the $170 shelf, with RSI(14) at 39.1 versus 51.1 on 2026-08-28 and no company news since the 2026-08-05 target cluster. The pullback restored headroom… Special situation · Cybersecurity · AI enterprise software catalyst · QUBT Quantum Computing Inc. LOW A second straight lower close after the failed $8.22 reclaim: 2026-09-02 settled $7.84 with the 50-day at $8.60 and the 200-day at $9.55 both descending overhead. The 2026-09-10 Lake Street appearance is attendance rather than disclosure… Retail squeeze · Quantum computing catalyst · RCEL Avita Medical, Inc. LOW Small-cap wound-care turnaround with a dated profitability inflection: the 2026-08-06 beat-and-raise lifted FY2026 guidance to $86-89M and put Q4 2026 on the calendar for cash-flow breakeven, and the 2026-08-18 PermeaDerm-I readout pulled… Defensive · Medtech & diagnostics catalyst · RDW Redwire Corporation LOW Post-SpaceX-IPO deflation broke RDW to a 2026-07-18 low near $8.51 (~67% off the 5/28 record). A relief bounce on Huntsville/Indiana facility news and $41.5M of H1 Stalker drone orders keeps running into a ~$850M dilution ceiling: the… Retail squeeze · Space economy · Defense & aerospace catalyst · RGTI Rigetti Computing, Inc. LOW Quantum pure-play basket is in outright hype-cycle deflation: RGTI ~$14.19 (2026-07-17), -27% MoM, and the $14 shelf that held the May CHIPS-stake gap and the June executive-order pop has broken. Inverse quantum ETFs printing +108% and the… Retail squeeze · Quantum computing catalyst · RIVN Rivian Automotive, Inc. LOW Post-binary delivery arithmetic: the raised 65,000–70,000 FY guide needs 42,441–47,441 H2 units against 22,559 delivered in H1, while the R2 second shift (2026-09-30) is not material until Q4. The 2026-09-03 close of $15.91 sits 41 cents… Earnings inflection · EV & autonomous mobility catalyst · RPD Rapid7, Inc. LOW The post-Q2 cost-out re-rating broke: back-to-back macro sessions on 2026-09-01 (-9.7%) and 2026-09-02 (-7.8%) returned RPD to a $11.00 close on 2026-09-04, through the $11.20 level this coverage published as the break condition and back… Earnings inflection · AI enterprise software · Semi foundry & equipment catalyst · RUM Rumble Inc. LOW The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10… Special situation · GPU cloud & neoclouds · AI datacenter infrastructure analysed · SATL Satellogic Inc. LOW The mania leg broke in July — the $6.33 shelf and the $4.97 range low both went — and the 2026-08-05 Q2 print handed the name a different story: revenue $15.9M (+259% YoY) vs $9.6M consensus, plus the first positive operating income and… Retail squeeze · Space economy catalyst · SENS Senseonics Holdings, Inc. LOW Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken… Defensive · Medtech & diagnostics catalyst · SIDU Sidus Space, Inc. LOW Post-print bounce fully unwound — $2.60 on 2026-08-14 to $2.21 on 2026-08-28 — with no company press release in between (IR page checked 2026-08-30). What is left is an asset argument: $166.5M cash and no term debt at 2026-06-30 against… Retail squeeze · Space economy analysed · SLN Silence Therapeutics Plc LOW First-in-class siRNA re-rated on the 2026-08-10 SANRECO readout (88% response vs 19% placebo, n=48) and immediately funded with a ~$175M raise priced at $13.50/ADS; with Phase 3 not starting until 1H 2027, the equity now trades on… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · SMCI Super Micro Computer, Inc. LOW Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all… Retail squeeze · AI datacenter infrastructure catalyst · SMMT Summit Therapeutics Inc. fresh LOW Class-validation leg reaccelerating: Akeso's 2026-09-02 HARMONi-2 interim showed a statistically significant OS win over pembrolizumab monotherapy, and 2026-08-25's HARMONi-GI1 was the first Phase III win outside NSCLC. The 2026-09-04… Earnings inflection · Oncology & immunology catalyst · SMR NuScale Power Corporation LOW SMR closed 2026-09-02 at $9.56, back near the top of the band between the 2026-08-18 close of $8.64 and the 2026-08-25 close of $9.81 — lifted by a sector-wide nuclear bid (Oklo +2.57%) rather than company news, a session after its own… Earnings inflection · Nuclear & uranium catalyst · SNAP Snap Inc. LOW The Q2 margin turn (revenue +19% YoY to $1.6B, adj EBITDA $250M, 2026-08-03) is priced by the sell side but not by the tape: the 2026-08-28 close of $5.43 is two cents off 2026-08-14 after three weeks of state-AG flow — Pennsylvania suing… Special situation · Mega-cap AI platforms analysed · SPIR Spire Global, Inc. LOW The two largest awards of the cycle — EUMETSAT ~€4M on 2026-08-25 and a two-year $28M NOAA HyMS contract on 2026-08-26 — landed into a lower close: $13.17 on 08-28 versus $13.94 on 08-21, with RSI(14) falling from 63.8 to 39.7 in a week.… Defensive · Space economy catalyst · TBI Trueblue, Inc. LOW Deep-cyclical industrial staffer re-rated +140% off the $3.18 low on a staffing-demand recovery and a data-center/energy labor boom lifting PeopleReady +19% YoY. Still loss-making (Q1 net -$19.8M), margins compressed, and the… Special situation · Cyclical industrials · Emerging markets catalyst · TEM Tempus AI, Inc. LOW Second-order re-rating on the 2026-08-19 Merck/Moderna INTerpath-001 win is now fully in sell-side language — three target actions between 08-31 and 09-02, topping at $80 — while price slid from $72.69 (08-21) to $64.62 (09-04) and ARK… Cyclical recovery · Medtech & diagnostics analysed · TITN Titan Machinery Inc. LOW Titan Machinery’s farm-equipment recovery re-rating requires falling total inventory and preserved earnings guidance at its next quarterly report. A weekly close below $23 would invalidate the market thesis before confirmation. Compounder · Cyclical industrials catalyst · TSLA Tesla, Inc. LOW The 2026-09-03 Cybercab launch landed after the bell and delivered a website update rather than a disclosure: rides live in limited Austin areas via the Robotaxi app, no ride price, no operating fleet count, no livestream, guests under… Compounder · EV & autonomous mobility · Physical AI & robotics catalyst · UPXI Upexi, Inc. LOW Upexi’s Solana-discount recovery requires positive audited net assets and a Nasdaq bid-price cure. The September 28 annual-report checkpoint is provisional, while a weekly close below $1.00 invalidates the recovery structure. Earnings inflection · Crypto exchanges & financials catalyst · UUUU Energy Fuels Inc. LOW Two sell-side target raises in consecutive sessions — HC Wainwright's $29.25 on 2026-09-01 and Cantor Fitzgerald's $33 reiteration on 2026-09-02 — moved the shares less than 1%, to a $14.29 close 48.4% under the 52-week high. With rare… Compounder · Nuclear & uranium catalyst · VIAV Viavi Solutions Inc. LOW Networking-optical test theme still accelerating and the laggard test-and-measurement sleeve is finally re-rating: Susquehanna lifted its target to $66 (2026-07-01) and the small-cap-over-hyperscaler rotation flagged 2026-06-29 favors… Cyclical recovery · Networking & optical · AI datacenter infrastructure analysed · VICR Vicor Corporation LOW Operating numbers still inflecting (Q2 guide ~$142M, book-to-bill >2.0, backlog $300.6M) but the chart has broken: $237.62 on 2026-07-17 is ~38% off the $382.65 July high, with $271 and $300 both lost and relentless CEO 10b5-1 supply. The… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure analysed · VMI Valmont Industries, Inc. LOW Beat-and-raise still being sold: after the 2026-07-21 print ($6.14 vs $5.75, FY26 guide lifted to $22.25–$23.50), shares closed 2026-08-28 at $476.28, 18.3% under the $582.78 52-week high, with the broken $520 shelf overhead and the $470… Theme leader · Industrial power & grid analysed · VOR Vor Biopharma Inc. LOW Legacy-pivot re-rating is holding its post-print range while the flow behind it thins: $22.65 on 2026-08-28 versus $23.67 on 2026-08-07, with RSI(14) down from 64.6 to 45.1 and no company release since the 2026-08-11 Q2 print. UPSTREAM MG… Special situation · Oncology & immunology · Semi foundry & equipment analysed · VSH Vishay Intertechnology, Inc. LOW Cycle-turn re-rate has fully round-tripped: down ~46% from $69.47 to the high-$30s, now under the $50 June placement and below every covering analyst's target. Q1's 1.34 book-to-bill and $1.6B backlog were real but sit at ~35x forward into… Earnings inflection · Industrial power & grid catalyst · VSTS Vestis Corporation LOW Post-spin uniform-rental turnaround: Q3 FY26 (2026-08-11) put adjusted EBITDA margin at 12.2% vs 9.8% a year earlier and lifted the FY26 free-cash-flow guide to $160–170M, while revenue still fell 1.8% YoY and missed. The CEO's 2026-09-02… Special situation · GPU cloud & neoclouds · Consumer discretionary rotation analysed · WEAV Weave Communications, Inc. fresh LOW Beaten-down vertical-SaaS front-office platform for healthcare SMBs, down ~36% YTD and basing off the $4.24 low, repositioning around AI-receptionist monetization (TrueLark, 2025). Still a ~17% grower with GAAP losses, so the re-rate is… Theme leader · AI enterprise software analysed · XXI Twenty One Capital, Inc. LOW The one re-rate catalyst just died: Tether's Strike–Elektron three-way merger was scrapped on 2026-07-21 and CEO Jack Mallers quit, dropping XXI to a fresh all-time low near $4.46. A leveraged-Bitcoin-treasury proxy stuck below 1.0x float… Compounder · Crypto exchanges & financials catalyst · YSS York Space Systems Inc. LOW Two Space Force selections — the 2026-08-18 NITE-STAR IDIQ pool and the 2026-08-25 Space Data Network Backbone award ($12M, one of five equal awards in a $60M pool) — landed and the tape still closed lower at $8.97 on 2026-08-28, a… Earnings inflection · Space economy analysed ·

Recently exited

28
PANW Palo Alto Networks, Inc. fresh HIGH AI-security spend narrative accelerating with third-party confirmation: IBM missed Q2 ($17.2B vs $17.86B) on 2026-07-14 and blamed budget migration into Cybersecurity — PANW +6.4%, CRWD +10%, BUG +6% same session. New ATH close $357.53… Compounder · Cybersecurity catalyst · SNOW Snowflake Inc. fresh HIGH The June digestion resolved upward, not downward — SNOW cleared the ~$244 June high and printed a fresh 52-week high at $284.99 before settling at $268.90 (2026-07-17). Q1 FY27 product revenue re-accelerated to +34% and the street is still… Cyclical recovery · AI enterprise software catalyst · ATI ATI Inc. fresh MEDIUM Titanium/superalloy aero-defense supplier digesting a June breakout above the reclaimed $183.30 ATH shelf: ~9% off the $204.09 high, RSI cooled to ~66, consensus PT $200.33 back above spot. Q2 lands 2026-08-06; peer CRS prints 2026-07-30… Defensive · Defense & aerospace analysed · GLW Corning Incorporated fresh MEDIUM Corning’s fiber agreements support its AI infrastructure story, but Q3 revenue must confirm demand before a weekly close below $143. Confirmation requires core sales of at least $4.9 billion, July’s guidance floor, and Optical… Cyclical recovery · AI datacenter infrastructure analysed · GLXY Galaxy Digital Inc. fresh MEDIUM Galaxy Digital's data-center revaluation depends on Q3 Helios rent confirming its approximately $80 million quarterly leasing forecast and margin above 90%, issued on 2026-08-05. Confirmation must precede a weekly close below $24; the… Special situation · Crypto exchanges & financials catalyst · NBIS Nebius Group N.V. fresh MEDIUM GPU-neocloud narrative re-accelerated after NVIDIA disclosed a 9.3% stake (7/20) and PT raises followed (Northland $410, Baird initiates Outperform $250); Alphabet's 7/22 "demand outpaces capacity" answers the Meta-Compute bear case. The… Compounder · GPU cloud & neoclouds analysed · RIOT Riot Platforms, Inc. fresh MEDIUM Riot Platforms’ AI-leasing thesis depends on binding project financing and resolution of its interim borrowing before maturity. The June-quarter filing gives an extendable October 15 deadline, while a later reported December 31 date… Special situation · GPU cloud & neoclouds catalyst · WTI W&T Offshore, Inc. fresh MEDIUM W&T Offshore’s oil-to-cash recovery case now tests a daily close at or above the market’s $4.89 trailing-year high before a daily close below $3.55 invalidates it. The 2026-09-09 close of $4.06 satisfies the prior $4.01 recovery hurdle;… Compounder · Oil, energy & geopolitical catalyst · WULF TeraWulf Inc. fresh MEDIUM TeraWulf’s AI-landlord conversion turns on CB-4 beginning to earn rent in September 2026 before a weekly close below $14.50. The company release index checked on 2026-09-10 provides no delivery confirmation, leaving the operating outcome… Special situation · GPU cloud & neoclouds catalyst · ARM Arm Holdings plc fresh LOW Data-center royalty doubled YoY for a second quarter, but Q2 FY27 royalty growth is guided to ~13% against 22% delivered. No Arm-specific disclosure has landed since 2026-07-29, so the bid is set by third parties — BofA's 2026-08-13… Cyclical recovery · Mega-cap AI platforms catalyst · BFLY Butterfly Network, Inc. fresh LOW Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but… Defensive · Medtech & diagnostics catalyst · COHR Coherent Corp. fresh LOW Coherent’s AI-optics recovery requires a named PhotonLink customer and production timing at the 2026-09-21 launch. Those disclosures and a subsequent weekly close above $281.86 complete the case before a weekly close below $264 invalidates… Cyclical recovery · AI datacenter infrastructure catalyst · HUT Hut 8 Corp. fresh LOW Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)… Special situation · GPU cloud & neoclouds catalyst · INTC Intel Corporation fresh LOW Funded legacy-pivot leg is holding the $101.65 pre-announcement shelf by under a dollar after the 2026-08-14 close of $102.50; CEO Tan's Form 4 (105,263 sh at $95.00) is the only fresh company datapoint in a week of 13F-derived coverage.… Special situation · Mega-cap AI platforms catalyst · KYMR Kymera Therapeutics, Inc. fresh LOW Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,… Defensive · Precision biotech & therapeutics catalyst · LRCX Lam Research Corporation fresh LOW The WFE/AI-memory capex trade that ran Lam +119% YTD into June has rolled into a group-wide correction — the worst month for chip stocks since 2008, memory momentum broken (Micron/SanDisk). The ~2026-07-29 FQ4 print is now the binary: it… Cyclical recovery · Semi foundry & equipment catalyst · MP MP Materials Corp. fresh LOW MP Materials' contracted rare-earth recovery needs Q4 2026 commercial magnet shipments to General Motors and a weekly close above $60.17. A weekly close below $50 or shipments delayed beyond that quarter invalidates the case. Compounder · Critical materials & rare earths catalyst · NVDA NVIDIA Corporation fresh LOW July de-rating unresolved and now compounded by capex scrutiny — Alphabet's first cash-flow-negative quarter since 2004 and Intel's punished $20B capex plan raise the question of whether hyperscaler spend slows. Jensen's open-weight-AI… Cyclical recovery · Mega-cap AI platforms catalyst · ONTO Onto Innovation Inc. fresh LOW June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation — TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its… Cyclical recovery · Semi foundry & equipment catalyst · PURR Hyperliquid Strategies Inc fresh LOW The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly 0.78x the value of its 17.6M HYPE stack — a treasury premium that has flipped to a discount,… Retail squeeze · Crypto exchanges & financials catalyst · QCOM QUALCOMM Incorporated fresh LOW The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math… Special situation · Mega-cap AI platforms catalyst · RKLB Rocket Lab Corporation fresh LOW Rocket Lab's stabilisation case rests on operating growth overcoming acquisition-financing uncertainty. Iridium approval on 2026-09-24 followed by a weekly close above the September 4 reference of $64.26 confirms the narrow case only if a… Compounder · Space economy catalyst · SHLS Shoals Technologies Group, Inc. fresh LOW Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed… Theme leader · Solar & clean energy · Industrial power & grid catalyst · SYRE Spyre Therapeutics, Inc. fresh LOW Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,… Defensive · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · TNGX Tango Therapeutics, Inc. fresh LOW Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)… Defensive · Oncology & immunology · Binary-catalyst biotech catalyst · TSM Taiwan Semiconductor Manufacturing Company Ltd. fresh LOW Q2 (7/16) beat every line and lifted FY26 growth guide above 40%, but the capex raise to $60–64B and a 2026-07-26 Samsung–Broadcom $200B foundry pact reopened the monopoly question. Theme cooled to maturing; price recovered to ~$415, still… Cyclical recovery · Semi foundry & equipment catalyst · VRT Vertiv Holdings Co fresh LOW Vertiv's grid-power expansion supports a recovery case requiring Q3 revenue to meet guidance and a weekly close above $285.78. The September 9 close of $262.89 leaves confirmation outstanding; a weekly close below $240 or Q3 revenue below… Cyclical recovery · AI datacenter infrastructure catalyst · WEST Westrock Coffee Company fresh LOW Westrock Coffee’s Conway expansion supports a cash-generation revaluation, but repeat cash flow remains unproven. Confirmation requires positive third-quarter 2026 free cash flow, maintained annual guidance and a weekly close above the… Special situation · Consumer discretionary rotation catalyst ·

Dormant

630
ALOT AstroNova, Inc. SUPREME Closed situation: Arcline's $29.00 all-cash take-private completed 2026-08-26, shares converted to cash and Nasdaq trading ended, with Nasdaq's Form 25-NSE filed the same day and no Form 15 on EDGAR as of 2026-09-06. The final $28.99 close… Earnings inflection · M&A & special situations analysed · AVNS Avanos Medical, Inc. SUPREME Closed record, not a live setup: AIP's $25.00/share all-cash take-private completed 2026-07-27 (EV ~$1.272B), AVNS left the NYSE that day, and the 2026-08-06 Form 15-12G — one holder of record — suspended SEC reporting. Nothing is dated… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · CBZ CBIZ, Inc. SUPREME Completion-and-clock trade now: the 2026-09-04 close of $54.85 sits $0.15 under signed $55.00 all-cash terms, in from $0.34 on 2026-08-21, after the go-shop lapsed 2026-08-27 and the same-day PREM14A disclosed 24 parties contacted, six… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · CCRN Cross Country Healthcare, Inc. SUPREME Terminated rather than live: the Knox Lane take-private closed 2026-07-21 at $13.25 cash, Nasdaq filed Form 25 that day, and the Form 15-12G/A of 2026-07-31 certifies approximately one holder of record. EDGAR has recorded no filing for the… Earnings inflection · M&A & special situations · Managed care & health services analysed · CNTA Centessa Pharmaceuticals plc SUPREME Closed cash-plus-CVR takeout; nothing trades. Lilly's UK scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. Since the last note the only motion is registry-side:… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · CRNX Crinetics Pharmaceuticals, Inc. SUPREME The settlement claim resolved: the Vertex merger became effective 2026-09-01 at $85.00 a share in cash, Nasdaq trading was suspended before that day's open and a Form 25 was requested. The final print is $84.95 on 2026-08-31; shares are… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · FBRX Forte Biosciences, Inc. SUPREME The spread paid as contracted: argenx reported 19,894,879 shares tendered (~87.13%) at the 2026-08-26 expiration, completed the back-end merger at $77.00 cash on 2026-08-27 and ended the Nasdaq listing. The final print was $76.99, a cent… Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · GBTG Global Business Travel Group, Inc. SUPREME Take-private in its last mile: stockholders adopted the $9.50 Long Lake merger on 2026-08-03 and the 2026-09-04 close of $9.48 leaves $0.02 gross against the unaffected $5.93. Only undated offshore clearances stand before the 2026-11-02… Earnings inflection · M&A & special situations · Consumer discretionary rotation analysed · KALV KalVista Pharmaceuticals, Inc. SUPREME Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11 and KALV stopped trading on Nasdaq that morning. An EDGAR check on 2026-09-05 shows no issuer filing since the 2026-08-14 Schedule 13G/A… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · LPRO Open Lending Corporation SUPREME Terminal and now deregistered: ANV's $3.15 all-cash tender took ~85.65% by 2026-07-27, the §251(h) merger closed 2026-07-30, Form 25-NSE went in the same day and Form 15-12G on 2026-08-10. Last public close $3.14 on 2026-07-29. Nothing… Earnings inflection · Fintech & consumer credit · M&A & special situations analysed · NUVL Nuvalent, Inc. SUPREME No tradable NUVL equity exists: GSK's $124 all-cash deal completed 2026-07-15, trading was suspended, and a Form 15-12G filed 2026-07-27 lists an approximate holder-of-record count of one. The 2026-09-18 zidesamtinib PDUFA still on some… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology analysed · OLPX Olaplex Holdings, Inc. SUPREME Closed by event and unchanged since: Henkel's all-cash takeout completed 2026-07-07 at $2.06 per share, Nasdaq delisting and a Form 15-12G followed, and Henkel's IR calendar now dates the first consolidated period containing the brand to… Earnings inflection · M&A & special situations · Consumer discretionary rotation catalyst · PAYO Payoneer Global Inc. SUPREME Merger-arb into a dated gate: the 2026-09-14 special meeting is eight days out, HSR early termination was granted 2026-07-28, and the 2026-09-04 close of $7.17 leaves $0.23 to Nuvei's $7.40 all-cash offer — the tightest spread since… Earnings inflection · M&A & special situations · Fintech & consumer credit catalyst · TBRG TruBridge, Inc. SUPREME Closed and deregistered — the IKS Health merger paid $26.25/share cash at the 2026-07-09 effective time, Form 25 the same day, Form 15-12G on 2026-07-24, and the adjusted series stops at $26.24 on 2026-07-08. The only live thread is a… Earnings inflection · M&A & special situations · Managed care & health services analysed · ABVX Abivax SA HIGH Nine weeks of silence since the 2026-07-30 FDA pre-NDA alignment ended in stabilisation rather than a lower low — the 2026-09-04 close of $114.79 with RSI(14) back to 38.8 from 23.7 on 2026-08-28, still under the $125.00 placement price.… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · AKTS Aktis Oncology, Inc. HIGH Post-initiation follow-through arrived late: after Wedbush ($35) and BMO ($37) took the covering cohort to five on 2026-08-19, the tape moved from $24.07 on 2026-08-21 to $25.78 on 2026-08-28, clearing the three-week $24 shelf. Five… Compounder · Oncology & immunology · Precision biotech & therapeutics analysed · ARIS Aris Mining Corporation HIGH Two-asset Colombian gold producer earning $1,767/oz Segovia AISC against a $4,450/oz realized price (Q2, reported 2026-07-29); the leg being bought is the volume step toward ~500 koz/yr, gated on the 5,000 tpd Marmato CIP plant delivering… Compounder · Critical materials & rare earths · Oil, energy & geopolitical catalyst · ARX Accelerant Holdings HIGH Fixed-price take-private: $20.25 all-cash from Thoma Bravo, with the 2026-09-04 close of $19.88 leaving a $0.37 gross spread on an insurance-regulatory calendar guided to H1 2027. The spread has tightened from $0.66 on 2026-08-21 on an… Earnings inflection · M&A & special situations · Managed care & health services catalyst · CLSK CleanSpark, Inc. HIGH Spring's binary resolved bullish: CleanSpark signed a $6.6B, 20-year Georgia data-center lease (2026-07-14) with an unnamed "global technology company," converting the BTC-miner-to-AI-infrastructure pivot from speculation into contracted… Special situation · Bitcoin miners · AI datacenter infrastructure catalyst · ELE Elemental Royalty Corporation HIGH Post-EMX royalty roll-up still compounding: Q2 2026 revenue $23.8M vs $9.1M a year earlier, guidance affirmed at 17,000–21,000 GEOs while gold traded near $4,608/oz on 2026-08-28 against a $4,500/oz guidance assumption. The 2026-08-11… Cyclical recovery · Precision biotech & therapeutics · Critical materials & rare earths catalyst · ESPR Esperion Therapeutics, Inc. HIGH Resolved and off the tape: the ARCHIMED take-private closed 2026-07-13 at $3.16 cash plus a non-transferable CVR of up to $100M, and Esperion filed a Form 15-12G on 2026-07-23 to suspend Exchange Act reporting. The last listed close was… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · GH Guardant Health, Inc. HIGH Carelon's 2026-09-01 decision to cover Shield from 2026-11-15 lifts stated reach to ~90M lives (~75% of eligible) — the payer datapoint the story needed — yet the close was $161.41 on 2026-09-04 versus $161.50 on 2026-08-28. FY26 guidance… Compounder · Medtech & diagnostics · Oncology & immunology catalyst · HNI HNI Corporation HIGH Steelcase cost-synergy ramp is still the entire earnings story — FY2026 guide raised 2026-07-30 to 20–25% non-GAAP EPS growth on 0.1% organic sales. Price has built a three-week shelf, $48.86 on 2026-08-14 to $49.66 on 2026-09-04, 3.0%… Special situation · Cyclical industrials · Housing, homebuilders & proptech catalyst · ITGR Integer Holdings Corporation HIGH Signed-deal instrument since 2026-08-03: KKR's $127.00 all-cash agreement leaves $1.67 above the 2026-08-28 close of $125.33. Four weeks after signing, no merger proxy is on file and no HSR filing date has been disclosed, so a year-end… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · MKTX MarketAxess Holdings, Inc. HIGH ICE's $167.00 all-cash deal (signed 2026-07-30) leaves MKTX trading purely as a spread: $167.00 less the 2026-08-28 close of $162.72 is $4.28 gross, in from $4.89 a week earlier. ICE's $3.75B bond pricing on 2026-08-11 took the financing… Earnings inflection · M&A & special situations · Prediction markets & betting catalyst · MMED MiniMed Group, Inc. HIGH Q1 FY2027 on 2026-09-01 turned the carve-out story from re-rate into acceleration: net sales $843M vs $827.065M consensus, +15.8% organic against 8.7% the prior quarter, FY2027 organic guide lifted to ~10.5%, GAAP EPS at break-even, and… Special situation · Medtech & diagnostics catalyst · MRX Marex Group plc HIGH Roll-up compounder in clean momentum continuation: the sell-side is now chasing price, with KBW $80, Barclays $76 and Piper $75 targets (Jul 9-15) leapfrogging the old $60 consensus, while the Bright Point clearing bolt-on (2026-07-09)… Cyclical recovery · M&A & special situations · Crypto exchanges & financials catalyst · OGN Organon & Co. HIGH Deal-pinned arbitrage with no discretionary leg left: the $14.00 all-cash Sun Pharma merger was approved by holders 2026-07-23, and the 2026-09-04 close of $13.78 leaves $0.22 gross into a stated early-2027 completion against a 2027-01-26… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · ONC BeOne Medicines Ltd. HIGH Two 2026-08-31 catalysts — a statistically significant OS win in HERIZON-GEA-01 and a US agreement exempting BeOne from Section 232 pharma tariffs — landed without producing a new high: the 2026-09-04 close of $358.26 is 5.1% under the… Compounder · Oncology & immunology · Precision biotech & therapeutics catalyst · P Everpure, Inc. HIGH Beat-and-raise landed on 2026-08-26 — FY2027 revenue guided to $5.03B–$5.07B from $4.41B–$4.51B, EPS $0.70 vs $0.58 consensus — and the tape sold it: the 2026-09-04 close of $99.51 sits 15.8% under the 08-14 high with RSI(14) at 32.6. The… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · PEB Pebblebrook Hotel Trust HIGH The August overheat has drained without a break: the 2026-09-04 close of $18.03 sits 8.7% under the 52-week high with RSI(14) at 48.1, versus 73.3 on 2026-08-28, while the 16-desk consensus target edged to $19.12. No rating action since… Earnings inflection · Travel & leisure · Housing, homebuilders & proptech catalyst · PVLA Palvella Therapeutics, Inc. HIGH The undated FDA window closed on 2026-08-31: the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations is complete under 505(b)(2), starting a 60-day agency clock on filing acceptance and the Priority Review decision that… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · RAMP LiveRamp Holdings, Inc. HIGH Shareholder gate cleared 2026-08-17 (51,578,202 for / 60,073 against), leaving CFIUS, HSR and non-US clearances as the only open conditions on Publicis' $38.50 cash offer. The 2026-09-04 close of $37.75 is $0.75 under contract, tighter… Earnings inflection · M&A & special situations · AI enterprise software analysed · RNG Ringcentral, Inc. HIGH Legacy UCaaS re-rating on AI mix (~13% of ARR) has widened from two target raises to a four-firm cluster: Wells Fargo $65 (08-25), Needham $85 (08-28), Oppenheimer $85 (09-01), RBC initiating Outperform at $85 (09-03). Close $73.39 on… Special situation · AI enterprise software · Cyclical industrials catalyst · RVMD Revolution Medicines, Inc. HIGH Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to… Compounder · Precision biotech & therapeutics · Oncology & immunology catalyst · SAFT Safety Insurance Group, Inc. HIGH The Mapfre $105.00 all-cash deal finally has filed dates: HSR filings made 2026-08-13 with the initial waiting period expiring 2026-09-14, a Massachusetts Form A filed 2026-08-25, and a preliminary proxy filed 2026-09-03 that still leaves… Earnings inflection · M&A & special situations · Managed care & health services catalyst · SCZM Santacruz Silver Mining Ltd. HIGH No company disclosure since the 2026-08-17 Q2 print, so the marginal driver is the metal: silver December futures opened $67.63/oz on 2026-09-04, +16.4% in a month, against Q2 cash cost of $15.54/oz and AISC $21.87/oz. Price closed $9.94… Compounder · Critical materials & rare earths · Bitcoin miners analysed · SHIP Seanergy Maritime Holdings Corp. HIGH Capesize spot printed $46,601/day on 2026-08-27, a new high for this run and well above the ~$30,998/day the company guided for Q3 on 2026-07-30, yet the stock closed $17.79 on 2026-08-28, still 2.1% under its $18.17 high. No company print… Compounder · Freight & logistics · Semi foundry & equipment catalyst · SMTI Sanara MedTech Inc. HIGH Merger-arb instrument since MIMEDX's 2026-07-29 agreement ($33.00 cash + 0.4735 MDXG per share). A Form S-4 now appears on EDGAR under MIMEDX's CIK with a 2026-08-24 consent exhibit, moving the deal into its documented phase; at the… Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · TECH Bio-Techne Corp HIGH Merger arb pinned 57 cents under Merck KGaA's $73.00 cash bid: the 2026-09-23 special meeting is dated, and the HSR clock restarted by the 2026-08-19 refiling should lapse around 2026-09-18, with no FTC clearance and no second request… Earnings inflection · M&A & special situations · Medtech & diagnostics catalyst · UTZ Utz Brands, Inc. HIGH The 2026-08-24 preliminary merger proxy filled the one gap in the prior read: Intersnack's $14.25 all-cash take-private now has a filed Schedule 14A, and the 2026-08-28 close of $14.20 leaves $0.05 of gross spread to a company-guided Q4… Earnings inflection · M&A & special situations · Networking & optical analysed · VRNS Varonis Systems, Inc. HIGH The June take-private option now has a named counterparty: Reuters, Bloomberg and the WSJ reported on 2026-09-02 and 2026-09-04 that Thoma Bravo-owned Proofpoint is in advanced talks to buy Varonis, and the session needed a circuit-breaker… Earnings inflection · Cybersecurity · AI datacenter infrastructure catalyst · ABT Abbott Laboratories MEDIUM Two named overhangs cleared in August and the tape handed the gain back: $112.47 on 2026-08-28 to $108.33 on 2026-09-04, RSI(14) 61.7 to 44.9, with the $103 post-Q2 gap shelf now 4.9% below. The narrative is saturated — retail-facing… Special situation · Medtech & diagnostics · Precision biotech & therapeutics analysed · ABX Abacus Global Management, Inc. MEDIUM The $9.00 shelf still holds — $9.61 on 2026-09-04 against $9.27 on 2026-08-14, RSI(14) 59.7 — with the $100M repurchase live since 2026-08-17 the only identifiable new bid and no company release since 2026-08-24. What remains is a… Special situation · Small-cap value rotation · Precision biotech & therapeutics analysed · ACB Aurora Cannabis Inc. MEDIUM The 2026-09-02 directors' circular came and went as a unanimous rejection with no raise, and Curaleaf reaffirmed 0.3463 shares plus US$0.75 cash the same day. The 2026-09-04 close of $3.95 sits just under the announced US$4.00, so the… Earnings inflection · M&A & special situations · Cannabis reclassification analysed · ACIW ACI Worldwide, Inc. MEDIUM Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +… Special situation · M&A & special situations · AI datacenter infrastructure catalyst · ADBE Adobe Inc. MEDIUM Deep-value AI-disruption leg in legacy software, now with an external validator: the 2026-08-13 Silver Lake–Workday take-private report put a sponsor price on marked-down per-seat SaaS. ADBE closed 2026-08-14 at $264.02, 28.2% off the… Special situation · AI enterprise software catalyst · AGIO Agios Pharmaceuticals, Inc. MEDIUM Mitapivat sickle-cell label-expansion binary into the 2026-11-01 PDUFA, funded by a real ramp (Q2 mitapivat revenue $44.7M vs $26.03M consensus, 2026-07-30). Nothing company-dated has landed since; the tape closed $33.10 on 2026-09-04… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy catalyst · AKAM Akamai Technologies, Inc. MEDIUM Legacy-CDN-to-AI-inference pivot got its first external validation since the failed July bounce: Q2 CIS +39% to $99M with >$2.8B YTD contract bookings (2026-08-06), then J.P. Morgan off Underweight to Neutral, PT $158 (2026-08-13). Price… Special situation · AI datacenter infrastructure · Cybersecurity analysed · ALAB Astera Labs, Inc. MEDIUM Q2 (2026-08-04) answered the July margin question: GM 73.7% vs ~73% guide, and Q3 guided $540–560M vs $416.5M consensus (~40% QoQ) with Scorpio X switches in volume production a quarter early. Price has not confirmed — the 2026-08-14 close… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · ALGT Allegiant Travel Company MEDIUM Allegiant closed the $1.5B Sun Country acquisition (2026-05-13) to become the largest US leisure airline just as fuel flipped to a tailwind and the whole sell-side re-rated it to $142–$160; the move has more than doubled off the low, and… Special situation · Travel & leisure · Semi foundry & equipment catalyst · ALK Alaska Air Group, Inc. MEDIUM The failed $44–47 shelf has not been reclaimed: the 2026-09-04 close of $42.04 holds above the $40.06 where the CEO bought 25,000 shares on 2026-08-20, but 34.2% under the $63.86 high with RSI(14) at 41.4. The new variable is dated —… Special situation · Travel & leisure · Cyclical industrials catalyst · ALKS Alkermes plc MEDIUM Legacy CNS commercial base converting into an OX2R sleep franchise on alixorexton; mechanism risk cleared with the FDA's 2026-08-05 ORZEYFUL approval, yet the 2026-08-28 close of $47.41 is 14.1% under the $55.22 high and the 2026-08-24… Special situation · Precision biotech & therapeutics catalyst · ALM Almonty Industries Inc. MEDIUM Non-China tungsten narrative now trades on one venue: the TSX exit took effect 2026-07-31 and the ASX removal 2026-09-01, leaving Nasdaq and Frankfurt. The operating case is unchanged — Sangdong throughput since 2026-07-01, Q2 revenue… Compounder · Critical materials & rare earths · Defense & aerospace analysed · AMAT Applied Materials, Inc. MEDIUM The $480 weekly line broke: 2026-09-04 reference close $454.71, 37.0% under the $722.23 high, RSI(14) 17.7, three-month price change -7.5%. Record Q3 revenue of $9.12B (+25% YoY) and a UBS target raised to $695 on 2026-09-01 have not… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure catalyst · AMBA Ambarella, Inc. MEDIUM Physical-AI pure-play narrative still accelerating (Rosenblatt top H2-2026 pick, PT $120; Zacks upgrade to #2 Buy 2026-07-21), but the post-Rosenblatt breakout to ~$80 round-tripped to ~$67.61 by 2026-07-24, forfeiting the $72 shelf on a… Cyclical recovery · Physical AI & robotics · AI chips & memory analysed · AMC Amc Entertainment Holdings, Inc. MEDIUM Box-office recovery flipped from meme-squeeze dormancy to a fundamental earnings inflection: Q2 (2026-07-20) adj EPS $0.14 vs $(0.06) est, revenue $1.597B beat, plus a Wedbush $4 / Benchmark $3 upgrade cluster (2026-07-21). Narrative… Special situation · Freight & logistics · Consumer discretionary rotation catalyst · AMP Ameriprise Financial, Inc. MEDIUM Wealth-platform operating leverage intact — Q2 (2026-07-23) adjusted operating EPS $11.07 +22%, ROE 55%, record $1.81T AUM/AUA — but four weeks after the 2026-08-11 high the tape has gone flat: $560.56 on 2026-09-04, 1.8% under the 52-week… Cyclical recovery · AI enterprise software · Cyclical industrials catalyst · ANDG Andersen Group Inc. MEDIUM Post-IPO roll-up re-rate that survived its binary: Q2 revenue $217.7M beat $199.3M on 2026-08-12 and FY2026 was affirmed at $980M–$1.0B, with four target raises to $49–57 on 2026-08-13. The print is behind it and no dated catalyst sits… Defensive · Managed care & health services · Biofuels & low-carbon fuels catalyst · ANF Abercrombie & Fitch Co. MEDIUM Legacy-apparel margin turnaround re-rated on the 2026-08-26 Q2 print: adjusted EPS $2.42 vs $1.99 consensus, FY26 EPS guide lifted to $13.10–$13.60, operating margin guide to 14.5–15.0%, ~7% of shares retired YTD. The narrative is maturing… Special situation · Consumer discretionary rotation analysed · ANRO Alto Neuroscience Inc. MEDIUM Precision-psychiatry re-rate now running on flow alone: no company news since the 2026-08-27 CFO promotion, no new sell-side revision since H.C. Wainwright's $55 on 2026-08-17. The 2026-09-04 close of $35.55 sits 3.0% under the $36.64… Earnings inflection · Precision biotech & therapeutics analysed · ARXS Arxis, Inc. MEDIUM Serial-acquirer compounding into defense and space: five closings since 2026-06-01, the latest StratEdge and Schatz on 2026-09-01/02 (in excess of $40M combined FY27 revenue, terms undisclosed). The 2026-07-29 raise to $1.960–1.980B is… Cyclical recovery · Space economy · Defense & aerospace analysed · ATEYY Advantest Corporation MEDIUM Broadcom's 2026-09-02 print (AI semis $16.7B, +221% YoY; Q4 guide $21.7B) did what NVIDIA's 2026-08-26 record could not — the ADR closed $217.58 on 2026-09-04, back above the $216.24 record shelf of 2026-06-25. The 2026-07-29 raise to… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · AUR Aurora Innovation, Inc. MEDIUM Q2 (2026-07-29) cleared the binary without breaking the plan: >200 driverless trucks and ~$80M exit run-rate reaffirmed, FY26 revenue guided $14–16M, ~$1.2B cash after a $215M net ATM raise. Price reclaimed the broken ~$6.00 June shelf to… Defensive · Physical AI & robotics · Freight & logistics catalyst · AVLN Avalyn Pharma Inc. MEDIUM Post-IPO inhaled-antifibrotic re-rating rebuilt to the 2026-09-04 close of $37.39 from the 2026-08-28 close of $34.69 with no company disclosure since the 2026-08-24 ERS notice; the 2026-09-07 posters carry no FVC data, leaving the… Earnings inflection · Precision biotech & therapeutics catalyst · AVTX Avalo Therapeutics, Inc. MEDIUM Post-LOTUS consolidation is grinding: the 2026-09-04 close of $19.23 is 1.8% under 2026-08-28 with RSI(14) at 44.6, and the only new company news since the Q2 print is a September conference slate (2026-09-03) plus 78,000 inducement… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · AYA Aya Gold & Silver Inc. MEDIUM Silver at $66.94/oz on 2026-09-06 still clears the $64.22/oz AgEq Q2 realized price against a $16.82/oz AgEq cash cost, while the US line closed $28.91 on 2026-09-04 with RSI(14) cooling to 57.7 from 70.7 on 2026-08-21. The ~2026-10-07 Q3… Compounder · Critical materials & rare earths analysed · AZTA Azenta, Inc. MEDIUM The prior break level fired: the 2026-09-04 weekly close at $31.33 unwound the whole news-free August advance from $37.40 (Aug 21). What remains is a cash-rich self-help case — $529M and no debt at June 30, the full $63M B Medical price… Special situation · Medtech & diagnostics · M&A & special situations catalyst · BBAR Banco BBVA Argentina S.A. MEDIUM Argentina country trade re-accelerated: June CPI printed 1.9% MoM on 2026-07-14 (first sub-2% of the cycle) and country risk broke to 402bp, tightest since April 2018, carrying BBAR to a fresh 52-week high of $22.47. Price now sits above… Compounder · Emerging markets catalyst · BBWI Bath & Body Works, Inc. MEDIUM The 2026-08-26 binary resolved two ways: Q2 adjusted EPS $0.62 vs $0.24 consensus, but ~$0.31 of it was an $80M tariff refund, and Q3 is guided to $0.07–$0.12 against $0.26. Five desks cut targets on 2026-08-27 into a $17–$24 band, yet the… Special situation · Consumer discretionary rotation · Small-cap value rotation analysed · BE Bloom Energy Corporation MEDIUM S&P 500 addition announced 2026-09-04 (effective before the 2026-09-21 open, replacing Molson Coors) puts a dated mechanical bid under a second-order AI-power name that has gone nowhere for three months: the 2026-09-04 close of $252.87… Theme leader · Industrial power & grid · AI datacenter infrastructure catalyst · BETA Beta Technologies, Inc. MEDIUM The $18.50 level published in August was never printed: BETA floored in the $19.19–$19.58 band where a director bought two ~$251k tranches on 2026-09-01/02, then closed $22.20 on 2026-09-04, back above the $21.00 weekly level lost on… Compounder · EV & autonomous mobility · Freight & logistics analysed · BH Biglari Holdings Inc. MEDIUM Seven weeks of shelf between $383.75 and $388.85 with no company news since the 2026-08-07 Q2 release; what moved is the collateral — Cracker Barrel fell to $54.69 on 2026-09-04 from $57.65 on 2026-08-21, and its estimated 2026-09-17 Q4… Special situation · Consumer discretionary rotation · M&A & special situations catalyst · BHE Benchmark Electronics MEDIUM Beat-and-raise on 2026-07-29 (rev $756M +18% YoY, AC&C +71% YoY, FY26 lifted to ~$3B/+13%) was fully sold: price round-tripped from the $98.67 52-week high to $81.75 on 2026-08-14. The AI-cooling and lidar picks-and-shovels leg is… Cyclical recovery · AI datacenter infrastructure · Cyclical industrials catalyst · BHVN Biohaven Ltd. MEDIUM The 2026-08-26 SK Biopharmaceuticals licence — $400M upfront, up to $150M milestones, mid-teens-to-low-twenties US royalties on opakalim — replaced the financing overhang with funded optionality, and the stock re-rated 13% that day to… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · BILL BILL Holdings, Inc. MEDIUM The post-print fade was retraced in five sessions: the last completed close was $50.31 on 2026-08-28 versus $47.82 on 2026-08-21, still under every mark in the $54–$60 target band set between 2026-08-20 and Wolfe's $60 on 2026-08-25. Year… Special situation · Fintech & consumer credit · AI enterprise software catalyst · BLDP Ballard Power Systems, Inc. MEDIUM The pivot is a fact with no disclosed GeoPura revenue; the first checkable figure arrives with the 2026-11-10 Q3 print, leaving a dead narrative trading an empty 30-day calendar. Special situation · Solar & clean energy · Industrial power & grid analysed · BLKB Blackbaud, Inc. MEDIUM Buyback-driven re-rating has flattened at the sell-side average: $47.10 on 2026-09-04 against $47.52 on 2026-08-21 and a $48.50 consensus target, while four officers — COO, CEO, CCO and CFO — filed open-market sales between 2026-08-06 and… Special situation · AI enterprise software analysed · BLZE Backblaze, Inc. MEDIUM Neocloud storage pick-and-shovel: the five-year ~$335M CoreWeave B2 Neo deal (2026-06-23) re-rated BLZE from the high-$7s to a 52-week high near $18, and sell-side is still chasing (Citizens to $16, 2026-07-23). Narrative accelerating but… Cyclical recovery · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · BMY Bristol-Myers Squibb Co. MEDIUM Post-guidance-reset re-rate printed a new 52-week high of $68.09 before the 2026-09-04 close of $66.82, but the first negative company headline of the leg — the zola-cel autoimmune CAR-T enrollment pause confirmed 2026-08-31 — arrived with… Special situation · Precision biotech & therapeutics · Oncology & immunology catalyst · BOLD Boundless Bio, Inc. MEDIUM Merger-arb wrapper on a cash shell: a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Eleven weeks after the 2026-06-23 announcement the Form S-4 is still absent — EDGAR's latest filing of any kind… Earnings inflection · M&A & special situations · Rare disease & gene therapy catalyst · BTU Peabody Energy Corporation MEDIUM Centurion is the whole company-specific leg: seaborne met printed $(17.0)M adjusted EBITDA on 2.5Mt in Q2 while the full-year Centurion target was cut to 2.0–2.5Mt on 2026-07-29, against group EBITDA of $24.0M. Thermal segments fund the… Special situation · Oil, energy & geopolitical · Critical materials & rare earths analysed · BWLP BW LPG Limited MEDIUM Financing leg resolved: $300M of 2.25% convertibles placed 2026-09-02, conversion price $30.4870 at a 40% premium, part-funding the $940M eight-ship HD Hyundai order without issuing shares at spot — and the stock still closed at a 52-week… Compounder · Freight & logistics · Oil, energy & geopolitical catalyst · CBLL CeriBell, Inc. MEDIUM The NTAP-funded delirium leg is intact but the flow behind it has thinned — no headline, estimate or target action since BTIG's $30 on 2026-08-18, RSI(14) off 86.0 (08-21) to 78.1 at the 2026-08-28 close of $23.73, still 4.7% under the… Defensive · Medtech & diagnostics · Managed care & health services analysed · CBRL Cracker Barrel Old Country Store, Inc MEDIUM Legacy-diner turnaround with both catalysts spent: the 2026-08-10 CEO handover passed without a repricing and no analyst has moved a target since 2026-07-28. Reference closes stepped down $57.79 (08-07) → $57.65 (08-21) → $55.66 (08-28)… Special situation · Consumer discretionary rotation · Managed care & health services catalyst · CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… Earnings inflection · M&A & special situations · AI enterprise software catalyst · CCS Century Communities, Inc. MEDIUM Post-Q2 re-rate is holding but no longer extending: the 2026-08-28 close of $69.16 is 6.2% under the $73.71 high with RSI 52.2. The 2026-08-25 new home sales print — 607k annual rate, -10.5% MoM, 9.6 months' supply — removed the demand… Compounder · Housing, homebuilders & proptech · Cyclical industrials catalyst · CERT Certara, Inc. MEDIUM The self-help leg is intact and quiet: FY26 guidance was reaffirmed at the 2026-08-04 Q2 print ($367–382M revenue, $0.31–0.36 adj EPS), the ~$13M cost takeout first shows up in Q3 numbers, and the shares have held four closes between $8.13… Special situation · AI enterprise software · Precision biotech & therapeutics analysed · CGEM Cullinan Therapeutics, Inc. MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics catalyst · CLMT Calumet, Inc. MEDIUM The eleven-week catalyst gap closed in 48 hours: 2026-09-01 cut remaining MaxSAF capital to $137M from a $1.2B plan, 2026-09-02 EPA small-refinery exemptions removed 71M RINs worth ~$170M.C. Wainwright's $75 (from $60) became the first… Special situation · Oil, energy & geopolitical · Biofuels & low-carbon fuels catalyst · CLW Clearwater Paper Corporation MEDIUM First index-level confirmation of the SBS round: Fastmarkets RISI raised its US SBS folding-carton assessment $20/ton in August (data published 2026-08-21) while other boxboard grades and containerboard stayed flat — yet price fell to… Special situation · Cyclical industrials · Semi foundry & equipment catalyst · CMBT CMB.TECH NV MEDIUM The 2026-09-03 half-year came and went and the tape extended through it: a 52-week closing high of $19.49 on 2026-09-04, RSI(14) 77.2, with no new company release on the US wire since 2026-08-27. What is left of the leg is $231.4M of… Special situation · Oil, energy & geopolitical · Freight & logistics catalyst · CMCO Columbus McKinnon Corporation MEDIUM First full combined quarter post-Kito Crosby beat hard (adj EPS $0.61 vs $0.27 est) and drove a guidance raise on all three lines on 2026-07-30; the leg being bought is deleveraging from 4.9x toward sub-4x by FY28 on $70M of synergies. No… Special situation · Cyclical industrials · M&A & special situations analysed · CME CME Group Inc. MEDIUM Listing calendar keeps thickening: wind power futures for Q4 (announced 2026-08-26) and E-mini Equity Factor futures for 2026-09-21 (announced 2026-08-27) join the 2026-08-11 slate of 24/7 silver (09-11), NHL futures (09-28) and Silicon… Special situation · Prediction markets & betting · Crypto exchanges & financials catalyst · CMPS COMPASS Pathways Plc MEDIUM Clinical binary resolved 2026-07-07; what trades now is regulatory execution — rolling NDA completion guided Q4 2026, H1 2027 launch, $433.3M cash into 2028. The 2026-09-14 FDA hearing on supervised psychedelic administration is the only… Earnings inflection · Precision biotech & therapeutics · Cannabis reclassification catalyst · COHU Cohu, Inc. MEDIUM Best fundamental print of the AI cycle (2026-07-30: rev $149M vs $144.08M cons.; Q3 guided $163–177M vs $146.33M) collided with a sector de-rate — the stock closed $52.88 on 2026-08-07, 28.5% under its $73.91 high and beneath the June… Cyclical recovery · AI datacenter infrastructure · Semi foundry & equipment analysed · COTY COTY INC MEDIUM Balance-sheet repair, not demand recovery: FY26 net debt fell to $2,912.1M but leverage still printed 3.4x as adjusted EBITDA fell 22% to $846.9M, and the 2026-08-19 print deferred FY27 guidance to the end-CY26 Consumer Beauty review. The… Special situation · Consumer discretionary rotation analysed · CRAI CRA International, Inc. MEDIUM Beat-and-raise from 2026-08-06 — record $210.8M quarter, FY26 constant-currency guide to $805–820M — remains only partly repriced: $174.99 on 2026-08-28, 20.8% under the $221.02 high, no company headline since 2026-08-08. The leg is a toll… Cyclical recovery · Managed care & health services catalyst · CRDO Credo Technology Group Holding Ltd MEDIUM Interconnect/AEC royalty narrative still accelerating, not fading — new 52-week highs on late-June initiations (Evercore $325, Stifel $350, BofA $340) plus the early-July AI-buildout rally. But it's now mainstream and widely held, entering… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · CSTL Castle Biosciences, Inc. MEDIUM The repair leg stalled rather than broke: $34.20 on 2026-08-21 to $32.91 on 2026-09-04, with no company release dated between the 08-20 conference notice and 09-04, while TissueCypher (+64% YoY in Q2) still carries the story. The… Defensive · Medtech & diagnostics · Oncology & immunology catalyst · CTOS Custom Truck One Source, Inc. MEDIUM Utility T&D / grid-capex cycle with CTOS as the laggard specialty-rental picks-and-shovels name; the June breakout to $11.36 has stalled, retracing ~10% to retest the ~$10 shelf into a binary 2026-07-29 Q2 print. Theme now maturing and… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure analysed · CTRN Citi Trends, Inc. MEDIUM The 2026-08-25 print resolved the binary the right way — comps +10.5%, gross margin 40.6% (+60bps), FY adjusted EBITDA guide lifted to $38–42M — and the shares still closed lower, because the raised FY sales range of $901.958M–$918.357M… Retail squeeze · Consumer discretionary rotation · Small-cap value rotation analysed · CTSH Cognizant Technology Solutions Corporation MEDIUM Legacy IT-services franchise re-underwritten as an enterprise-AI deployment partner; the leg still works but has run through its own consensus — the 2026-08-28 close of $64.04 sits above the $63.94 29-analyst mean, no target has been… Special situation · AI enterprise software · Cyclical industrials analysed · CXT Crane NXT, Co. MEDIUM The post-print give-back stopped rather than reversed: $50.20 on 2026-08-21 and $50.06 on 2026-09-04, RSI back to 49.5, with the $47 washout shelf untested since the 2026-08-19 $48.06 open. The sell-side anchor reset lower in the same… Special situation · M&A & special situations · Cyclical industrials catalyst · DFIN Donnelley Financial Solutions, Inc. MEDIUM Mix-shift leg intact and still untested: software was 44.3% of Q2 net sales at a record 36.7% adjusted EBITDA margin on the 2026-07-30 print, and no company release has followed in the 31 days since. Shares closed $48.32 on 2026-08-28,… Special situation · AI enterprise software · Cyclical industrials analysed · DGII Digi International Inc. MEDIUM Hardware-to-ARR re-rating accelerating: the 2026-08-05 Q3 print put ARR at $191M (+52% YoY) with a record 29.1% adj-EBITDA margin, and FY26 revenue guidance jumped to $529–533M from $490–508M. Price closed 2026-08-14 at $85.12, 0.1% off… Special situation · AI chips & memory · Bitcoin miners catalyst · DLTR Dollar Tree Inc. MEDIUM The guide-raise resolved on 2026-08-27 — FY26 adjusted EPS moved to $7.70–$8.05 from $6.70–$7.10 against a $7.04 consensus mark — and the tape paid nothing: $131.42 on 2026-09-04 versus $131.48 on 2026-08-21. With Q3 EPS guided $0.80–$0.95… Special situation · Consumer discretionary rotation · Managed care & health services analysed · DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… Earnings inflection · Oncology & immunology · Medtech & diagnostics analysed · DSGN Design Therapeutics, Inc. MEDIUM Frataxin-protein-surrogate leg: RESTORE-FA's primary endpoint is now blood FXN protein change, and Larimar's FDA alignment on skin FXN as a surrogate for accelerated approval gives that path an external precedent. The company has issued… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy analysed · DVA DaVita Inc. MEDIUM The census-recovery re-rate stayed dead through August, but the 2026-08-21 washout close of $173.82 held: DVA closed 2026-08-28 at $180.68 with RSI(14) back to 44.9 from 10.9. The 2026-08-25 Humana value-based deal (>10,000 MA members, CKD… Special situation · Managed care & health services analysed · DXC DXC Technology Company MEDIUM The AI-native pivot on a declining $12B IT-services base is being digested rather than abandoned: a fourth AI-framed launch landed 2026-08-12 (DXC Workplace Services on OASIS), then price advanced from $10.80 on 08-21 to $11.21 on 08-28… Special situation · AI enterprise software · Cyclical industrials analysed · DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · EDRY EuroDry Ltd. MEDIUM The August divergence closed the other way: BDI 3,488 on 2026-09-03 (from 2,841 on 08-21), with Panamax spot $22,113/day and Supramax $21,090/day now both above the $20,398/day Q2 TCE. EDRY closed $57.43 on 2026-09-04 at a 52-week high… Compounder · Freight & logistics · Cyclical industrials catalyst · ELF e.l.f. Beauty, Inc. MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… Earnings inflection · Consumer discretionary rotation · Managed care & health services catalyst · ENTG Entegris, Inc. MEDIUM June's sentiment re-rate rolled over; the 2026-08-04 beat-and-raise re-based the story on numbers — Q2 sales $883.2M vs $835.5M consensus, Q3 guide $905–935M vs $879.8M — and drew three target raises on 08-05 (UBS $215). At $152.08 the… Cyclical recovery · AI chips & memory · Analog semiconductors catalyst · EPC Edgewell Personal Care Company MEDIUM Two legs — a refused $30 take-private (2026-06-22) and a first positive organic quarter (fiscal Q3 +1.1%, adjusted EPS $0.72 vs $0.62) — hold the shares 2.7% under the $29.66 high at the 2026-09-04 close of $28.87. Seventy-four days on… Earnings inflection · M&A & special situations · Consumer discretionary rotation catalyst · EVER EverQuote, Inc. MEDIUM The 2026-08-03 Q2 print resolved the plateau binary bullish: revenue $195.1M (+25% YoY) broke the three-quarter ~$190M band, adjusted EBITDA hit a record $30.1M, and Q3 was guided $198–208M above the $201.6M consensus. The leg is now… Defensive · Managed care & health services · Crypto exchanges & financials catalyst · FET Forum Energy Technologies, Inc. MEDIUM Oilfield-equipment operating-leverage re-rating, still maturing: the 2026-07-30 beat ($1.16 adj EPS vs $0.56) and raised FY26 guide were reiterated at EnerCom on 2026-08-18. Everything new since is supply — four insider Form 4 sales from… Cyclical recovery · Cyclical industrials · Semi foundry & equipment analysed · FIGR Figure Technology Solutions, Inc. MEDIUM Kiavi closed 2026-09-01, eleven weeks ahead of the merger end date, and the tape did not pay for it: the 2026-09-04 close of $35.96 sits below the 2026-08-28 close of $36.05 and 51.3% under the $73.91 high. Q2 marketplace volume was $4.3B,… Cyclical recovery · Crypto exchanges & financials · Fintech & consumer credit catalyst · FLYW Flywire Corporation Voting MEDIUM Execution re-rating rather than a thematic bid: the 2026-08-04 Q2 print delivered TPV $8.2B (+38.2%) and a raised FY guide of 21–27% FX-neutral growth, and five desks marked targets up between 2026-08-05 and 2026-08-31. Price sits 5.1%… Defensive · Fintech & consumer credit · AI enterprise software analysed · FORM FormFactor, Inc. MEDIUM Probe-card pick-and-shovel to the HBM4 test ramp; after a parabolic run to a fresh $160.27 ATH (2026-06-30) on Russell 1000 inclusion, the 2026-07-02 chip selloff cut FORM ~24% to ~$121. HBM inflection intact (record DRAM quarter, second… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · FSLR First Solar, Inc. MEDIUM Section 232 supplied a new leg: the 2026-08-06 proclamation sets a $0.38/W minimum import price on modules from 2026-12-04, above the ~$0.36/W FSLR struck on Q2 US bookings. Baird upgraded 2026-08-11 with a target moved to $318 from $205.… Theme leader · Solar & clean energy · Cyclical industrials analysed · GCMG GCM Grosvenor Inc. MEDIUM The fee-annuity re-rate is intact but idling: the 2026-09-04 close of $13.27 sits 4.7% under the adjusted 52-week high of $13.93 and on the 50-day average at $13.24, with RSI(14) at 42.9 versus 75.2 on 2026-08-14. Q2 reported FRE of $50.3M… Theme leader · Crypto exchanges & financials · Biofuels & low-carbon fuels catalyst · GCT GigaCloud Technology Inc MEDIUM Back at the high on flow rather than news: the 2026-08-28 close of $52.95 is 0.6% under the 2026-08-07 high of $53.25, yet RSI(14) reads 54.1 against 85.9 at that high and no company headline has landed since the 2026-08-06 Q2 beat… Defensive · Consumer discretionary rotation · Small-cap value rotation catalyst · GEN Gen Digital Inc. MEDIUM Legacy pivot re-rating extended to a new high: the 2026-08-06 guidance raise (FY27 $5.375-5.475B) carried the adjusted close to $30.65 on 2026-09-04, 2.2% under the $31.33 52-week high with RSI 73.8, while the consensus target lifted to… Special situation · Cybersecurity · Fintech & consumer credit catalyst · GERN Geron Corporation MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · HCC Warrior Met Coal, Inc. MEDIUM Against it, Q2 index realization fell to 66% of Platts PLV from 80%. The narrative is maturing — priced into guidance since 2026-08-05, with no company-dated event before the ~2026-10-30 print. Defensive · Oil, energy & geopolitical · Critical materials & rare earths analysed · HPK HighPeak Energy, Inc. MEDIUM The post-print harvest-half story is intact but the flow behind it has thinned: HPK closed 2026-08-28 at $8.10, 2.6% under the 2026-08-21 high of $8.32, with RSI(14) back to 52.5 from 65.4, while WTI quoted $83.44. No company-dated event… Compounder · Oil, energy & geopolitical · Small-cap value rotation catalyst · HPP Hudson Pacific Properties, Inc. MEDIUM Refinancing binary now ten days out: the 10-Q (2026-08-10) fixes the Hollywood Media Portfolio loan maturity at 2026-09-09 with the longer-term extension unresolved. The equity gave back the post-print move — $14.50 on 08-21 to $13.14 on… Earnings inflection · Freight & logistics · M&A & special situations catalyst · HRB H&R Block, Inc. MEDIUM A defended-franchise cash-return story re-rated on 2026-08-11: fiscal Q4 adjusted EPS of $2.38 beat $2.21, and the FY2027 guide of $6.04–6.24 adjusted EPS topped $5.86 consensus, with 7.9% of shares retired in FY2026 at an average $47.48… Special situation · Biofuels & low-carbon fuels · Managed care & health services analysed · HRI Herc Holdings Inc. MEDIUM Second-order AI/power play: Herc rents the cranes and gensets that build data centers. Peer United Rentals raised FY26 guidance (2026-04-23), confirming an accelerating theme — but the stock sits +71% off its low and drifts into a binary… Theme leader · AI datacenter infrastructure · Industrial power & grid catalyst · HTZ Hertz Global Holdings, Inc MEDIUM The 2026-08-06 Q2 beat re-lit a squeeze the index deletion had just flushed: adjusted corporate EBITDA $81M cleared the top of a $50–80M guide, GAAP swung to +$64M, and the stock ran roughly 50% in two sessions amid 73.85%-of-float short… Retail squeeze · Squeeze & momentum setups · EV & autonomous mobility catalyst · HUBS Hubspot, Inc. MEDIUM HubSpot is trading as laggard beta on the Salesforce-led software re-rate — CRM +22.6% on 2026-08-27 — carrying HUBS from $240.01 on 08-21 to $260.68 on 08-28 with no company disclosure since the 2026-08-05 guidance reset. Price now sits… Special situation · AI enterprise software catalyst · IBTA Ibotta, Inc. MEDIUM One print re-rated the name: 2026-08-03 Q2 revenue $88.905M vs $80.062M consensus, adj EPS $0.46 vs a $(0.30) estimate, Q3 guided $86–90M vs $83.376M est. Shares gapped 21.72% on 2026-08-04 and closed 2026-09-04 at $38.39, 1.2% off the… Defensive · AI enterprise software catalyst · ICLR ICON plc MEDIUM Restatement-discount unwind has stalled: the 2026-08-28 close of $170.02 gives back part of the August advance, RSI(14) cooled from 67.2 to 56.3, and the only company communication since the 2026-08-06 notes pricing is a 2026-08-20 ESG… Cyclical recovery · Precision biotech & therapeutics · Oncology & immunology analysed · IDYA IDEAYA Biosciences, Inc. MEDIUM Three legs now: the darovasertib NDA under FDA RTOR guided complete H2 2026, the Genentech MTAP/PRMT5 tie-ups, and — new on 2026-08-31 — an FDA-agreed Phase 3 design for IDE849 in ES-SCLC. The 2026-08-31 and 2026-09-01 headlines did not… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics catalyst · IESC IES Holdings, Inc. MEDIUM Q3 FY26 (2026-07-31) resolved the post-index-inclusion fade in the bulls' favour — revenue $1.243B (+40%), backlog $4.53B (+91% since FY25 close), Communications +51% — and the 2-for-1 split distributing 2026-08-21 is the only dated event… Cyclical recovery · AI datacenter infrastructure · Industrial power & grid analysed · IKT Inhibikase Therapeutics, Inc. MEDIUM The stalled leg resolved upward on no news: IKT closed $2.50 on 2026-09-04 against a fresh 52-week high of $2.52, with RSI(14) back to 57.5 from 44.9 on 2026-08-28 and still no press release after the 2026-08-11 Q2 report. A single-asset… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · IMAX Imax Corp MEDIUM Premium-large-format royalty narrative is maturing: a second target above spot arrived (B. Riley $61, 2026-08-24) and shares set a $54.79 high, then gave back 8.0% to close $50.38 on 2026-08-28 as The Dog Stars opened to roughly $8M… Compounder · Oil, energy & geopolitical · Freight & logistics catalyst · IMOS ChipMOS TECHNOLOGIES INC. MEDIUM Memory-cycle re-rating in an AI costume just re-accelerated: June 2026 revenue +37.2% YoY and Q2 +28.7% YoY (both records since 2014, reported 2026-07-10) erase the May deceleration scare, and price bought back the ~17% fade to sit ~$68… Theme leader · AI chips & memory · Semi foundry & equipment catalyst · IMVT Immunovant, Inc. MEDIUM Single-asset FcRn story: batoclimab was discontinued after the 2026-04-02 TED Phase 3 miss, leaving IMVT-1402 plus $797.8M cash (2026-06-30) and two undated 2H CY2026 readouts (D2T RA topline, CLE proof-of-concept) ahead of 2027… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · INTA Intapp, Inc. MEDIUM Agent attach on a compliance-locked professional-firm base keeps producing dated headlines — Celeste-powered Intake/Conflicts/Time re-architecture (2026-08-19), Alt360 DealCloud distribution (2026-08-18), Legora integration (2026-08-25) —… Theme leader · AI enterprise software · AI datacenter infrastructure analysed · IPAR Interparfums, Inc. MEDIUM Nothing company-dated has landed since the 2026-08-04 print: the last covering-firm action was BWS Financial's Sell/$85 on 2026-08-17, and the 2026-09-04 close of $116.69 sits 6.1% above the $110 shelf. The 09-15 annual meeting and… Compounder · Consumer discretionary rotation catalyst · IT Gartner, Inc. MEDIUM Post-derate re-rating is holding price while the information flow stays empty: the 2026-08-28 close of $198.39 sits above every published target except BMO's $206 and above the $185.15 Hold consensus, and RSI(14) has reset from 76.7 to… Special situation · AI enterprise software · AI datacenter infrastructure catalyst · IVA Inventiva S.A. MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · JBIO Jade Biosciences, Inc. MEDIUM The July shelf near $21 broke: the 2026-09-04 close was $19.90 with RSI(14) at 24.2, and the decline from the 2026-08-21 close of $21.34 came with no Jade filing after 2026-08-14 and no release beyond the 2026-09-01 conference notice. Four… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology catalyst · JRSH Jerash Holdings (US), Inc. MEDIUM Sourcing-migration story is still two-for-two on guidance: Q1 FY2027 revenue of $50.23M (+26.7% YoY) beat consensus and the company's own guide on 2026-08-10, and Q2 is guided to $49–51M against $47.85M. Fundamentals have stood still… Retail squeeze · Consumer discretionary rotation · Small-cap value rotation catalyst · KELYA Kelly Services, Inc. MEDIUM Both macro tests cleared — the 2026-08-28 benchmark revision at -79,000 (-0.1%) was milder than the ten-year 0.2% average, and the 2026-09-04 jobs report printed +162,000 with July revised from -23,000 to +21,000. Price holds within 2.4%… Special situation · Managed care & health services · Small-cap value rotation catalyst · KEYS Keysight Technologies, Inc. MEDIUM Analyst-migration re-rate's second leg (Morgan Stanley to Overweight, PT $400, 2026-07-13) has stalled — silent tape near 28x forward, empty calendar until the ~2026-08-19 Q3 FY26 print. The $290–300 breakout-shelf entry hasn't come;… Cyclical recovery · AI datacenter infrastructure · Networking & optical catalyst · KMX CarMax Inc. MEDIUM Turnaround re-rating went live in July: KMX broke the $50–$53 shelf to close $57.33 on 2026-07-17 (+17.2% in five sessions) after a Q1 FY27 blowout (EPS $1.31 vs ~$0.95, revenue $8.01B +6.2%), CEO Keith Barr buying 9,400 shares at $53.005… Special situation · Consumer discretionary rotation · Fintech & consumer credit catalyst · KNSA Kiniksa Pharmaceuticals International, plc MEDIUM Post-print commercial re-rating has stopped receiving new information: the $980–995M FY26 ARCALYST guidance raise is 33 days old, no sell-side target has moved since 2026-07-30, and the 2026-08-12 fireside produced no number. Price closed… Defensive · Rare disease & gene therapy · Precision biotech & therapeutics analysed · LAD Lithia Motors, Inc. MEDIUM Legacy dealer group re-rating on non-store earnings: the 2026-07-29 Q2 beat ($10.03 adj EPS vs $8.78) came from Driveway Finance while same-store revenue fell 1.6%. The 2026-08-25 hire of Toyota Financial Services' former CEO over DFC, F&I… Special situation · Consumer discretionary rotation · Fintech & consumer credit analysed · LBRX LB Pharmaceuticals Inc MEDIUM Single-asset schizophrenia binary where the sell-side keeps marking up behind a flat tape: H.C. Wainwright went $45→$60 on 2026-08-24, lifting the eight-analyst average to $53.38 against a 2026-08-28 close of $47.73, while RSI(14) cooled… Earnings inflection · Precision biotech & therapeutics analysed · LGND Ligand Pharmaceuticals Incorporated MEDIUM Royalty-aggregator compounding story: Q2 (2026-08-06) royalty revenue $48.0M was +32% YoY, adj EPS $2.37 beat $1.84, and the FY26 EPS floor rose to $9.00–$9.50 with XOMA (closed 2026-07-14) adding ~$1.50 in 2027. The shares sit at $285.60,… Cyclical recovery · Precision biotech & therapeutics catalyst · LILA Liberty Latin America Ltd. MEDIUM Break-up leg holds: the adjusted series set a 52-week high of $8.77 after Morgan Stanley's 2026-08-20 cut to Underweight $7.00, and price closed $8.52 on 2026-09-04. But the flow behind the story has thinned — no company-dated headline… Defensive · M&A & special situations · Emerging markets catalyst · MASS 908 Devices Inc. MEDIUM Post-divestiture handheld chemical-detection pure play still holding the 2026-08-11 beat-and-raise re-rate: the 2026-08-28 close of $10.73 sits 3.3% under the $11.10 52-week high with RSI(14) cooled from 86.0 to 72.2. Special situation · Medtech & diagnostics · Defense & aerospace analysed · MCS The Marcus Corporation MEDIUM Theatrical-recovery re-rating is drifting sideways with no company input: no release and no target revision since 2026-08-04, leaving consensus at $32.25 while the 2026-08-28 close of $29.02 sits 6.5% under the $31.03 52-week high.… Compounder · Freight & logistics · Consumer discretionary rotation catalyst · MEI Methode Electronics MEDIUM Data-center power pivot is revenue-confirmed — record >$80M FY26 segment sales and an FY27 guide ($1.025–1.075B vs ~$952M Street) — but the post-print momentum leg has faded ~26% from the $20.38 high to ~$15. The re-rate is spent and the… Special situation · AI datacenter infrastructure · Industrial power & grid catalyst · MESO Mesoblast Limited MEDIUM FY2026 printed 2026-08-27 — revenue US$120.3M vs US$17.2M, net loss down 44% to US$57.5M, cash US$103M — and the ADR still closed $17.32 on 2026-09-04, capped by the 2026-07-15 high of $18.07. The catalyst the July leg leaned on has… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy analysed · MGTX MeiraGTx Holdings plc MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · MIRM Mirum Pharmaceuticals, Inc. MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · MNPR Monopar Therapeutics Inc. MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy analysed · MNTN MNTN, Inc. MEDIUM The post-Q2 profitability-crossover re-rating held rather than extended: the 2026-08-28 close was $13.23 versus $12.90 a week earlier while RSI(14) cooled from 91.4 to 73.2. A 2026-08-21 Texas order denying MNTN's motion to dismiss Alpha… Defensive · AI enterprise software catalyst · MYRG MYR Group, Inc. MEDIUM AI/datacenter power-buildout supercycle lifting grid/electrical contractors; MYRG confirmed it with a record Q1 and a late-June breakout to fresh ATHs (~$487) above the $484.71 shelf. Theme accelerating + cluster-confirmed, but the Q2… Cyclical recovery · Industrial power & grid · AI datacenter infrastructure catalyst · NEOG Neogen Corporation MEDIUM The first rating change of the cycle landed on 2026-08-26 — Piper Sandler to Overweight, target $14 from $13 — and the tape did not follow: $11.66 on 2026-08-28 against $11.95 on 2026-08-21 and 4.0% under the $12.15 high. Nothing… Special situation · Medtech & diagnostics · M&A & special situations analysed · NESR National Energy Services Reunited Corp MEDIUM MENA national-oil-company capex via the only US-listed pure play, re-rated by the 2026-08-05 $300M Kuwait award and the 2026-08-10 Q2 beat ($520.8M vs $446.97M). Both are fully in the tape: no sell-side target has moved since 2026-08-13,… Cyclical recovery · Oil, energy & geopolitical · Managed care & health services analysed · NGNE Neurogene Inc. MEDIUM Rett gene-therapy story stays fully financed (~$360.2M pro forma, runway into Q1 2029) and clean at 1E15 vg across N=35 at the 2026-08-10 cutoff. The 2026-09-09 IRSF community webinar is the only company-dated appearance before the… Earnings inflection · Rare disease & gene therapy catalyst · NKTR Nektar Therapeutics MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · NOG Northern Oil and Gas, Inc. MEDIUM Geopolitical crude leg — WTI $92.09 on 2026-09-03 after Hormuz tanker strikes — is repricing a levered non-op E&P that still trades 12.7% below its $29.64 52-week high. Q2 delivered $159M free cash flow and a buyback at a $20.37 average,… Compounder · Oil, energy & geopolitical catalyst · NTSK Netskope, Inc. MEDIUM Post-lockup repair leg extended on price, not on estimates: $15.09 on 2026-08-28 vs $14.51 on 2026-08-21, while the consensus target crept only $17.25 → $17.36.P. Morgan's 2026-08-26 raise stopped at $16, below the mean. The 2026-09-02 Q2… Earnings inflection · Cybersecurity · AI datacenter infrastructure catalyst · NVCR NovoCure Limited MEDIUM Post-TRIDENT commercial-inflection leg still carried by the 2026-07-23 Q2 print (rev $183.584M vs $172.437M cons., first positive adj. EBITDA $10.8M, FY guide $710–725M). Price $17.94 on 2026-09-04 is 10.3% under the $19.99 high and held… Earnings inflection · Oncology & immunology · Medtech & diagnostics analysed · NWL Newell Brands Inc. MEDIUM Post-print re-rating still shelved: the 2026-09-04 close of $6.11 sits 2.8% under the $6.29 52-week high with RSI(14) at 53.2, and the covering leg behind the 7/31 +15% is largely spent (10.52% of float short at the 2026-08-14 settlement,… Special situation · Consumer discretionary rotation · Cyclical industrials catalyst · NXT Nextpower Inc. MEDIUM Falling knife has based and turned: after a -34% unwind from the $163 high to a ~$107 June base, a fresh cluster (Truist initiate Buy $140 07-14, Guggenheim upgrade Buy 07-15) plus a 07-15 surge is re-rating the M&A-drift story. The… Theme leader · Solar & clean energy · Industrial power & grid analysed · ODTX Odyssey Therapeutics, Inc. MEDIUM First-in-class oral RIPK2 inhibitor OD-001 re-rated the story: 27% clinical remission / 61% response in Phase 2a UC (April 2026 topline), $433.1M cash into 2H 2028, and a first initiation at Buy/$44 on 2026-08-27. Price ran 68% in three… Earnings inflection · Oncology & immunology · AI datacenter infrastructure catalyst · OII Oceaneering International Inc. MEDIUM The offshore EBITDA inflection is intact — FY adjusted EBITDA guided $400–440M — but the 2026-09-04 close of $51.40 sits above the $46 four-analyst consensus target with zero Buy ratings, and RSI(14) has decayed to 36.7 from 47.7 on 08-28.… Special situation · Oil, energy & geopolitical · Physical AI & robotics catalyst · OOMA Ooma, Inc. MEDIUM The 2026-08-26 Q2 FY2027 print resolved the binary favourably: revenue $83.228M beat the ~$81.63M consensus and FY2027 guidance went to $332.0–333.5M from $326.0–328.5M, with residential revised to flat-to-up-1%. B. Riley lifted its target… Special situation · GPU cloud & neoclouds · Semi foundry & equipment catalyst · OTEX Open Text Corporation MEDIUM The growth leg died at the 2026-08-06 reset — FY27 revenue guided $5.135-5.185B versus $5.246B in FY26, adjusted EBITDA margin 32-33% versus 36.3%. What is left is cash return against a flat shelf: $807.5M FY26 free cash flow, a… Special situation · AI enterprise software · Cyclical industrials catalyst · OWL Blue Owl Capital Inc. MEDIUM Private-credit-stress bottom trade picked up a second strand: Blue Owl managed funds led a $2.4B GPU-equipment financing for IREN on 2026-08-28, days after Oppenheimer took its target to $17. Price closed $12.02 on 2026-08-28, 5% below the… Compounder · Biofuels & low-carbon fuels · AI datacenter infrastructure catalyst · OXM Oxford Industries, Inc. MEDIUM Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims — 4% of market cap,… Special situation · Consumer discretionary rotation · Small-cap value rotation analysed · PARR Par Pacific Holdings, Inc. MEDIUM Distillate scarcity is still deepening — inventories 107.1 Mbbl for the week ended 2026-08-07, reported as the lowest for the date since 1996 — and the 2026-08-25 Laramie agreement adds a non-crack cash lever, roughly $146M expected to… Compounder · Oil, energy & geopolitical analysed · PD PagerDuty, Inc. MEDIUM The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront… Special situation · AI enterprise software · M&A & special situations analysed · PENG Penguin Solutions, Inc. MEDIUM Q3 (July 7) broke the model wide open: revenue $478.7M vs $405.5M consensus (+48% YoY), EPS $0.84 vs $0.54, FY26 growth guide lifted 12%→22% and FY27 pre-guided ~30%. The stock then round-tripped from $89.86 to ~$60 on the $750M… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · PENN PENN Entertainment, Inc. MEDIUM Q2 (2026-08-06) kept the digital turnaround on schedule — interactive adj-EBITDA loss $9.5M (+$52.5M YoY), Q4-2026 profitability target and $1.963B retail EBITDAR midpoint intact — but the tape decoupled: prediction-market headlines took… Special situation · Prediction markets & betting · Crypto exchanges & financials catalyst · PESI Perma-Fix Environmental Services, Inc. MEDIUM Post-award drift with no new information: the shares closed 2026-09-04 at $18.70, 3.8% under the $19.43 52-week high, recovering from $17.30 on 2026-08-21 with zero company disclosure since 2026-08-12. The 2026-09-30 funding lapse was… Earnings inflection · Nuclear & uranium analysed · PGEN Precigen, Inc. MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · PK Park Hotels & Resorts Inc. MEDIUM BMO's 2026-09-01 upgrade to Outperform ($14→$18) was the first rating change of the cycle, but the tape did not follow: PK closed 2026-09-04 at $15.26, back on the $15.32 shelf it cleared in August and 5.6% under the $16.17 high, with… Defensive · Travel & leisure · Housing, homebuilders & proptech catalyst · PLMR Palomar Holdings, Inc. MEDIUM A cat-light Atlantic season and three FY26 guidance raises carried the reference close to $136.58 on 2026-09-04, 5.7% under the $144.79 high, with RSI(14) at 74.9 and no company-dated catalyst until the ~2026-11-03 Q3 print. The 2026-09-10… Compounder · Managed care & health services · Oil, energy & geopolitical catalyst · PNRG PrimeEnergy Resources Corporation MEDIUM Geopolitical crude bid re-fired after the 2026-07-08 US strikes and Hormuz blockade — WTI back to ~$80 from $68.86, PNRG +8.9% MTD to $186.51 and above the 200-day. Structurally better than June: GCX in-service flipped Waha gas positive,… Retail squeeze · Oil, energy & geopolitical · Small-cap value rotation catalyst · PPTA Perpetua Resources Corp. MEDIUM Funded domestic-antimony developer whose news flow stopped paying: the 2026-08-18 Idaho district court ruling largely upheld federal approvals and the 2026-08-31 update reported 5,800m drilled plus 6.4m of 16.2 g/t gold, yet the close was… Compounder · Critical materials & rare earths · Industrial power & grid analysed · PRCH Porch Group, Inc. MEDIUM Reciprocal-pivot re-rate has largely printed: $9.26 (6/5) to $15.98, now consolidating at $13.68 after KBW's 7/13 valuation downgrade that still raised its target to $16.25. Narrative intact but maturing; the 2026-08-04 Q2 print is the… Special situation · Housing, homebuilders & proptech · Managed care & health services catalyst · PRGS Progress Software Corporation MEDIUM Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a maturing low-beta compounder —… Special situation · AI enterprise software · M&A & special situations catalyst · PRM Perimeter Solutions, Inc. MEDIUM Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 — 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45.… Defensive · Managed care & health services · M&A & special situations catalyst · PTGX Protagonist Therapeutics, Inc. MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · QTWO Q2 Holdings Inc MEDIUM JPMorgan's 2026-08-24 raise to $72 from $60 removed the last published target sitting under the market, leaving a $67–$82 analyst band around the 2026-08-28 close of $65.13. The 2026-07-29 beat-and-raise (FY26 $881–886M, 28.6% adj. EBITDA… Cyclical recovery · AI enterprise software · Crypto exchanges & financials analysed · RAPP Rapport Therapeutics, Inc. MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · RCKT Rocket Pharmaceuticals, Inc. MEDIUM Price has stalled where the 2026-08-03 safety leg left it — $3.86 on 2026-09-04, unchanged from the 2026-08-28 close — with no company disclosure since the 08-10 Q2 print and three Form 144 sale notices filed 08-18. Two webcast fireside… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · RDIB Reading International Inc MEDIUM The squeeze premium in the thin voting class has deflated — the 2026-09-04 weekly close of $14.99 broke the $15 level published on 2026-08-29 by a cent — while the deleveraging leg hardened: an 8-K filed 2026-09-04 discloses a signed… Retail squeeze · Consumer discretionary rotation · Freight & logistics analysed · RELY Remitly Global, Inc. MEDIUM Operating-leverage leg intact but stalling: since the 2026-08-05 Q2 raise to $1.978–1.988B / $410–415M, the only new information has been supply — a Form 4 dated 2026-08-26 shows CFO Mehta selling 25,000 shares at $26.15, one dated… Compounder · Fintech & consumer credit · Crypto exchanges & financials catalyst · RGEN Repligen Corporation MEDIUM Bioprocessing-recovery rerating now carries a deal overhang: the 2026-07-28 beat-and-raise (adj EPS $0.54 vs $0.45; FY26 sales to $813–835M) took RGEN within 3.2% of its $182.03 high, but the BioLife merger S-4 went effective and the… Cyclical recovery · Freight & logistics · Medtech & diagnostics catalyst · RLYB Rallybio Corporation MEDIUM The S-4/A filed 2026-08-26 marks Rallybio Net Cash at ~$82.2M as of 2026-08-15 but still leaves the record date and meeting date blank, so no timetable is public. The cash discount stays inverted while burn runs and the clock has no fixed… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · RMAX Re/Max Holdings, Inc. MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… Earnings inflection · M&A & special situations · Housing, homebuilders & proptech analysed · RRGB Red Robin Gourmet Burgers, Inc. MEDIUM Deleveraging turnaround repricing: ~$96M / 116-unit refranchising cuts net debt ~$147M→~$51M, removing the going-concern tail that pinned RRGB near $2.46. Tape +38.7% since the ~2026-05-20 Q1 print, into the low-$7s near the $7.89 high.… Special situation · Consumer discretionary rotation catalyst · SAP SAP SE MEDIUM Post-Q2 repair leg took its first downgrade and held: UBS cut SAP to Neutral on 2026-08-26 over slow agentic-AI delivery, and the ADR round-tripped the drop within two sessions to close $221.54 on 2026-08-28, helped by Salesforce's… Theme leader · AI enterprise software · Small-cap value rotation analysed · SBSW Sibanye-Stillwater MEDIUM Record H1 (EBITDA R31.8bn +111%, net debt/EBITDA 0.18x) and an interim dividend at the top of policy re-rated a de-geared PGM producer; then the 2026-09-03 USW walkout at Stillwater — the only US primary palladium mine — put palladium… Compounder · Critical materials & rare earths · Cybersecurity catalyst · SE Sea Limited MEDIUM Three-engine re-acceleration — Shopee GMV +30%, Monee loan book +71%, Garena's best quarter in 5 years — drove a Q1 beat (2026-05-12) and a +19% one-month recovery off the $77 low. Fundamentally accelerating, but the stock is short-term… Compounder · Emerging markets · Fintech & consumer credit catalyst · SEPN Septerna, Inc. MEDIUM Post-print breakout failed: the 2026-09-04 weekly close of $36.75 lost the $38 shelf top and put price back inside the July $33.10–$38.04 range, RSI(14) at 15.3, with no adverse company news since the 2026-08-10 Q2 beat. Six broker targets… Defensive · Precision biotech & therapeutics catalyst · SKM SK Telecom Co., Ltd. MEDIUM The funding overhang that framed this name closed on 2026-08-27: KKR and the IMM–Stonebridge consortium signed for ₩3.08T of equity into SK Horizon, the AIDC entity being carved out of SK Broadband, with SKT keeping 51% — asset-level… Special situation · AI datacenter infrastructure · Emerging markets catalyst · SMRT SmartRent, Inc. MEDIUM RSI(14) cooled 87.8→74.7 while price only slipped $1.49→$1.43, so the momentum extreme unwound sideways. Still no dated catalyst until the ~November Q3 print. Special situation · Small-cap value rotation · Housing, homebuilders & proptech analysed · SMWB Similarweb Ltd. MEDIUM CEO supply continued and was absorbed: a 2026-08-27 Form 4 reports 383,127 option shares sold at ~$9.00–$9.05, taking two-week insider sales to 1,092,724 shares, yet the 2026-09-04 close of $8.84 sits 7.3% above the 08-21 low close. The… Special situation · AI enterprise software · AI datacenter infrastructure analysed · SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics catalyst · SNEX StoneX Group Inc. MEDIUM The momentum leg stayed dead, but the tape stopped breaking: closes ran $64.85 on 2026-08-11 to $69.46 on 2026-09-04 with RSI(14) back to 53.9. New since the last note is the 2026-08-26 8-K authorizing repurchase of up to 5.0M shares for… Special situation · Crypto exchanges & financials · Prediction markets & betting catalyst · SOPH SOPHiA GENETICS SA MEDIUM Cloud-genomics platform story from the 2026-08-04 Q2 print (net dollar retention 117% vs 107%, FY26 guide up to $94–96M, AstraZeneca two-programme CDx deal) is now maturing: the shares eased to $8.09 on 2026-09-04, 9.3% off the $8.92 high,… Theme leader · Medtech & diagnostics · AI enterprise software catalyst · SPSC SPS Commerce, Inc. MEDIUM De-rating-repair leg: Q2 (2026-07-30) beat on adjusted EPS $1.27 vs $1.09 with EBITDA +19% on 6% revenue growth, while the FY26 revenue band was cut on the 2026-06-30 3P divestiture. Price reclaimed the ~$70 200-day, but the fresh Morgan… Special situation · AI enterprise software · Freight & logistics analysed · STTK Shattuck Labs, Inc. MEDIUM Receptor-side TL1A: SL-325 delivered the first human data for a DR3-blocking antibody on 2026-06-08 — complete receptor occupancy at 0.1 mg/kg, anti-drug antibodies in 3.7% of dosed subjects — and the shares are up 74.1% over three months.… Compounder · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · SYNA Synaptics Incorporated MEDIUM Standalone story ended at the 2026-06-25 all-stock takeout; At the 2026-09-04 closes the gross discount compressed to ~1.4% (1.350 × $74.38 = $100.41 vs $98.99), a fourth consecutive tightening mark, while EDGAR showed no S-4 amendment as… Earnings inflection · M&A & special situations · Analog semiconductors analysed · TBLA Taboola.com Ltd. MEDIUM Legacy open-web ad network repricing as a toll booth on AI answer surfaces: the 2026-06-16 DeeperDive ad-network launch (35% take rate, open to third-party LLMs/agents) plus the 2026-07-01 Wikitree win drove a breakout to 52-week highs… Special situation · AI enterprise software · AI datacenter infrastructure catalyst · TNXP Tonix Pharmaceuticals Holding Corp. MEDIUM Tonmya's second full launch quarter printed ~$11.0M net sales and 12,592 prescriptions (+100% QoQ) on 2026-08-10, roughly 1.75x the $7.723M revenue consensus, while the stock closed 2026-09-04 at $13.14 — 57.9% under its $31.21 52-week… Defensive · Precision biotech & therapeutics · Small-cap value rotation catalyst · TOI The Oncology Institute, Inc. MEDIUM Delegated-capitation pivot confirmed at the 2026-08-06 Q2 print — FY26 guide raised to $650–670M, and management said capitated revenue should roughly double in 2027 off ~$150M — but the re-rating is decaying: $7.05 high on 2026-08-07,… Special situation · Managed care & health services · Small-cap value rotation catalyst · TRVI Trevi Therapeutics, Inc. MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · TTMI TTM Technologies, Inc. MEDIUM The 2026-08-05 binary resolved bullishly — Q2 revenue $1.004B beat both the $930–970M guide and $962M consensus, book-to-bill rose to 1.49, Q3 guided $1.100–1.140B vs $1.073B consensus. Yet the 2026-08-14 close of $140.0 is 36.8% below the… Cyclical recovery · AI datacenter infrastructure · Defense & aerospace analysed · ULCC Frontier Group Holdings, Inc. MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… Earnings inflection · Travel & leisure · Oil, energy & geopolitical catalyst · UNH Unitedhealth Group Incorporated MEDIUM Margin-repair re-rating in the largest US managed-care book: FY26 adjusted EPS guidance was raised to $19.50–$20.00 on 2026-07-16, yet the 2026-09-04 close of $397.14 sits 9.0% below the $436.35 52-week high with a three-month price change… Special situation · Managed care & health services analysed · UROY Uranium Royalty Corp. MEDIUM The equity cooled from $4.38 (2026-08-21, RSI 79.9) to $4.25 (2026-08-28, RSI 55.3), leaving a maturing narrative whose only company-dated test is the first combined-company report, estimated ~2026-09-14. Cyclical recovery · Nuclear & uranium · Precision biotech & therapeutics catalyst · USO United States Oil Fund, LP MEDIUM The driver rotated: Rubio's 2026-08-25 shift from strikes to sanctions drained the escalation bid, but EIA's 0.095M bbl crude build vs 1.600M expected (08-26) and oil rigs -5 to 447 vs 454 est (08-28) carried USO to $129.70. The narrative… Earnings inflection · Oil, energy & geopolitical · Freight & logistics catalyst · VCYT Veracyte, Inc. MEDIUM Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev… Cyclical recovery · Medtech & diagnostics · Oncology & immunology catalyst · VEEV Veeva Systems Inc. MEDIUM Post-print re-rating: the 2026-08-26 Q2 FY27 beat (revenue $928.0M +18%, 44.8% non-GAAP operating margin, FY27 guide raised to $3,682–3,687M) contradicted the Salesforce CRM-share-loss story that had taken the shares to $185.91 on… Theme leader · AI enterprise software · Medtech & diagnostics catalyst · VET Vermilion Energy Inc. MEDIUM European gas made new highs without the equity: TTF printed a three-year high above €68/MWh on 2026-08-25 while the shares closed 2026-08-28 at $12.46, below their 2026-08-21 close and 13.0% under the $14.32 high. With 58% of European gas… Compounder · Oil, energy & geopolitical catalyst · VG Venture Global, Inc. MEDIUM LNG-export narrative re-accelerating on Europe's winter gas scramble plus a Middle East risk premium; VG ran +23% off the $12 mid-July shelf to $14.31 as Plaquemines ramps and CP2 advances. The 2026-08-11 pre-market Q2 print is the binary… Compounder · Oil, energy & geopolitical · AI datacenter infrastructure catalyst · VIA Via Transportation, Inc. MEDIUM Busted-IPO transit-software re-rating, now a month past its trigger: the 2026-08-06 beat-and-raise carried the shares from $19.41 (2026-07-31) to $28.13 (2026-09-04), but the pace has slowed to +4.2% over the ten sessions since 2026-08-21… Defensive · EV & autonomous mobility · AI enterprise software analysed · VIOT Viomi Technology Co., Ltd MEDIUM Compliance-clock recovery: after the 2026-07-22 Nasdaq sub-$1 deficiency notice, the ADSs closed 2026-09-04 at $1.14, and 10 consecutive closes at or above US$1.00 convert the deficiency into a written compliance confirmation before the… Earnings inflection · Consumer discretionary rotation · Semi foundry & equipment analysed · WDAY Workday, Inc. MEDIUM The 2026-08-27 print removed the fundamental leg of the bear case — cRPO +14.2% inside the guided 13.5–14.5% band, FY27 margin guide lifted to 31.0%, a new $4.0B buyback — while the Q3 cRPO guide of 11–12% sits under the ~13.3% consensus.… Earnings inflection · AI enterprise software catalyst · WEX WEX Inc. MEDIUM Hated fuel-card/fintech inflecting: the 2026-07-22 Q2 beat (Adj EPS $5.35 vs $5.05) and FY26 guide raise to $19.68-$20.08 discredit the EV-kills-fuel-cards and rate-cut-kills-float bear case; PTs jumped to $200-210 (Mizuho/KBW, 7/24).… Special situation · Fintech & consumer credit · Cyclical industrials catalyst · WIX Wix.com Ltd. MEDIUM Base44 margin inversion is the live leg and the market is now paying up for it: after the 2026-08-04 beat ($563.1M, +15%; adj EPS $1.39 vs $1.16) and the ~60% 2H gross-margin guide, price ran from the 2026-08-07 close of $60.20 to $66.14… Special situation · AI enterprise software · AI datacenter infrastructure catalyst · WK Workiva Inc. MEDIUM The post-Q2 earnings-power re-rate has pulled the sell-side up with it: Stifel moved $70→$95 on 2026-08-27 and Baird $74→$95 on 2026-09-01, both above the 2026-09-04 close of $76.55. RSI(14) cooled from 77.1 to 65.1 while price barely… Special situation · AI enterprise software · Binary-catalyst biotech catalyst · WNC Wabash National Corp. MEDIUM The regulatory binary resolved in Wabash's favour: Commerce's final China AD/CVD determinations came back affirmative with a 2026-08-24 CVD determination date (FR 2026-17749/17750, publication scheduled 2026-08-31), leaving the duty wall… Special situation · Cyclical industrials · Freight & logistics catalyst · XGN Exagen Inc. MEDIUM Post-print re-rating off the 2026-08-04 Q2 beat (revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M) is now digesting rather than extending: $7.92 on 2026-08-21 to $7.58 on 2026-09-04 with RSI(14) cooling from 86.7 to… Defensive · Medtech & diagnostics analysed · YETI YETI Holdings, Inc. MEDIUM Tariff-margin-recovery turnaround now getting sell-side confirmation: Goldman upgraded to Buy/$63 on 2026-07-20 (vs Canaccord's $45 Hold a month earlier), pushing YETI through the $51.89 multi-year high. The leg still hinges on the… Special situation · Consumer discretionary rotation · Freight & logistics catalyst · YEXT Yext, Inc. MEDIUM The 2026-09-01 binary resolved mixed: non-GAAP EPS $0.21 beat the $0.17 estimate and adjusted EBITDA hit $34.0M (30.6% margin), but revenue $111.103M missed $111.300M consensus and ARR was flat at $440.8M for a second straight quarter.… Special situation · AI enterprise software catalyst · ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · ZBRA Zebra Technologies Corporation MEDIUM The 2026-08-04 guidance-raise re-rating (adj EPS $6.35 vs $4.36; FY26 EPS to $20.75–$21.25) has gone sideways rather than broken: the 2026-09-04 close of $362.74 sits 5.3% under the $383.06 high with RSI(14) back to 44.5 from 76.4, and… Theme leader · AI enterprise software · Physical AI & robotics catalyst · ZETA Zeta Global Holdings Corp. MEDIUM Palantir Foundry re-platforming now has a management clock — phase one guided complete within 30–40 days of the 2026-07-06 Citi event, landing on the ~2026-08-04 Q2 print. Price reclaimed the $21 shelf that capped the June recovery (+14%… Theme leader · AI enterprise software catalyst · ZIP ZipRecruiter, Inc. MEDIUM Q2 print on 2026-08-05 put revenue at $118.1M (+5% YoY, +10% QoQ) with Quarterly Paid Employers +12% sequentially and adjusted EBITDA margin at 12% vs 8% a year earlier, alongside a debt reduction of more than half — a trough-reversal read… Special situation · Managed care & health services · AI datacenter infrastructure catalyst · ZURA Zura Bio Limited MEDIUM Pipeline-breadth re-rating still unpaid: the 2026-08-11 Q2 print added polymyalgia rheumatica as a third tibulizumab indication and Wedbush ($22) plus Guggenheim ($20) re-rated on 2026-08-12, yet the 2026-08-28 close of $5.72 sits 18.8%… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · ZYME Zymeworks Inc. MEDIUM The 2026-08-25 FDA approval of Ziihera in first-line HER2+ gastroesophageal cancer converts Zymeworks from a burn-funded developer into a milestone-and-royalty recipient — a $250M payment from Jazz against $322.5M of cash at 2026-06-30,… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · AAON AAON, Inc. LOW Beat-and-raise on 2026-08-10 (Q2 sales $627.0M, +101.2%; FY guide up to $2.235–2.307B) landed with gross margin 24.3% vs 26.6% and the FY margin guide cut to 25–26%. Targets were cut the next day and the entire 2026-05-07 re-rating gap has… Cyclical recovery · AI datacenter infrastructure · Cybersecurity catalyst · ABEO Abeona Therapeutics Inc. LOW The post-print drift has continued without repair: the 2026-08-28 close of $5.92 sits two cents above the $5.90 shelf the prior note named as the break, with RSI(14) at 21.8 and no Abeona press release at all between 2026-08-13 and… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · ABNB Airbnb, Inc. LOW The post-Q2 re-acceleration re-rating has reached its loudest phase — two $220 targets (DA Davidson 08-31, Rosenblatt initiation 09-01) and a dedicated CNBC spotlight on 08-27 — while the 2026-09-04 close of $181.94 sits 4.5% under the… Compounder · Consumer discretionary rotation · AI enterprise software catalyst · ACDC ProFrac Holding Corp. LOW Brent pushed above $96 on 2026-09-03 as the US resumed strikes on Iran and Hormuz transit fell to roughly 4.9 mb/d, yet ACDC closed $5.15 on 2026-09-04, still under its 2026-08-14 close of $5.37. The crude-beta leg has now failed on two… Earnings inflection · Oil, energy & geopolitical · Managed care & health services catalyst · ACHC Acadia Healthcare Company, Inc. LOW Second consecutive weekly close under the surrendered $30.20 shelf ($28.13 on 2026-09-04) with no company-dated catalyst before the est. late-October Q3 print. The FY26 guide (adj. EBITDA $590–615M) is intact, but reported short interest… Special situation · Managed care & health services catalyst · ACHR Archer Aviation Inc. LOW The 2026-08-10 Boeing re-rating has failed outright: the 2026-09-04 close of $5.71 sits below the $6.26 pre-announcement reference the deal leg was measured against, and neither the 2026-08-24 AEG vertiport agreement nor the 2026-09-03 "No… Compounder · Defense & aerospace · Physical AI & robotics analysed · ACLS Axcelis Technologies, Inc. LOW Axcelis has stopped falling without being re-bid: $115.57 on 2026-08-28 to $115.08 on 2026-09-04, RSI(14) down to 22.0, 39.9% under the $191.6 high. What is left is a de-rated implant franchise plus an undated China SAMR ruling into the… Earnings inflection · Semi foundry & equipment · AI chips & memory catalyst · ACMR ACM Research, Inc. LOW The base break published 2026-08-16 has held without extending: the 2026-09-04 close of $74.44 is two cents above the 2026-08-28 weekly close and still under the $76.29 June base low close, with RSI(14) down to 32.8 and no company-dated… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure analysed · ACN Accenture PLC LOW The post-crash mean-reversion leg stalled once its funding stopped: the $7.5B buyback's dated demand ended 2026-08-31, price closed $186.72 on 09-04 against $189.61 on 08-28, and Morgan Stanley carried a Hold at $130 on 09-03. Nothing… Special situation · AI enterprise software · Managed care & health services catalyst · ADI Analog Devices, Inc. LOW Q3 FY2026 delivered the AI-content proof — revenue $4.02B +40% YoY, Communications +84%, Q4 guided $4.3B ±$100M — but the bid never arrived: Broadcom's 2026-09-02 AI beat and raise (AI revenue $16.7B, Q4 guided $21.7B) left ADI at $362.25… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · ADSK Autodesk, Inc. LOW The asset-operations re-rating leg broke: after the 2026-08-27 beat-and-raise, ADSK fell 4.28% on 2026-08-28 and a further 8.26% to a $217.90 close on 2026-09-04 with no company release attached, taking out the $250 weekly level. Nine… Special situation · AI enterprise software · Housing, homebuilders & proptech catalyst · ADTN ADTRAN Holdings, Inc. LOW The ADVA margin-recovery re-rate has fully round-tripped and nothing replaced it: with no company release since 2026-08-11, the close walked from $7.72 on 2026-08-28 to $7.10 on 2026-09-04 at RSI(14) 16.7 — the drawdown's most oversold… Special situation · Networking & optical · Cyclical industrials analysed · AEM Agnico Eagle Mines Ltd. LOW Gold-equity operating leverage intact, but the macro sponsorship broke on 2026-08-28: Fed Chair Warsh's Jackson Hole "we have work to do" line took over 3% out of gold and reset the shares from $216.06 to $206.25, RSI(14) 91.9 to 66.6. The… Compounder · Critical materials & rare earths · Housing, homebuilders & proptech catalyst · AFRM Affirm Holdings, Inc. LOW The +80%-off-March recovery re-rate has matured and rolled over: Morgan Stanley pulled its Overweight ('valuation call') on 2026-06-25, and price faded ~30% from the $100 high back onto the reclaimed 200-day near $70 while targets stayed… Compounder · Fintech & consumer credit · Consumer discretionary rotation catalyst · AGX Argan, Inc LOW AI-data-center gas-EPC theme still accelerating (4.1+ GW gas backlog, $973.6M cash, zero debt), but AGX has round-tripped from the $805.75 ATH to $563, losing both the ~$675 breakout and ~$600 shelves. Mean reversion toward the pre-run… Cyclical recovery · AI datacenter infrastructure · Industrial power & grid catalyst · AGYS Agilysys, Inc. LOW Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that… Special situation · AI enterprise software analysed · AIP Arteris, Inc. LOW Q2 (2026-08-06) beat and raised — revenue $24.1M +46%, TTM variable royalties $8.6M +65%, FY26 guide lifted to $95-98M — and the stock still closed $28.32 on 2026-08-14, 41.7% under the 6/30 high. The $33 weekly break fired while the… Cyclical recovery · AI chips & memory · AI datacenter infrastructure catalyst · AIRO AIRO Group Holdings, Inc. LOW The drone-tariff leg failed on its own date: Section 232 took effect 2026-09-03 but Blue UAS-listed products got a 180-day deferral to ~2027-02-09, and price broke the $8.00 level to close $7.40 on 2026-09-04 with RSI(14) at 25.1. What is… Earnings inflection · Defense & aerospace · Small-cap value rotation catalyst · AKBA Akebia Therapeutics, Inc. LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… Earnings inflection · Precision biotech & therapeutics catalyst · ALGM Allegro MicroSystems, Inc. LOW The June AI data-center power-attach re-rate has flipped from being marked up to marked down: TD Cowen cut its target to $66 (2026-07-13) and Barclays downgraded to Equal-Weight at $48 (2026-07-20), the first target below the June range —… Cyclical recovery · Analog semiconductors · AI datacenter infrastructure analysed · ALHC Alignment Healthcare, Inc. LOW Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares… Earnings inflection · Managed care & health services · Small-cap value rotation catalyst · ALLE Allegion Public Limited Company LOW Post-Q2 gap still open but the bid behind it has drained: $157.12 on 2026-09-04 with RSI(14) at 39.3, down from 51.9 on 2026-08-21, and price now 4.6% under the $164.75 consensus target with no broker off Neutral since the 2026-07-23… Special situation · Housing, homebuilders & proptech · AI datacenter infrastructure catalyst · ALMS Alumis Inc. LOW The lupus leg is gone: LUMUS missed BICLA at Week 48 and every secondary in the overall 408-patient population on 2026-09-01, and the stock closed 2026-09-04 at $11.10 with RSI(14) at 18.2, 63.4% below the $30.30 high. What is left is a… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · ALNT Allient Inc. LOW Record-orders story intact — Q2 2026 bookings $201.3M (+49% YoY), 1.31x book-to-bill, backlog $298.0M — but the supply picture changed after the note: the CEO's trusts sold 70,000 shares at $112.49–$115.765 on 2026-08-10 and 13D holder… Cyclical recovery · Cyclical industrials · Physical AI & robotics analysed · ALTO Alto Ingredients, Inc. LOW Ethanol-to-specialty/low-carbon pivot re-rated ~6x off $0.92, but both fuel catalysts — the June 45Z cash sale and the Russell index add — are spent, and price has round-tripped from the $6.11 July high to ~$4.64, losing the $5.10-$5.20… Special situation · Biofuels & low-carbon fuels · Cyclical industrials catalyst · AMBQ Ambiq Micro, Inc. LOW Q2 (2026-08-11) net sales $33.9M, +89.7% YoY and a $36–37M Q3 guide above the $34.0M Street have bought nothing: the 2026-09-04 close of $57.45 sits 36.5% under the $90.48 high with RSI(14) at 31.7. A Form 4 filed 2026-09-02 shows the CEO… Defensive · AI chips & memory · Small-cap value rotation analysed · AMKR Amkor Technology, Inc. LOW A second anchor — the $1.5B Nvidia advanced-packaging/test partnership (2026-07-23) stacked on the 2026-06-16 TSMC 10-yr Arizona deal — is re-rating Amkor from single-customer Apple OSAT toward US AI back-end anchor. But every catalyst… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · AMN AMN Healthcare Services LOW Healthcare-staffing cyclical recovery, real but maturing and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading… Special situation · Managed care & health services · Prediction markets & betting catalyst · AMRX Amneal Pharmaceuticals, Inc. LOW Legacy-generics-to-specialty re-rate is intact on fundamentals — 2026-07-30 Q2 beat, second FY2026 raise, Kashiv closed 2026-08-10 — but the tape has bled to a 2026-09-04 close of $17.44 with RSI(14) 31.4, and the 2026-09-03 shelf… Special situation · Precision biotech & therapeutics analysed · ANAB AnaptysBio, Inc. LOW Single-question Chancery stub: the next dated docket step is the defendants' answering brief on 2026-09-25, while June-quarter results are still absent from the public record through 2026-09-06 and momentum has decayed — RSI(14) 38.7 at… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · AOSL Alpha and Omega Semiconductor Limited LOW Post-parabola digestion. The Apr–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully priced, above the $30.50 consensus PT with no fresh company catalyst in 11+ weeks; the 2026-07-15 pop was a newsletter-driven volume spike,… Cyclical recovery · AI datacenter infrastructure · AI chips & memory analysed · APH Amphenol Corporation LOW AI-interconnect content leg unchanged since the 2026-07-29 print — orders $10.7B, book-to-bill 1.23:1, Q3 guided above consensus — but the bid has not come back: $157.74 on 2026-08-28 is flat on the week while RSI(14) slid from 43.4 to… Cyclical recovery · AI datacenter infrastructure · Analog semiconductors catalyst · APPS Digital Turbine, Inc. LOW Post-Q1 re-rating story: the 2026-08-05 print showed revenue $166.0M (+27% YoY), App Growth Platform +56%, adjusted EBITDA +69%, and FY2027 guidance raised to $650–670M — but the shares have given back most of the 43% pop and closed… Special situation · AI enterprise software · Precision biotech & therapeutics analysed · ARCT Arcturus Therapeutics Holdings Inc. LOW Platform-repossession re-rating extended: the CSL exit returned global KOSTAIVE plus flu/RSV/EBV rights with $12M cash and ~$16M of released liabilities against $191.5M cash, and the shares have run 95.5% in three months to a 2026-08-28… Earnings inflection · Oncology & immunology catalyst · AREC American Resources Corporation LOW Critical-minerals refining milestones keep landing at affiliated ReElement — Marion air permit 2026-08-19, seven commercial hires 2026-08-24, Critical Minerals Institute platinum membership 2026-09-03 — with no bid behind them: $2.43 on… Cyclical recovery · Critical materials & rare earths analysed · ARES Ares Management Corporation LOW Private-credit compounder still saturated rather than broken: FRE compounding near 20% YoY on $671B AUM while the 2026-09-04 close of $140.15 sits 21.3% under the $178.13 trailing high. Nothing resolved since 2026-08-23 — Leonard Green… Compounder · Biofuels & low-carbon fuels · Semi foundry & equipment catalyst · ARHS Arhaus, Inc. LOW The $9.00 weekly-close level that defined the post-2026-08-06 repricing has gone: the week ending 2026-08-28 closed at $8.98 with no new company disclosure, leaving the +12.5% written-comp inflection intact on paper but unbid. Two… Defensive · Consumer discretionary rotation · Freight & logistics catalyst · ASX ASE Technology Holding Co., Ltd. LOW Advanced-packaging pricing power is real — quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm — but the tape topped at $45.51 the same day and sits ~15% lower inside a 13% semi… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure catalyst · ATEN A10 Networks Inc LOW AI-security re-rate off the 2026-06-15 TrojAI deal has stalled: ATEN churning ~$35 below the $37.36 ATH, momentum cooling as Mizuho lifts its target to $34 but stays Neutral — analyst catch-up, not fresh conviction. The 2026-08-05 Q2 print… Theme leader · AI datacenter infrastructure · Networking & optical analysed · ATHM Autohome Inc. LOW No company disclosure since the 2026-08-20 print; what moved is the research around it — Citi lifted its target from $17 to $22 on 2026-08-24, Goldman from $19 to $21, and consensus now reads $21.44, below the 2026-09-04 close of $22.03.… Special situation · Emerging markets · Crypto exchanges & financials catalyst · AUTL Autolus Therapeutics plc LOW The post-raise re-rating has stalled. After the 2026-08-03 guidance raise to $140–150M and the 2026-08-11 Q2 beat ($45.7M vs $34.0M consensus), the shares set a $2.54 52-week high and then closed $2.24 on 2026-09-04 with RSI(14) back at… Defensive · Oncology & immunology · Rare disease & gene therapy analysed · AVR Anteris Technologies Global Corp. LOW Post-catalyst drift: the CMS/first-patient/France de-risking sequence is spent, and Q2 (reported 2026-08-12) missed both lines — EPS $(0.30) vs $(0.21), revenue $1.009M vs $1.500M — yet the 2026-08-14 close held $9.40 with RSI 66.9.… Defensive · Medtech & diagnostics · Oncology & immunology catalyst · AVTR Avantor, Inc. LOW The post-print re-rating extended a third leg: $14.97 on 2026-09-04 versus $14.58 on 2026-08-28, now 4.0% under the $15.60 52-week high, with RSI(14) back up to 71.2 and no company press release since 2026-07-29. Price sits above six of… Special situation · Medtech & diagnostics · Precision biotech & therapeutics analysed · AVXL Anavex Life Sciences Corp. LOW The two overhangs cleared — both delinquent 10-Qs filed 2026-08-28, Nasdaq compliance confirmed 2026-09-02 — and the shares still fell from $3.24 on 2026-08-21 to $2.86 on 2026-09-04. What is left is the 2026-09-24 contested vote: PVG's… Earnings inflection · Binary-catalyst biotech · Crypto exchanges & financials catalyst · BABA Alibaba Group Holding Limited LOW The cloud re-rating leg has become a funding-and-litigation question: the high-$118s shelf broke and the week ended 2026-09-04 closed $113.24, $1.24 above the $112 line, while September delivered a securities-fraud complaint (S.D.N.Y.,… Compounder · AI enterprise software · AI datacenter infrastructure catalyst · BAK Braskem S.A. LOW The subsidiary perimeter resolved first: Braskem Idesa's prepackaged Chapter 11, filed 2026-08-17 in SD Texas, cuts over US$920M of debt and leaves existing shareholders one-third of reorganized equity, with a combined disclosure-statement… Earnings inflection · Emerging markets · M&A & special situations catalyst · BAND Bandwidth Inc. LOW Late-stage small-cap CPaaS squeeze: +360% YoY into the mid-$70s, ~5% below the $79.08 high, with Citizens ($86, 2026-07-20). Riley ($85) both lifting targets in July. A confirmed Q2 print on 2026-07-29 is a binary two trading days out —… Retail squeeze · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · BB BlackBerry Limited LOW Q1 FY27 gave the pivot real numbers (QNX $72.3M vs the $60-64M guide, FY27 raised to $594-621M), but the parabola broke: after a $13.59 high the stock fell ~37% to ~$8.54 on a meme unwind plus insider selling. Narrative maturing, price… Retail squeeze · AI enterprise software · Cybersecurity catalyst · BBBY Bed Bath & Beyond, Inc. LOW Lemonis "Everything Home" roll-up keeps closing deals — Container Store now wholly owned (2026-07-08), TwoPonds folded in (2026-07-01) — but the tape has bled from $5.83 to ~$4.96 and sits on the $4.26 52-week low as shares balloon past… Special situation · Cyclical industrials · Crypto exchanges & financials catalyst · BBY Best Buy Company, Inc. LOW Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop… Special situation · Consumer discretionary rotation · AI datacenter infrastructure catalyst · BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · BEEM Beam Global LOW Beam Global is repricing from EV-charging hardware toward a drone/defence/AI-data-centre battery supplier after the 2026-08-19 Q2 beat ($8.562M vs $8.193M consensus; -$0.14 vs -$0.20 est.) and a 22.7% after-market move to $1.49. Attention… Special situation · EV & autonomous mobility catalyst · BHC Bausch Health Companies Inc LOW The post-print round trip is complete: the 2026-07-29 beat-and-raise (adj EPS $1.26 vs $1.04 consensus) carried BHC to a $7.90 high and the 2026-08-28 close of $6.32 handed all of it back. What is left is roughly $2.4B of equity on… Special situation · Precision biotech & therapeutics · Binary-catalyst biotech analysed · BIOA BioAge Labs, Inc. LOW ESC Congress came and went 2026-08-28 to 08-31 with no ZEUS dataset and no substitute venue named, so the mechanism question stays open into the only binary left — QUELL-CV hsCRP topline guided to 2H 2026. The sole company action since the… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology catalyst · BIRK Birkenstock Holding plc LOW The $36 weekly break played through: the last completed close was $34.00 on 2026-09-04 with RSI(14) at 28.4, leaving the May 2026 low of $31.12 as the only structure left in the fiscal-year range. Guidance still reads 15% cc growth and… Defensive · Consumer discretionary rotation catalyst · BJRI BJ's Restaurants, Inc. LOW The momentum leg is finished: a 2026-09-04 weekly close at $59.89 gave back the $60.77 pre-print shelf and the whole 2026-07-30 guidance-raise re-rating, with no analyst revision since 2026-07-31. What is left is a reset case — Q2 comps… Special situation · Consumer discretionary rotation · Small-cap value rotation catalyst · BKNG Booking Holdings Inc. LOW The published $200 weekly level failed — the 2026-09-04 close was $193.29, giving back the whole post-Q2 advance while the covering board widened to 37 analysts at an average $236.70 target. What remains is a saturated capital-return… Compounder · Travel & leisure · AI enterprise software catalyst · BKSY BlackSky Technology Inc. LOW Gen-3 subscription ramp landed in Q2 (2026-08-06): revenue $33.316M vs $30.68M est, +50% YoY, adjusted EBITDA $4.7M, FY26 guide affirmed at $130–150M. But EPS missed at $(0.54) vs $(0.36), cash is $36.9M against a $50–60M capex guide, and… Defensive · Space economy · Defense & aerospace catalyst · BMA Banco Macro S.A. LOW The company story is still broken — Q2 NPLs 6.25%, coverage 95.39%, FY cost of risk guided to 6.5–7% on 2026-08-20 — but the ADR recovered to $78.57 on 2026-09-04 from $72.84 on 2026-08-21 as country risk fell from 517bp to below 500 on… Compounder · Emerging markets catalyst · BRBR BellRing Brands, Inc. LOW The $10.40 weekly-close shelf broke by a cent on 2026-09-04 at $10.39, with RSI(14) at 52.6 — a reset from drift rather than from a bid. The company news room has been silent on corporate items since the 2026-08-04 Q3 EBITDA cut to… Defensive · Consumer discretionary rotation catalyst · BRKR Bruker Corporation LOW Post-ASMS instrument re-rate broke back toward the $64.54 high and added a second leg: semiconductor-metrology strength (orders +20% YoY) pulled Leerink to $70 and top targets to $65–70. But at ~$62 the name sits ~13% over its 50-DMA and… Special situation · Medtech & diagnostics · AI chips & memory catalyst · BROS Dutch Bros Inc. LOW Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the… Defensive · Consumer discretionary rotation analysed · BSIN Big Sky Industrial Inc. LOW Helium/45Q legacy pivot at a new high — $1.54 on 2026-09-04, 2.5% off the $1.58 52-week high — with no company disclosure since the 2026-08-20 Sidoti deck, leaving a maturing narrative whose next dated test is the Q3 print (~2026-11-10).… Special situation · Oil, energy & geopolitical · Industrial power & grid analysed · BTBT Bit Digital, Inc. LOW Both legs of the wrapper are now rolling over: WhiteFiber (WYFI, ~70.5% owned) de-rated from $38.50 to $27.57 as the June neocloud mania cooled, and BTBT slid to ~$1.50, a step above its $1.25 low. SOTP discount still ~49% (~$745.6M WYFI… Special situation · GPU cloud & neoclouds · AI datacenter infrastructure catalyst · BTDR Bitdeer Technologies Group LOW Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the… Special situation · Bitcoin miners · AI datacenter infrastructure analysed · BTE Baytex Energy Corp. LOW July's Hormuz flare re-armed the oil-geopolitical premium, but it has since drained — WTI slipped to the low $70s and the 2026-07-17 sanctions wind-down passed with no barrel shortage, a contained-conflict bid rather than a supply shock.… Compounder · Oil, energy & geopolitical catalyst · BVS Bioventus Inc. LOW The M&A leg from the 2026-08-05 unsolicited-proposal disclosure is intact but undated: 17 sessions, no committee update, and price back to the 2026-08-28 close of $13.84, 9.3% under the $15.26 high, with RSI(14) unwound 70.5 → 58.1 → 47.9.… Earnings inflection · Medtech & diagnostics · Managed care & health services analysed · BWIN The Baldwin Insurance Group, Inc. LOW Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,… Earnings inflection · Semi foundry & equipment analysed · BXC BlueLinx Holdings Inc. LOW The re-rating leg broke: the 2026-08-28 close of $79.42 lost the $80 shelf and sits under the whole $83–$84 target band raised 2026-08-05/06, while July new home sales at 607,000 SAAR (-10.5% MoM, Census 2026-08-25) cut against the Q3… Cyclical recovery · Housing, homebuilders & proptech catalyst · CABA Cabaletta Bio, Inc. LOW Autoimmune CD19 CAR-T reset story, now funded — $225.1M cash at 2026-06-30, runway into mid-2027 — but registrational RESET-Myositis data are guided to mid-2027 and the BLA to 2H27, so no clinical datapoint resolves inside 30 days.… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · CACI CACI INTERNATIONAL CLA LOW The post-guide re-rate is unwinding rather than extending: the 2026-09-04 close of $623.61 gave up the ~$646 post-print shelf, RSI(14) has fallen from 82.3 on 2026-08-13 to 41.0, and the 2026-09-01 stopgap funds the Pentagon only to… Special situation · Defense & aerospace catalyst · CAKE Cheesecake Factory Incorporated (The) LOW Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the… Special situation · Consumer discretionary rotation catalyst · CAL Caleres Inc LOW Q2 was pulled forward one day to 2026-09-09 (announced 2026-09-01), compressing the read into a single session: FY2026 consensus of $1.62 adjusted EPS sits at the top of the company's own $1.40–$1.65 guide, Famous Footwear is guided down… Earnings inflection · Consumer discretionary rotation · Small-cap value rotation catalyst · CARG CarGurus, Inc. LOW The post-print re-rate keeps bleeding out: $38.98 on 2026-08-07 to $36.56 on 2026-08-28, RSI(14) down to 44.0, with the $39.03 high unretaken. Seven bank targets sit at $39–$44 and no bank has moved a rating; five insiders sold in August… Special situation · Managed care & health services · Consumer discretionary rotation catalyst · CCXI Churchill Capital Corp XI LOW De-SPAC humanoid pure-play still bleeding premium: $17.07 (2026-08-14) → $14.57 (2026-08-21) → $13.40 (2026-09-04), RSI(14) down to 25.9. The only company-dated item since the 2026-07-14 confidential S-4 is an 2026-08-27… Earnings inflection · M&A & special situations · Physical AI & robotics catalyst · CDNL Cardinal Infrastructure Group Inc. LOW Post-blowoff digestion is deepening: the ~4x data-center site-work roll-up has bled from a $96 high back to its $63 average analyst target, now below the $73 secondary price and the 50-DMA. Q1 organic +64% and an $854M backlog keep… Cyclical recovery · AI datacenter infrastructure · Cyclical industrials catalyst · CDW CDW Corporation LOW Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is… Theme leader · AI datacenter infrastructure · AI enterprise software catalyst · CECO CECO Environmental Corp. LOW 2nd-order AI-power name — Q1 orders +97% YoY and a first-ever >$1B backlog (2026-04-28) feed the datacenter/electrification capex wave, and the closed Thermon merger doubled EBITDA. But price rolled over ~25% off the $101.24 ATH to $75.63,… Theme leader · AI datacenter infrastructure · Industrial power & grid catalyst · CERS Cerus Corporation LOW Two lower weekly closes now sit under the broken $2.70 shelf — $2.65 on 2026-08-28, then $2.59 on 2026-09-04 — with RSI(14) at 24.3 and an empty news tape behind the decline. The operating record is unchanged (FY26 product guide $229–231M,… Special situation · Precision biotech & therapeutics · Small-cap value rotation analysed · CEVA CEVA, Inc. LOW Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets,… Cyclical recovery · AI chips & memory · Physical AI & robotics catalyst · CGC Canopy Growth Corporation LOW The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,… Earnings inflection · Cannabis reclassification · Consumer discretionary rotation catalyst · CHYM Chime Financial, Inc. LOW Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating… Earnings inflection · Fintech & consumer credit catalyst · CLDX Celldex Therapeutics, Inc. LOW Single-asset binary: the Phase 3 EMBARQ-CSU1/CSU2 topline guided to September/October 2026 is the entire equity, and the window opens within days. The pre-readout re-rating is built and cooling — $39.12 on 2026-08-28, 12.8% under the… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · CLFD Clearfield, Inc. LOW The May earnings-miss squeeze has fully round-tripped to a dead tape in the mid-$30s, below the ~$36 gap base, with the retail-sentiment narrative spent. The sole live driver is the 2026-08-05 fiscal-Q3 print — guided to a sharp sequential… Retail squeeze · Networking & optical · AI datacenter infrastructure catalyst · CLOV Clover Health Investments, Corp. LOW The $4.00 shelf named as the break has held — a 2026-09-04 close of $4.25 with RSI(14) back to 48.9 from 36.3 — but the leg is now event-dependent: CMS's Eleventh Circuit opening brief leads with a venue argument that could vacate the… Earnings inflection · Managed care & health services · Binary-catalyst biotech catalyst · CLPT ClearPoint Neuro, Inc. LOW Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72… Cyclical recovery · Medtech & diagnostics · Rare disease & gene therapy catalyst · CLS Celestica, Inc. LOW AI-datacenter EMS picks-and-shovels story still fundamentally climbing after the 2026-04-27 Q1 crush (rev +53% to $4.05B, FY26 guide raised to $19B), but the tape broke ~21% off its $474 June high and heads into a binary 2026-07-27 Q2… Cyclical recovery · AI datacenter infrastructure · Cyclical industrials analysed · CNMD CONMED Corporation LOW Fifty-seven days have passed without a process headline: the 2026-07-10 sale report is still the only leg, and price has started giving ground — $49.32 on 2026-09-04 against the $51.07 close of 2026-08-21, back onto the August shelf. No… Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · COCO The Vita Coco Company, Inc. LOW Q2 FY26 (2026-07-23) beat on every line — net sales $216.2M +28.1%, EPS $0.82 vs ~$0.55, FY guide raised to $790–805M — and the stock still closed $62.25 on 2026-08-07, -25.9% from the post-print high. Beat-and-raise absorbed by sellers;… Compounder · Consumer discretionary rotation · Cybersecurity analysed · CODI Compass Diversified LOW The post-Q2 re-rating is being given back: after a 2026-08-11 high of $12.71 on TD Cowen's $12.50→$18. Riley's upgrade to $15, price closed $11.45 on 2026-08-28 with no company-dated catalyst before the ~2026-11-02 Q3 print. Four insiders… Special situation · M&A & special situations · Consumer discretionary rotation analysed · COMP Compass, Inc. LOW Now stretched into a binary ~2026-07-29 Q2 print ($4.0–4.2B guide) with an open NY AG antitrust probe. Special situation · Housing, homebuilders & proptech · Cyclical industrials catalyst · CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · CPIX Cumberland Pharmaceuticals Inc. LOW Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical… Special situation · M&A & special situations · Precision biotech & therapeutics analysed · CRL Charles River Laboratories International, Inc. LOW The August demand-recovery repricing is complete and the leg now rests on one date: the 2026-09-24 Investor Day, where long-term financial targets get reset. The 2026-09-04 close of $288.5 sits 3.4% under the $298.58 52-week high with… Special situation · Medtech & diagnostics · Precision biotech & therapeutics catalyst · CROX Crocs, Inc. LOW Legacy-brand turnaround with the raised guide intact and the tape still unwinding: after the 2026-07-30 beat-and-raise (FY2026 adj EPS $13.70–$14.00), closes went $131.72 (08-14) → $122.11 (08-21) → $117.53 (09-04), RSI(14) 26.9, -16.8%… Special situation · Consumer discretionary rotation · Cyclical industrials catalyst · CRS Carpenter Technology Corp LOW Aero-defense superalloy pricing cycle intact (three contracts at >30% hikes; Q4 op-income guide $205-210M, +37% YoY), but the July flush to $532 has been bought back to ~$603 straight into the 2026-07-30 Q4 print — now four sessions out… Cyclical recovery · Defense & aerospace · Critical materials & rare earths catalyst · CRTO Criteo S.A. LOW Takeover-premium leg is dead and nothing replaced it: 55 days after the 2026-07-06 Vista/Quinti report no party has confirmed anything, and the freshest headlines are a Huber Research double downgrade (2026-08-24) and a Zacks cut to Strong… Earnings inflection · M&A & special situations · AI enterprise software analysed · CRVS Corvus Pharmaceuticals, Inc. LOW The 2026-08-27 Blood publication put final Phase 1 numbers on soquelitinib — median OS 28.1 months, 9 responses among 24 less-pretreated patients at 200 mg BID — and the tape did not pay for it: $14.16 on 2026-08-28 versus $14.46 on 08-21,… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · CSCO Cisco Systems, Inc. LOW Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4… Special situation · AI enterprise software · Networking & optical catalyst · CSIQ Canadian Solar Inc. LOW The reshoring re-rating broke at the 2026-08-27 print: Q2 EPS -$1.40 vs -$1.18 consensus, Q3 revenue guided $1.3–1.5B against $1.813B consensus, and the 2026-08-28 close of $13.14 is under the $14 shelf. What replaces it is a policy leg —… Special situation · Solar & clean energy · Cyclical industrials catalyst · CVLG Covenant Logistics Group, Inc. LOW The margin-inflection leg broke at its own catalyst: Q2 (2026-07-29) adjusted OR 95.9% vs 94.6% PY — second straight quarter of YoY deterioration — revenue $332.9M missed $340.4M, and Stephens cut its 23-day-old target to $54 on 07-31.… Defensive · Freight & logistics · Managed care & health services catalyst · DDD 3D Systems Corporation LOW June's $50M raise at $3.05 (16.4M sh) is already underwater: shares last $2.775 (2026-07-02), below the offering floor, with ~$50M shelf undrawn and soft Q2 guidance (rev $93–95M, adj. EBITDA still negative) into the 2026-08-10 print. A… Special situation · Critical materials & rare earths · Defense & aerospace analysed · DFDV DeFi Development Corp. LOW Levered Solana proxy still trading below the SOL it holds — 0.66× on The Block's 2026-09-06 page — but the funding mix flipped: the 2026-09-04 pricing of 1,375,000 perpetual preferred shares at $8.00 against a $10.00 stated amount, at a… Compounder · Crypto exchanges & financials catalyst · DFTX Definium Therapeutics, Inc. LOW Voyage hit at p<0.0001 on 2026-08-12 and the tape has sold it since: $40.98 on 2026-08-28 versus the $46.14 pre-readout close, RSI 39.8, the $48.45 high untouched. Panorama topline (245 participants, 2:1:2, 50 µg arm) is guided to… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · DIOD Diodes Incorporated LOW The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through… Theme leader · Analog semiconductors · AI datacenter infrastructure analysed · DJT Trump Media & Technology Group Corp. LOW Fusion pivot is the leg: the 2025-12-18 all-stock TAE Technologies merger (>$6B, ~50/50 fully diluted) is what's actually being bought, while the crypto-treasury leg was terminated 2026-08-07. The S-4 was still unfiled as of 2026-08-05,… Special situation · Cyclical industrials · AI datacenter infrastructure analysed · DNTH Dianthus Therapeutics, Inc. LOW The August re-rate has rolled over on no news: the last Dianthus disclosure is the 2026-08-04 Q2 print, and the 2026-08-28 close of $105.84 sits 8.7% under the $115.96 high with RSI(14) at 41.9 versus 56.6 a week earlier. Nothing… Earnings inflection · Rare disease & gene therapy · Oncology & immunology catalyst · DNUT Krispy Kreme, Inc. LOW The asset-light conversion is intact — net leverage 5.4x at Q2 versus 7.5x a year earlier — but the August promotional bid faded before its own catalyst ended, closing $3.38 on 2026-09-04 against $3.59 on 2026-08-21 with the Pokémon… Retail squeeze · Consumer discretionary rotation · M&A & special situations catalyst · DOCN DigitalOcean Holdings, Inc. LOW The $113 weekly-close condition broke: the week ending 2026-08-28 closed at $111.21, under the 200-day reported at $113.47 and the $117.54 July placement price. Q2 (2026-08-04) still accelerated — revenue +29% YoY, AI ARR $234M +212%, RPO… Theme leader · GPU cloud & neoclouds · AI datacenter infrastructure analysed · DOCU DocuSign, Inc. LOW Legacy e-signature base re-wrapped as AI agreement management: IAM at 12.6% of ARR (2026-04-30) against a ~18% fiscal-year-end target, while total growth is guided to ~8%. The 2026-09-03 Q2 print is the binary, and it arrives with the… Special situation · AI enterprise software · Cyclical industrials catalyst · DRD DRDGOLD Ltd. LOW The RSI(14) 91.0 spike that followed the 2026-08-19 FY2026 beat has drained to 64.4, with the ADR at $28.58 on 2026-09-04 against the $30.70 post-print close of 2026-08-21 — a give-back that tracked dollar gold ($4,633.90 quoted… Compounder · Critical materials & rare earths · Crypto exchanges & financials catalyst · DUOT Duos Technologies Group, Inc. LOW The pivot is now structural: the rail subsidiary was sold 2026-08-05 (related party — interim CFO owns 50% of the buyer), leaving an edge-colocation operator carrying a 2026-07-16 five-year 10 MW hyperscaler contract worth >$111M. The tape… Special situation · AI datacenter infrastructure · GPU cloud & neoclouds catalyst · DXCM DexCom, Inc. LOW CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is… Defensive · Medtech & diagnostics · Precision biotech & therapeutics analysed · DXYZ Destiny Tech100 Inc. LOW June-30 NAV printed 2026-08-28 at $34.30 vs $24.56 at Q1, and the 2026-08-28 close of $34.74 sits on top of it — the scarcity premium is gone. What remains is a levered call on Anthropic's Sept/Oct listing with a $1B Jefferies ATM economic… Retail squeeze · AI datacenter infrastructure · Space economy analysed · EFOR Everforth, Inc. LOW Legacy IT-services base re-rating on an AI-delivery pivot, now in its quiet stretch: the post-print overbought condition fully unwound — RSI(14) 94.5 on 2026-08-07 to 46.7 at the 2026-08-28 close of $31.95 — while price held a ~2.3% band.… Special situation · Defense & aerospace · AI enterprise software catalyst · ELVN Enliven Therapeutics, Inc. LOW Funded, FDA-aligned pre-pivotal CML story whose sell-side re-rating leg is spent: ten houses now publish $64–$82 targets, yet the 2026-08-28 close of $57.86 is 5.4% under the $61.15 high with RSI(14) down to 42.4 from 76.4 on 08-07. No… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · ELVR Elevra Lithium Limited LOW The August leg failed at the print: the ADR closed $59.09 on 2026-08-28 versus $67.76 on 2026-08-21, even as the FY26 report guided FY27 production to 198,000–210,000 dmt against FY26's 197,967 dmt and GFEX carbonate settled CNY 158,700/t… Compounder · Critical materials & rare earths · Cyclical industrials analysed · ENOV Enovis Corporation LOW Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the self-help story, but price has rolled over from $34 toward $27 while three brokers cut targets.… Special situation · Medtech & diagnostics · Cyclical industrials catalyst · ENPH Enphase Energy, Inc. LOW IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled — stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST… Special situation · Solar & clean energy · Industrial power & grid analysed · ENVA Enova International, Inc. LOW Credit normalisation plus 20%+ origination growth is intact, but the re-rating has rolled over: $232.72 on 2026-08-28 is 12.3% under the $265.45 high with RSI 35.3, and the late-August slide was sector-wide (OneMain -4.9%, Credit… Compounder · Fintech & consumer credit · Biofuels & low-carbon fuels catalyst · EPAM EPAM SYSTEMS, INC. LOW Compounder narrative broken on 2026-08-06: FY26 organic constant-currency growth cut to 2.0%–3.0%, Q3 guided to ~1.7% YoY. Price has stalled rather than extended lower ($99.90 close 2026-08-11 vs $97.43 on 2026-08-07), but the AI-native… Special situation · AI datacenter infrastructure catalyst · EQNR Equinor ASA LOW European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a $1.125B buyback bid. Defensive · Oil, energy & geopolitical · Cybersecurity catalyst · ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… Earnings inflection · Oncology & immunology · Binary-catalyst biotech analysed · ERO Ero Copper Corp. LOW August's squeeze re-rating has been handed back: the 2026-09-04 close of $34.90 sits 13.6% under the $40.40 high, with three rating cuts in four sessions (BTG Pactual and Bradesco BBI 09-01, Freedom Broker 09-04, the last while raising its… Cyclical recovery · Critical materials & rare earths · Industrial power & grid catalyst · EVH Evolent Health, Inc LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… Earnings inflection · Managed care & health services · Oncology & immunology analysed · EXFY Expensify, Inc. LOW Legacy expense-SaaS pivot re-rated on the 2026-08-06 Q2 print: revenue $33.9M beat $33.688M, paid-member decline halved to -2% YoY, FY26 FCF guide doubled to $12M-$14M, ~7% of shares retired, and New Expensify ARR from net-new customers… Special situation · AI enterprise software · Fintech & consumer credit analysed · EXLS ExlService Holdings, Inc. LOW Post-refinancing re-rating has stalled: the 2026-08-21 close of $37.53 was never exceeded, price sat at $36.63 on 2026-09-04 with RSI(14) easing 71.1 to 65.1, and the 2026-09-02 exit of insurance/healthcare head Vivek Jetley to Hexaware… Theme leader · AI enterprise software · Managed care & health services analysed · EXTR Extreme Networks, Inc. LOW Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still accelerating but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull… Special situation · Networking & optical · AI enterprise software catalyst · FAC Factorial Energy Inc. LOW Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania — down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217%… Defensive · Solar & clean energy · Freight & logistics analysed · FBIN Fortune Brands Innovations, Inc. LOW Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays… Special situation · Housing, homebuilders & proptech · Cyclical industrials catalyst · FCEL FuelCell Energy, Inc. LOW Street targets re-rated up to the price rather than the reverse: average PT $22.83 across 8 analysts vs the 2026-08-07 close of $20.43, after B. Riley $13→$32 (6/29) and UBS $22→$27 (7/14). The AI-power bid still works (7/30 Microsoft… Retail squeeze · AI datacenter infrastructure · Industrial power & grid catalyst · FIG Figma, Inc. LOW Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,… Earnings inflection · AI enterprise software catalyst · FIVN Five9, Inc. LOW Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26… Special situation · AI enterprise software · AI datacenter infrastructure catalyst · FN Fabrinet LOW Optical cluster re-accelerated in July (AAOI +390% YTD, LITE +138%, COHR +107%) while Fabrinet sits ~$478, +0.7% YTD and ~36% under its $748.89 high. Revenue compounds at +30% but the tape has decoupled from its own theme — a… Cyclical recovery · Networking & optical · AI datacenter infrastructure analysed · FOSL Fossil Group, Inc. LOW The 2026-08-12 beat-and-raise has been fully given back: the 2026-08-28 close of $5.35 sits beneath the $5.38 pre-print close, and the $6.09 52-week high still predates the news. The margin turnaround is proven and absorbed — two analysts… Special situation · Consumer discretionary rotation · Small-cap value rotation catalyst · FOUR Shift4 Payments, Inc. LOW Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary… Earnings inflection · Fintech & consumer credit · Travel & leisure catalyst · FPS Forgent Power Solutions, Inc. LOW Second secondary in five weeks — ~43.6M shares at $49 on July 2, now including company primary dilution — confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The… Theme leader · Industrial power & grid · AI datacenter infrastructure catalyst · FRD Friedman Industries Inc. LOW Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the… Defensive · Cyclical industrials · Managed care & health services catalyst · FSLY Fastly, Inc. LOW The post-Q2 re-rating leg has round-tripped: $27.69 intraday on 2026-08-10, an 8.1% drop on 2026-08-24 to $22.94, and a 2026-08-28 close of $23.04 sitting eight cents above the pre-spike 2026-08-07 close of $22.96. Insider selling… Special situation · AI enterprise software · AI datacenter infrastructure analysed · FTRE Fortrea Holdings Inc. LOW The 2026-09-02 all-cash ~$45M purchase of Worldwide's early-phase unit was the first company-dated news since the 2026-07-29 Q2 print, and the tape handed it back: $18.81 on 2026-08-28 to $17.70 on 2026-09-04, with the July $17.73–$18.49… Special situation · Binary-catalyst biotech · Managed care & health services catalyst · FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… Earnings inflection · Cyclical industrials · Freight & logistics analysed · G Genpact Limited LOW Agentic-operations pivot keeps compounding in the segment data — ATS +24.1% to $363M, FY guide lifted to at least 25% on 2026-08-06 — while the 73% legacy book grew 1.9% and caps consolidated growth near 7%. The 10-Q filed 2026-08-07… Special situation · AI enterprise software · Managed care & health services catalyst · GCO Genesco Inc. LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… Earnings inflection · Consumer discretionary rotation catalyst · GDRX GoodRx Holdings, Inc. LOW Legacy-marketplace pivot: Pharma Direct +76% YoY and subscriptions +39% now carry the story while prescription transactions fall 26%, but the 2026-08-05 guidance raise to $790–805M has a bid — shares closed $3.48 on 2026-09-04, 30.8% under… Special situation · Managed care & health services · Precision biotech & therapeutics analysed · GENI Genius Sports Limited LOW Sports-data toll-booth under the prediction-market boom, but the boom arrived and the toll didn't: Kalshi/Polymarket cleared $50B+ of World Cup volume (Coindesk, 2026-07-14) while GENI slid $6.43 → $6.30 and printed $5.98 intraday July 17.… Cyclical recovery · Prediction markets & betting · AI datacenter infrastructure catalyst · GFI Gold Fields Ltd ADR LOW Margin-to-cash story intact from H1 (2026-08-25: $2.225bn adjusted FCF, dividend +132%, realised $4,678/oz), but the macro leg inverted on 2026-09-04 when 162k August payrolls against ~53k expected pushed September hike odds to roughly 65%… Compounder · Critical materials & rare earths catalyst · GFS GlobalFoundries Inc. LOW Photonics/CHIPS delivery kept accelerating — comms/data-center revenue +62% YoY in Q2 (2026-08-05), $300M Commerce LoI 2026-07-29 — while the multiple collapsed 39.2% from the $89.83 52wk high to $54.58 on 2026-08-14. What's on offer is a… Cyclical recovery · Semi foundry & equipment · Networking & optical catalyst · GGAL Grupo Financiero Galicia S.A. LOW Argentina disinflation is still working — June CPI printed 1.9% MoM on Jul 14, an improvement on May's 2.1% — but the ADR faded the good print, dropping ~7% on the week to ~$50 and losing both the $51.07 50-day and the $52.86 200-day.… Compounder · Emerging markets catalyst · GLUE Monte Rosa Therapeutics, Inc. LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… Earnings inflection · Precision biotech & therapeutics · Oncology & immunology catalyst · GOLF Acushnet Holdings Corp. LOW Premium-golf consumable franchise (Titleist Pro V1) that ran to a $119.65 all-time high on a defensive-quality rotation, then bled ~11% of the mania premium back to the ~$104–105 June breakout shelf ($104.66 on 2026-07-24). The 2026-08-06… Compounder · Consumer discretionary rotation · Cybersecurity catalyst · GRND Grindr Inc. LOW Q2 beat-and-raise (2026-08-06: revenue $138.1M +33%, FY guide ~$540M) has fully round-tripped — $15.25 on 2026-09-04, inside the July shelf and 15.0% under the $17.94 high. Two new dated items: the UK group action resolved 2026-09-02 for… Special situation · Fintech & consumer credit · AI enterprise software catalyst · GRPN Groupon, Inc. LOW Squeeze narrative failed rather than resolved: the reported short base fell to 12.68M shares (69.00% of float, 8.19 days to cover, 2026-09-05) from 13.73M while the stock slid from $19.59 to $18.87 — covering into weakness. The $18 shelf… Retail squeeze · Squeeze & momentum setups · Consumer discretionary rotation catalyst · GSHD Goosehead Insurance, Inc. LOW The post-print re-rating rolled over: the 2026-09-04 close of $65.21 gives back most of the August leg after director/10%-owner Serena Jones sold 29,750 Class A shares at $67.56–$70.15 on 2026-08-19/20, the Form 4 signed on the same… Earnings inflection · Managed care & health services · Housing, homebuilders & proptech analysed · GSM Ferroglobe PLC LOW US trade-remedy leg: the 2026-08-03 USITC affirmative vote forces AD/CVD orders on Australian and Norwegian silicon metal, on top of Angola/Laos orders live since 2026-03-17. Q2 (2026-08-04) delivered the sequential recovery — $13.1M adj… Cyclical recovery · Critical materials & rare earths · AI chips & memory catalyst · GTM ZoomInfo Technologies Inc LOW Legacy B2B data business trying to re-price as the data layer under AI go-to-market agents. The 2026-08-05 post-print gap is intact but unextended — $3.97 on 2026-08-21, RSI(14) cooled 76.9→58.9 — and the 2026-08-11 Microsoft Copilot MCP… Special situation · AI enterprise software · AI datacenter infrastructure catalyst · GTN Gray Media, Inc. LOW August's double catalyst — the FCC's 2-1 repeal of the 39% ownership cap (2026-08-06) and the Q2 beat-and-raise (2026-08-07) — keeps decaying: the 2026-08-28 close of $4.83 sits 20.5% under the $6.07 52-week high with RSI(14) at 45.6… Special situation · Fintech & consumer credit · Precision biotech & therapeutics analysed · GTX Garrett Motion Inc. LOW Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · GWRE Guidewire Software, Inc. LOW The pre-print re-rating resolved on 2026-09-03: FY2026 ending ARR of $1,242M cleared the $1,229-1,237M guide, but the FY2027 ARR guide of $1,450-1,460M implies ~18% growth against 19% delivered, and the shares fell roughly 20% on… Theme leader · AI enterprise software · GPU cloud & neoclouds analysed · HELE Helen of Troy Limited LOW Deleveraging stub coiling rather than breaking: HELE closed $28.40 on 2026-09-04, fractionally under a 50-day line that has risen to $28.43, still 6.0% below the 2026-08-14 closing high of $30.22, while short interest built to 13.14% of… Special situation · Consumer discretionary rotation · M&A & special situations catalyst · HELP Cybin Inc. LOW Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No… Retail squeeze · Precision biotech & therapeutics · Cannabis reclassification catalyst · HIMX Himax Technologies, Inc. LOW A guide-beating Q2 (2026-08-06) and a $43 Baird mark have still not bought a bid: $13.64 on 2026-08-28, 42.7% under the $23.79 high, RSI(14) 38.7, with the $13 May-gap shelf immediately below. No company-dated event falls inside 30 days —… Theme leader · AI enterprise software · Analog semiconductors analysed · HIVE HIVE Digital Technologies Ltd. LOW BTC-miner→AI-compute re-rating has its first blue-chip proof — BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR — but the stock stalled ~$3.79 below its early-June highs as BTC bled ~45-50% off… Special situation · Bitcoin miners · GPU cloud & neoclouds catalyst · HMY Harmony Gold Mining Company Limited LOW The August momentum leg has round-tripped: 2026-08-27 results paired a record 1,280c FY26 dividend (R8.15bn) with FY27 guidance of 1.30–1.40 Moz at R1.30–1.395m/kg, both softer than FY26's 1,429,551 oz at R1,191,698/kg. What is left is a… Compounder · Critical materials & rare earths · Industrial power & grid catalyst · HOV Hovnanian Enterprises, Inc. Class A LOW The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter… Earnings inflection · Housing, homebuilders & proptech · Cyclical industrials catalyst · HROW Harrow, Inc. LOW Show-me on an H2 ramp with nothing company-dated to resolve it before the ~November Q3 print: the reaffirmed $350–365M FY2026 guide needs the back half to roughly double H1's $114.9M against $292.4M loans payable net, and sell-side FY… Earnings inflection · Precision biotech & therapeutics · Managed care & health services catalyst · HTLD Heartland Express, Inc. LOW The margin-recovery leg printed on 2026-07-30 (operating ratio 91.0% vs 105.9%) and drew no lasting bid: price slid from $12.84 on 2026-08-21 to $12.44 on 2026-09-04, RSI 43.9, at the bottom of the August $12–$13 band, while freight… Special situation · Freight & logistics · Cyclical industrials analysed · HURN Huron Consulting Group Inc. LOW AI-disruption discount still unwinding, but the bid has stopped widening: the 2026-08-28 close of $159.84 is below the 2026-08-21 close of $161.64, no analyst has moved a target since 2026-07-29, and Huron has published nothing since the… Theme leader · AI datacenter infrastructure · Managed care & health services analysed · IART Integra LifeSciences Holdings Corporation LOW Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only… Special situation · Medtech & diagnostics analysed · ICHR Ichor Holdings LOW Memory-capex WFE subsystem re-rating broke on the 2026-08-03 Q2 print: revenue $294.8M missed $300.2M consensus, the $78 June shelf failed, and the 2026-08-07 close was $68.32 against a $112.28 high. Q3 guidance still beats ($315–345M vs… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… Earnings inflection · M&A & special situations · Cyclical industrials analysed · IMRX Immuneering Corporation LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · INDI indie Semiconductor, Inc. LOW Automotive ADAS-silicon design-win story keeps improving on paper ($7.4B backlog, $25M radar order, ams OSRAM sensor buy) while the tape stays broken below the ~$4.00 50-day MA; TD Cowen's 2026-07-13 lift to a $4.50 Hold is a thaw, not a… Cyclical recovery · Analog semiconductors · AI chips & memory catalyst · INFQ Infleqtion, Inc. LOW Funded-quantum leg keeps extending while the tape does not: B. Riley initiated Buy with a $23 target on 2026-09-04, the third published target above $20, yet the 2026-09-04 close of $12.85 sits within a penny of the 2026-08-14 close of… Compounder · Quantum computing catalyst · INHD Inno Holdings Inc. LOW The residual balance-sheet case broke on its own published level: the 2026-09-04 weekly close of $4.53 is under the $4.75 flagged on 2026-08-29, and the CFO who signed the 2026-08-18 10-Q left the board and the finance seat effective… Retail squeeze · Squeeze & momentum setups · Oil, energy & geopolitical catalyst · INNV InnovAge Holding Corp. LOW The 2026-09-08 Q4/FY2026 print — company-confirmed on 2026-08-26, after the close — is the binary: FY2026 adjusted EBITDA against the raised $85–90M guide, and first FY2027 guidance into the rate headwind KeyBanc flagged alongside its… Special situation · Managed care & health services · Consumer discretionary rotation catalyst · INOD Innodata Inc. LOW AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16… Cyclical recovery · AI enterprise software · AI datacenter infrastructure catalyst · IPX IperionX Limited LOW US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue,… Compounder · Critical materials & rare earths · Defense & aerospace catalyst · IQ iQIYI, Inc. LOW Long-form streaming growth is broken in the reported numbers (Q1 2026 revenue -13% YoY, operating income to a RMB228.4m loss), so what is left is the micro-drama/overseas pivot — newly branded as Undercurrent Theater in early August 2026 —… Special situation · Semi foundry & equipment · Squeeze & momentum setups analysed · IRWD Ironwood Pharmaceuticals, Inc. LOW Third straight fortnight of drift: $4.29 on 2026-08-21 to $4.26 on 2026-09-04, RSI 46.8, 21% under the $5.39 high, with the raised 2026-08-06 FY26 guide (revenue $460–485M, adjusted EBITDA above $310M) attracting no new bid. A deleveraging… Earnings inflection · Precision biotech & therapeutics · M&A & special situations catalyst · JACK Jack In The Box Inc. LOW June's move was a float mechanic — Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price… Retail squeeze · Squeeze & momentum setups · Consumer discretionary rotation catalyst · JBLU JetBlue Airways Corporation LOW Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B… Earnings inflection · Travel & leisure · Oil, energy & geopolitical analysed · JELD JELD-WEN Holding, Inc. LOW JELD-WEN's post-2026-08-03 re-rating has stalled: the 2026-09-04 close of $2.30 is back below the 2026-08-28 close of $2.53, RSI(14) has cooled from 71.2 to 61.0, and no company disclosure has landed since the 2026-08-05 analyst updates.… Earnings inflection · Housing, homebuilders & proptech catalyst · JOBY Joby Aviation, Inc. LOW eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment… Earnings inflection · EV & autonomous mobility · Defense & aerospace catalyst · JWEL Jowell Global Ltd. LOW Low-float China e-commerce microcap that repriced +106% intraday on 2026-08-10 with no filing behind it; the leg being bought is float scarcity (2.38M shares out, $7.3M market cap) plus a 0.04x sales optic. Nothing on the calendar resolves… Retail squeeze · Biofuels & low-carbon fuels · Semi foundry & equipment analysed · KALU Kaiser Aluminum Corporation LOW Section 232 aluminum supply-shock (50% duty through 2027) plus a Q1 earnings inflection already repriced KALU ~+175% YoY to a $195 high; the move is maturing toward saturated with price at/above every published target. The estimated… Special situation · Cyclical industrials · Critical materials & rare earths analysed · KC Kingsoft Cloud Holdings Limited LOW China AI-compute capacity story is intact on fundamentals — AI gross billing +90% YoY and past half of public-cloud revenue in Q1 (reported 2026-05-27) — but the price leg broke: -32.3% from the $18.21 high with RSI(14) back at 70.0. The… Cyclical recovery · AI datacenter infrastructure · Emerging markets catalyst · KEEL Keel Infrastructure Corp. LOW Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero… Special situation · AI datacenter infrastructure · Bitcoin miners analysed · KFRC Kforce Inc. LOW Cyclical staffing recovery is fully printed — Q1 returned to YoY growth, Q2 guided +~4% — but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A… Special situation · Managed care & health services · AI datacenter infrastructure catalyst · KGS Kodiak Gas Services, Inc. LOW Legacy-pivot repricing has stalled into a four-week range: the 2026-09-04 close of $62.59 sits between the 2026-08-10 low of $59.72 and the 2026-08-14 close of $65.35, with no company press release since 2026-08-06 and no dated catalyst… Special situation · Industrial power & grid · AI datacenter infrastructure analysed · KLAC KLA Corporation LOW The $190 break held and no base replaced it: the 2026-09-04 close of $185.60 sits $1.61 above the 2026-08-21 weekly close, 38.4% under the $301.37 high, with RSI(14) at 31.4. UBS cut to $200 on 2026-09-01 while Bernstein reaffirmed $250 on… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · KLC KinderCare Learning Companies, Inc. LOW Distressed post-IPO childcare name has retraced ~180% off its $1.75 spring low to $4.93 as growth shifts to B2B/employer care and before-after-school (Champions +17% YoY), while the core ECE business still shrinks (−3% enrollment). The ~13… Special situation · Consumer discretionary rotation · Managed care & health services analysed · KMTS Kestra Medical Technologies, Ltd. LOW WCD share-capture story intact on fundamentals — FY26 revenue $95.1M (+59%), fiscal Q4 gross margin 54.8% — but the bid has thinned: the close was $25.64 on 2026-08-28, 9.6% under the $28.35 52-week high, with RSI(14) at 13.5 against 67.8… Defensive · Medtech & diagnostics catalyst · KNX Knight-Swift Transportation Holdings Inc. LOW Beat-and-raise is filed (Q2 adj EPS $0.63; Q3 guided $0.71–$0.77) but the equity is flat since 2026-08-21 at $71.99 while the driver stalled rather than reaccelerated — all-mode tender rejections 13.57% on 2026-08-25 versus a July 4 peak… Compounder · Freight & logistics · Cyclical industrials catalyst · KOD Kodiak Sciences Inc LOW Binary-catalyst re-run now inside its guided window: DAYBREAK's one-year wet-AMD topline is due before 2026-09-30, and the tape has gone the other way — $35.36 on 2026-09-04, RSI(14) 24.4, a fourth lower step from $42.64 on 2026-07-17, and… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics catalyst · KODK Eastman Kodak Company LOW The post-print advance has round-tripped its momentum: the 2026-08-04 AM&C inflection ($105M, +40% YoY) is still the only evidence for the pivot, and with no Kodak filing since then the 2026-09-04 close of $9.29 sits on the $9.20 shelf… Special situation · Cyclical industrials · Industrial power & grid analysed · KOPN Kopin Corporation LOW Legacy microdisplay maker repriced as an AI-interconnect supplier on Q2 revenue of $12.7M (+51% YoY, beat $12.428M) and guided Q4 2026 GAAP profitability — but the partner release cadence stopped on 2026-08-18, the next company-dated event… Special situation · AI datacenter infrastructure · Defense & aerospace analysed · KOS Kosmos Energy Ltd. LOW Jubilee ramping toward ~90,000 bopd gross (J76 online, J77/J50 imminent) with GTA LNG volumes climbing. Highest-beta E&P expression bounced ~15% off the $2.00 June low; re-accelerating but still a ~$2.30, 'CCC'-rated, most-levered… Compounder · Oil, energy & geopolitical catalyst · KSS Kohls Corporation LOW Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided… Retail squeeze · Consumer discretionary rotation · Squeeze & momentum setups catalyst · KVYO Klaviyo, Inc. LOW The August repair topped at $20.15 on 2026-08-28 and gave back to $18.61 by 09-04 while the Chief Legal Officer and co-founder Ed Hallen sold into $20.01-$20.49 on 08-28 and 08-31. The AI-agent CRM leg now needs K:BOS on 09-09/10 to… Theme leader · AI enterprise software · AI datacenter infrastructure catalyst · LAC Lithium Americas Corp. LOW The $3.00 shelf held to the tick — the 2026-09-04 weekly close printed exactly $3.00 while the lithium carbonate benchmark sat at 152,000 CNY/t, +8.38% on the month and +102.7% year-on-year (Trading Economics). With roughly 67.3M Yorkville… Compounder · Critical materials & rare earths · Freight & logistics catalyst · LAR Lithium Argentina AG LOW Commodity transmission is now broken in both directions: the GFEX front carbonate quote came off to ~CNY 152,000/t on 2026-09-04 from CNY 156,140/t on 2026-08-22 while the shares went $6.83 to $6.79. The saturated lithium-recovery story… Compounder · Critical materials & rare earths · M&A & special situations catalyst · LEGN Legend Biotech Corporation LOW In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst… Compounder · Rare disease & gene therapy · Precision biotech & therapeutics catalyst · LGIH LGI Homes, Inc. LOW The 2026-06-24 legislative gap is filled: LGIH closed $55.00 on 2026-09-04, under the $56.06 gap origin, after the 2026-08-04 beat-and-raise bought only five weeks of range. Freddie Mac's 30-year survey reversed to 6.71% on 2026-09-03, a… Compounder · Housing, homebuilders & proptech · Cyclical industrials catalyst · LGN Legence Corp. LOW AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled… Cyclical recovery · AI datacenter infrastructure · Industrial power & grid analysed · LILAK Liberty Latin America Ltd. LOW Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already… Defensive · M&A & special situations · Emerging markets catalyst · LIND Lindblad Expeditions Holdings Inc. LOW The post-print fade has extended: after the 2026-08-03 beat carried price to a $34.48 high, LIND closed $29.59 on 2026-08-28 with RSI(14) at 29.3 and no company-dated event before the ~2026-11-03 (est.) Q3 print. The occupancy/pricing… Defensive · Consumer discretionary rotation · Travel & leisure analysed · LNC Lincoln National Corp. LOW Legacy-risk-transfer re-rating: the 2026-07-30 Talcott deal cedes ~$5.8B of GUL statutory reserves for ~$200M all-in statutory capital, alongside a Q2 adjusted EPS beat at $2.24 vs $1.96. But the information is out, price sits 2.1% under… Special situation · M&A & special situations · Managed care & health services catalyst · LOVE The Lovesac Company LOW The 2026-08-27 notice made the binary real: Q2 FY27 lands before the open on 2026-09-10 against a company bar of $157–166M net sales and −$4M to +$2M adjusted EBITDA. Price closed $16.69 on 2026-09-04, under the 50-day at $16.95 and above… Earnings inflection · Consumer discretionary rotation · Small-cap value rotation catalyst · LQDA Liquidia Corporation LOW Post-print rejection intact: LQDA closed $68.66 on 2026-09-04, four cents above the 2026-08-21 break close of $68.62, with RSI(14) at 30.4 and the 2026-09-03 SSc-RP Fast Track absorbed without a new bid. The narrative leg now on offer is… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · LRMR Larimar Therapeutics, Inc. LOW Single-asset FA regulatory binary sitting on the line that defines it: the week ending 2026-09-04 closed $3.83, 0.8% above the twice-tested $3.80 shelf, after five weeks with no company press release since the 2026-08-04 Q2 update. The… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · LZ LegalZoom.com, Inc. LOW AI-reset narrative — a busted online legal-forms IPO repositioning as an AI-enabled SMB subscription platform (Anthropic partner, AI "digital mailroom") — drove a +29% 30-day rip into July. But it's stretched into the 2026-08-05 Q2 print,… Special situation · Cyclical industrials · AI datacenter infrastructure catalyst · M Macy's Inc. LOW Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus — the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by… Special situation · Consumer discretionary rotation catalyst · MAMA Mama's Creations, Inc. LOW The 2026-09-03 binary resolved for the fundamentals and against the tape: Q2 FY2027 revenue $54.58M (+55%) and EPS $0.06 both beat, gross margin recovered to 24.0% from 23.6%, and the shares still closed 2026-09-04 at $15.16, below the… Defensive · Cyclical industrials · Small-cap value rotation analysed · MANH Manhattan Associates, Inc. LOW Cloud-conversion re-rating has printed a new 52-week high: the 2026-08-28 close of $223.28 is 0.2% under the $223.76 high, RSI(14) 79.7, with price 4.2% above the $213.90 aggregate analyst target. The only new input since the 2026-07-28… Special situation · AI enterprise software · Freight & logistics analysed · MARA MARA Holdings, Inc. LOW AI/HPC power-buildout re-rate is the leg being bought — the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW — but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board… Special situation · Bitcoin miners · AI datacenter infrastructure catalyst · MATV Mativ Holdings, Inc. LOW The deleveraging and margin leg is intact on the numbers but the flow behind it has drained: RSI(14) fell from 92.0 on 2026-08-07 to 37.5 on 2026-08-28 as the close slipped to $12.13, leaving price near the $11.50 gap-fill from the… Special situation · Cyclical industrials · Managed care & health services catalyst · MAX MediaAlpha, Inc. LOW MediaAlpha pre-announced Q3 revenue, contribution and adjusted EBITDA at or above the top end of the $330–355M guide on 2026-09-03, and the tape faded it — $12.22 on 09-03, $12.05 on 09-04, RSI(14) 40.5, 15.6% under the $14.27 high.… Theme leader · AI enterprise software catalyst · MAZE Maze Therapeutics, Inc. LOW APOL1 kidney proof-of-concept intact and funded into 2029, but the only news since the last note was a conference calendar: the 2026-09-02 release scheduled fireside chats on Sept 9, 10 and 15 and repeated the late-2026/early-2027 HORIZON… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · MBX MBX Biosciences, Inc. LOW The Q3 commitment landed early — first patient dosed in the pivotal Phase 3 oPTimize trial on 2026-08-27 — and the tape sold it: $66.33 on 08-21 to $61.72 on 09-04, RSI(14) 30.2, 12.7% under the $70.70 high. The compiled consensus stayed… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · MCHP Microchip Technology Incorporated LOW AI-data-center re-rating leg is unwinding — round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93%… Special situation · AI datacenter infrastructure · Analog semiconductors catalyst · MDB MongoDB, Inc. LOW Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side… Cyclical recovery · AI enterprise software · AI datacenter infrastructure catalyst · MEDP Medpace Holdings, Inc. LOW Bookings-inflection leg (Q2 awards $795.7M, +28.2% YoY, 1.13x book-to-bill, FY26 guide raised 2026-07-22) unchanged on fundamentals, but the tape has given back part of the August recovery — $600.65 on 08-28 to $591.29 on 09-04 — while the… Cyclical recovery · Precision biotech & therapeutics · Oncology & immunology analysed · MGM MGM RESORTS INTERNATIONAL LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… Earnings inflection · M&A & special situations · Prediction markets & betting catalyst · MKSI MKS Inc. LOW Operating leg accelerating into a de-rating tape: Q2 (2026-08-05) beat at $1.248B revenue / $3.30 adj EPS, Q3 guide $1.310–1.390B tops the $1.243B Street, leverage down to 3.0x — and the stock still fell 4.49% on the print and sits 31.4%… Cyclical recovery · Semi foundry & equipment · AI datacenter infrastructure analysed · MLKN MillerKnoll, Inc. LOW The August breakout is still unwound: $22.92 on 2026-09-04, 5.6% under the $24.29 adjusted 52-week high, RSI(14) back to 46.8 from 37.1 with no operating data changed since 2026-06-24. Everything now sits on the 2026-09-22 Q1 FY2027 print… Special situation · Housing, homebuilders & proptech · Cyclical industrials catalyst · MMYT MakeMyTrip Limited LOW MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x… Earnings inflection · Travel & leisure · Fintech & consumer credit catalyst · MOH Molina Healthcare, Inc. LOW Trough-year Medicaid recovery is intact on the numbers — FY26 adjusted EPS guided to at least $5.25 on 2026-07-22 — but the price leg has stalled: three weeks of closes near $200 under the $205 breakout-gap floor, with RSI(14) down to… Special situation · Managed care & health services analysed · MOV Movado Group, Inc. LOW Q2 FY2027 (2026-08-26) cleared every line — 59.4% gross margin, $0.54 adjusted EPS vs $0.35, sales $169.8M vs $164.2M — and the shares still closed 2026-09-04 at $33.97, below the $34.96 pre-print level. Management guided second-half gross… Special situation · Consumer discretionary rotation · Cyclical industrials analysed · MPWR Monolithic Power Systems, Inc. LOW The AI-power read-across stopped transmitting: NVIDIA printed $96.2B revenue and $89B Data Center on 2026-08-26 and guided Q3 to $108B, yet MPWR closed 2026-09-04 at $1,223.86 — through the 2026-06-26 pivot of $1,313.32, RSI(14) at 20.0,… Cyclical recovery · AI datacenter infrastructure · AI chips & memory analysed · MRAM Everspin Technologies, Inc. LOW Sympathy bid off the Micron-led memory supercycle and Russell 2000 inclusion floored the post-parabola markdown in the low-$20s, but the ~2026-07-28 Q2 print is now the binary: Everspin must show a non-casino datacenter/AI design win or… Retail squeeze · AI chips & memory · Squeeze & momentum setups analysed · MTH Meritage Homes Corporation LOW Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still… Compounder · Housing, homebuilders & proptech · Cyclical industrials catalyst · MTSI MACOM Technology Solutions Holdings, Inc. LOW AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · MTUM LOW The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the… Compounder · AI chips & memory · AI datacenter infrastructure catalyst · MXL MaxLinear, Inc. LOW The AI-optical revenue leg still compounds — Q3 guided to $210–220M against Q2's $168.8M — while the price leg makes new lows: the 2026-09-04 close of $62.74 is 51.0% below the $128.03 high with RSI(14) at 25.1, after roughly $50M of… Cyclical recovery · Networking & optical · AI datacenter infrastructure catalyst · MYE Myers Industries, Inc. LOW Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" — MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).… Special situation · Small-cap value rotation · Cyclical industrials catalyst · MYGN Myriad Genetics, Inc. LOW Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now… Special situation · Precision biotech & therapeutics · Medtech & diagnostics catalyst · NABL N-able, Inc. LOW The cyber-pivot re-rating leg died with the 2026-08-10 guidance cut; what has bid the stock since is the issuer itself — a $50M buyback increase approved 2026-08-27 lifting total authorization to $125M. The 2026-09-04 close of $4.06 sits… Special situation · Cybersecurity · AI enterprise software analysed · NBR Nabors Industries Ltd. LOW Leveraged ~2x oil-beta proxy on the Hormuz war premium, +90% YTD near $100 but now rolling over: Susquehanna cut its target to $85 (2026-07-08) as the sell-side stops chasing, and the ~2026-07-23 Q2 print — the first to lap the premium —… Compounder · Oil, energy & geopolitical · Managed care & health services catalyst · NCLH Norwegian Cruise Line Holdings Ltd. LOW The published $16 break fired: the week ending 2026-09-04 closed at $15.57, the second failed shelf in sixteen days after $18 gave way on 2026-08-20. Crude drove both — WTI settled $91.48 on 2026-09-01 — and with RSI(14) at 17.3, no… Defensive · Travel & leisure · Consumer discretionary rotation catalyst · NEO NeoGenomics, Inc. LOW Oncology-dx turnaround accelerating — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2… Special situation · Precision biotech & therapeutics · Medtech & diagnostics catalyst · NEXA Nexa Resources S.A. LOW Cyclical zinc-recovery confirmed and fully priced: Q1 EBITDA +126% YoY and Aripuanã's record 13kt ramp drove a run to the $16.89 high, but the equity now chops $12–13 while LME zinc printed a fresh 2026 high near US$3,622 — a bearish… Special situation · M&A & special situations · Critical materials & rare earths analysed · NOK Nokia Corporation LOW AI-networking legacy re-rate extending on a harder catalyst leg — first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme accelerating, but the 2026-07-23 pre-open Q2 print is… Special situation · Networking & optical · AI datacenter infrastructure analysed · NP Neptune Insurance Holdings Inc. LOW The 2026-07-21 beat-and-raise has round-tripped: the 2026-08-14 weekly close of $31.71 is under the $32 post-print shelf, BMO cut to Market Perform on 2026-07-30, and the CFO sold 100,000 shares into $30.74–$32.12 on Aug 12–13. Operations… Defensive · Managed care & health services · Oil, energy & geopolitical catalyst · NRIX Nurix Therapeutics, Inc. LOW Roche-partnered BTK degrader holding the post-Phase-3 shelf but running out of dated events: the 2026-09-01 release named four September investor conferences and no medical meeting, so the 09-09/12 SOHO window looks set to pass without… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · NSIT Insight Enterprises, Inc. LOW Genuine VAR margin-mix turnaround (Q1 GM +240bps, cloud GP +35%) but a derivative AI tag: hardware GP guided flat, sales +1%. Range-bound $102–123 since the early-June rejection; ~$110 already sits above the ~$103 street target with a… Special situation · AI datacenter infrastructure · AI enterprise software analysed · NVEC NVE Corporation LOW The single-quarter re-rate has round-tripped: the 2026-08-28 close of $100.89 lost the $105 gap shelf, RSI(14) is 27.6, and the shares are up 0.8% over three months despite an 81% revenue quarter reported 2026-07-22. No company news or… Earnings inflection · Analog semiconductors · Physical AI & robotics catalyst · NWPX NWPX Infrastructure, Inc. LOW Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended — last near $148, ~35% above the… Special situation · AI datacenter infrastructure · Cyclical industrials analysed · NXPI NXP Semiconductors N.V. LOW The 2026-07-28 beat-and-raise still is not being paid for: the 2026-09-04 close of $227.84 sits 1.0% above the 2026-08-21 weekly close that defended $225, no desk has revised a target since the UBS cut to $270, and Broadcom's record… Theme leader · Analog semiconductors · AI chips & memory catalyst · ODD ODDITY Tech Ltd. LOW Broken compounder with exactly one dated event: the 2026-09-09 pre-market Q2 print. Price ran $13.22 (2026-08-21) to $14.35 (2026-08-28) on no company disclosure since 2026-07-22, leaving it ~30% above the $11.07 consensus target of 10… Earnings inflection · Consumer discretionary rotation · Precision biotech & therapeutics catalyst · ODFL Old Dominion Freight Line, Inc. LOW Freight-cycle recovery in the top-margin LTL name is drawing a broadening upgrade cluster now printing above spot (Stifel $256 Jul 21, Truist $250 Jul 15, RJ $241 Jul 13), but growth is still rate and mix with tons/day negative. The… Defensive · Freight & logistics · Cyclical industrials analysed · OEC Orion S.A. LOW Deep-cyclical carbon black where the 2024–25 tire-restock leg already failed (-32.5% from the $10.72 52-week high). What is left is a trough-and-deleverage read: Q2 2026 adj. EBITDA $58.2M (+26% sequential, -15% YoY), FY26 guide reaffirmed… Defensive · Cyclical industrials · Managed care & health services catalyst · OFIX Orthofix Medical Inc. LOW The CMS-reversal re-rate is finished and the structure went with it: the $9.80 shelf gave way on the 2026-08-28 weekly close of $9.70, 40.2% below the $16.23 high, while the published sell-side range collapsed from $16–24 to $12–14. Raised… Special situation · Medtech & diagnostics · Small-cap value rotation analysed · ON ON Semiconductor Corporation LOW The AI-power re-rate is unwinding, not consolidating: ON closed $87.37 on 7/17, below the 6/26 Synaptics deal-gap floor, with targets cut twice in three weeks (TD Cowen to $95 on 7/13, Mizuho to $125 on 7/1). Merger-arb supply plus a fixed… Theme leader · Industrial power & grid · AI chips & memory analysed · ONDS Ondas Inc. LOW The tariff leg is spent: Section 232 duties took force 2026-09-03 and ONDS closed $7.62 on 2026-09-04, below every close of proclamation week and 45.6% under the $14.01 high. What is left is delivery — a $140–$155M Q3 guide against… Retail squeeze · Defense & aerospace catalyst · OPI Office Properties Income Trust Common shares of beneficial interest LOW Post-reorg asset-sale arithmetic — $511.5M equity, $1.707B debt, 32 properties identified for sale — is trading on nothing new: no company release since 2026-08-05 and no EDGAR filing since Redwood's 2026-08-19 13D/A cut to 18.0%, with a… Retail squeeze · M&A & special situations · Housing, homebuilders & proptech analysed · ORBS Eightco Holdings Inc. LOW Eightco is a listed wrapper on 301,971,219 WLD, 16,278 ETH and $90M of indirect OpenAI SPV equity — ~$380M of stated holdings on 2026-09-02 against a $388.35M market cap, so no discount remains to close. The collapse from a $45.08 high to… Theme leader · Crypto exchanges & financials · Cybersecurity analysed · ORIC Oric Pharmaceuticals, Inc. LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · OTLY Oatly Group AB LOW The 2026-07-22 guidance doubling (FY constant-currency growth 8–10% from 3–5%) is six weeks old with no follow-on company news; RSI(14) rebuilt to 67.1 at the 2026-08-28 close of $14.67 from 43.7 a week earlier on no information, and the… Special situation · Consumer discretionary rotation · Managed care & health services analysed · OUST Ouster, Inc. LOW Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49… Retail squeeze · Physical AI & robotics · Defense & aerospace catalyst · PAY Paymentus Holdings, Inc. LOW Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print — the read is a recovering base, not a chase. Cyclical recovery · Fintech & consumer credit · AI enterprise software catalyst · PBI Pitney Bowes Inc. LOW PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) — the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul… Special situation · M&A & special situations · Cyclical industrials catalyst · PCOR Procore Technologies, Inc. LOW The 2026-07-29 re-rating has unwound: the 2026-09-04 close of $58.01 completed the week below the $58.74 shelf, retracing the whole newsless August advance to $63.49, with RSI(14) back at 49.0 from 73.2. No company release has come since… Theme leader · AI enterprise software · Housing, homebuilders & proptech analysed · PCT PureCycle Technologies, Inc. LOW Post-dilution repair story: the June 10–15 raise (~$145M equity + $287.5M 4.75% converts, ~$11.08 conv) roughly halved the stock to ~$8 while the commercial ramp (Q1 record 8.4M-lb output, +161% revenue) held. The 2026-07-15 Mitsui/RM… Retail squeeze · Squeeze & momentum setups · Critical materials & rare earths catalyst · PDFS PDF Solutions, Inc. LOW Yield-analytics software re-rated on a real margin step — operating margin ~18%→25%, Platform revenue +36% YoY (Q1 reported 2026-05-07) — but the ~+280% run peaked at $69.05 on 2026-07-02 and flushed 11.5% intraday; the name is now… Cyclical recovery · Semi foundry & equipment · AI enterprise software analysed · PI Impinj, Inc. LOW Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS… Earnings inflection · Freight & logistics · Consumer discretionary rotation analysed · PII Polaris Inc. LOW The re-rating leg is gone and the drift continued: PII closed 2026-09-04 at $62.52 with RSI(14) at 26.2, just above the $62 weekly-close line, after the 2026-08-21 loss of the $66.06 June shelf. What is left is an earnings-floor argument… Special situation · Cyclical industrials · Consumer discretionary rotation analysed · PKOH Park-Ohio Holdings Corp. LOW The 2026-08-05 beat-and-raise leg is intact on the numbers and stalled on price: $45.76 on 2026-08-28 against the $52.51 high of 2026-08-07, RSI(14) down to 41.1 from 61.4 a week earlier, and two officers each selling 12,000 shares on… Theme leader · Industrial power & grid · Cyclical industrials analysed · PLAY Dave & Buster's Entertainment, Inc. LOW Turnaround narrative dead since the 2026-06-15 comp miss (-5.4%, EPS $0.16 vs ~$0.598); the stock printed a fresh low at $8.72 on 2026-09-04, breaking the $9.40 July floor. The company confirmed Q2 FY2026 results for 2026-09-14 after the… Earnings inflection · Consumer discretionary rotation catalyst · PLTK Playtika Holding Corp. LOW The control-premium leg is dead: the 2026-09-04 weekly close of $2.20 took out the $2.37 level published 2026-08-23, and the strategic review has run five months with no disclosure. What is left is a refinancing stub — $800M of… Earnings inflection · M&A & special situations · Consumer discretionary rotation analysed · PLUG Plug Power, Inc. LOW The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure… Retail squeeze · Solar & clean energy · Industrial power & grid analysed · POWI Power Integrations, Inc. LOW The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it — NVTS is… Theme leader · Industrial power & grid · AI datacenter infrastructure analysed · PRLD Prelude Therapeutics Incorporated LOW Value still hangs on one counterparty decision: Incyte's $100M exercise fee on PRT12396, with the option window running to February 2027. Nothing company-dated has printed since the 2026-08-11 Q2 release and the next 30 days are empty,… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · PSQL Pasqal Holding SA LOW Newly listed neutral-atom quantum pure-play: the 2026-08-27 de-SPAC left ~$360M cash against €16.5M of 2025 commercial revenue, and the 2026-08-28 debut close of $19.11 has round-tripped to $7.96 on 2026-09-04. Attention is fresh — KACST… Defensive · Quantum computing · Cyclical industrials analysed · PVH PVH Corp. LOW The $75 shelf is gone: PVH closed the week at $74.33 on 2026-09-04 after a Q2 print whose $3.70 adjusted EPS carried roughly $1.80 of tariff refunds, a $439M goodwill impairment, revenue down 3%, EMEA down 6%, and a Q3 guide of $2.50–$2.65… Special situation · Consumer discretionary rotation · Cyclical industrials analysed · QDEL QuidelOrtho Corporation LOW Deal leg is dead and still unresolved: the 2026-06-29 rumor gap was fully retraced by the $13.75 close of 2026-08-10, and the August drift to $14.74 has round-tripped to $13.97 on 2026-09-04 with no company disclosure in between. An… Earnings inflection · Medtech & diagnostics · Semi foundry & equipment analysed · QRVO Qorvo, Inc. LOW Qorvo trades as a fixed-ratio merger spread: 0.960 SWKS plus $32.50 cash. Skyworks' $74.02 close on 2026-09-04 implies $103.56 against Qorvo's $102.84 — about 0.70% gross, the thinnest of this coverage, after the acquirer rallied 12.5% in… Earnings inflection · Analog semiconductors · M&A & special situations catalyst · QUIK QuickLogic Corporation LOW The eFPGA/defense royalty squeeze has fully unwound: QUIK is ~$13, roughly 47% below the $24.33 June high, and the $18 shelf broke exactly as the Russell inclusion passed. July's post-quantum IP announcement drew no bid — good news into no… Retail squeeze · AI chips & memory · Defense & aerospace catalyst · QURE uniQure N.V. LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy catalyst · RARE Ultragenyx Pharmaceutical Inc. LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · RBLX Roblox Corporation LOW Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU… Earnings inflection · Consumer discretionary rotation · Critical materials & rare earths catalyst · REAL The RealReal, Inc. LOW The $10.00 line published as the break condition fired: a 2026-09-04 weekly close at $9.86 with RSI(14) 30.9 gives back the entire 2026-08-06 beat-and-raise (record GMV $617M, +22%; FY guide lifted to $2.535–2.565B). What is left is a… Special situation · Consumer discretionary rotation analysed · REAX The Real Brokerage, Inc. LOW The binary resolved — the RE/MAX combination closed 2026-08-24 — and the deal move unwound with it: RSI(14) went from 88.0 on 2026-08-21 to 38.0 at the 2026-09-04 close of $18.67, under the mechanically restated $19.50 July shelf. What… Special situation · Housing, homebuilders & proptech · Semi foundry & equipment catalyst · RFAI RF Acquisition Corp II LOW The float-squeeze leg has already printed and is now decaying: 98.95% preliminary redemptions left almost no tradable stock into the 2026-08-19 approval, RFAI peaked at a $58.00 close on 2026-08-21 and closed $41.50 on 2026-09-04. Sixteen… Retail squeeze · Squeeze & momentum setups · AI datacenter infrastructure analysed · RH LOW Squeeze leg now ratified by the sell side — TD Cowen $220 (2026-08-08) and Wells Fargo $225 (2026-08-11) against B of A's reinstated Underperform $156 (2026-08-03) — and it resolves into the 2026-09-10 Q2 print with ~56.7% of float still… Retail squeeze · Consumer discretionary rotation · Squeeze & momentum setups catalyst · RHI Robert Half Inc. LOW White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No… Special situation · Cyclical industrials · Managed care & health services catalyst · RLAY Relay Therapeutics, Inc. LOW The $26–$31 sell-side band is the bull case, but nothing clinical is dated before the year-end ReDiscover-2 enrollment update. Earnings inflection · Oncology & immunology catalyst · RLMD Relmada Therapeutics, Inc. LOW The re-rate narrative failed: the $4.75 March PIPE strike broke on the 2026-08-21 weekly close and the tape kept eroding to $4.43 on 2026-09-04, with no dated clinical event before the year-end 2026 IND. What is left is $217.7M of cash at… Earnings inflection · Oncology & immunology · Binary-catalyst biotech catalyst · RMBS Rambus Inc. LOW Memory theme is ripping — Micron +68% YTD with HBM sold out through 2027 — but Rambus has decoupled, down ~42% from its 2026-06-03 high of $174.10 to $101.44 while the cycle proxy sits near records. Interface content is a DIMM-unit story,… Cyclical recovery · AI chips & memory · AI datacenter infrastructure catalyst · RPAY Repay Holdings Corporation LOW The Visa-headline pop has round-tripped — $4.01 on 2026-08-21 back to $3.88 on 2026-09-04 — while the deal file stayed silent: the only company items since are an 2026-08-26 NxtEdge AP partnership and a 2026-09-03 IR hire, leaving… Earnings inflection · M&A & special situations · Fintech & consumer credit analysed · RZLT Rezolute, Inc. LOW The August screener bid fully round-tripped: $5.09 on 2026-08-21 to $4.58 on 2026-09-04, back under the $4.60/$4.61 summer shelf, with no clinical news since 2026-06-17. The registrational upLIFT topline is still guided only to "2H-2026"… Earnings inflection · Binary-catalyst biotech · Rare disease & gene therapy catalyst · S SentinelOne, Inc. LOW The 2026-08-27 binary resolved against the profit line: Q2 revenue $292M (+21%) beat and FY revenue guidance rose to $1.202–1.207B, but FY adjusted EPS was cut to $0.30–0.32 from $0.32–0.38, and price went $21.19 (08-21) → $19.88 (09-04)… Theme leader · Cybersecurity · AI enterprise software catalyst · SABR Sabre Corporation LOW June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a… Special situation · Travel & leisure · AI enterprise software catalyst · SAH Sonic Automotive, Inc. LOW GPU-normalization narrative broke at the 2026-07-30 print: revenue and adjusted EPS beat consensus, but adjusted EPS fell 17% YoY, franchised segment income −23%, and EchoPark FY26 GPU guidance was cut ~$300 at the midpoint. Shares… Special situation · Consumer discretionary rotation · EV & autonomous mobility catalyst · SAIL SailPoint, Inc. LOW Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so… Theme leader · Cybersecurity · AI enterprise software catalyst · SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · SANM Sanmina Corporation LOW The prior break level gave way: the 2026-08-21 weekly close at $188.89 retraced the entire June re-rate. FQ3 on 2026-07-27 beat and raised — $3.46B revenue, +69.7% YoY, FY26 EPS guide lifted to $11.90–12.20 — and the tape answered with a… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · SDGR Schrodinger, Inc. LOW Agentic-AI software leg: the 2026-08-05 Bristol Myers Squibb agreement to deploy Bunsen at scale landed with a double beat (Q2 revenue $58.889M vs $47.228M consensus) and a raised drug-discovery guide of $65–75M. ACV grew 27% while… Theme leader · AI datacenter infrastructure · Precision biotech & therapeutics analysed · SEER Seer, Inc. LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · SFIX Stitch Fix, Inc. LOW The $3.50 shelf broke: closes of $3.58 (2026-07-24) and $3.59 (2026-08-14) gave way to $3.15 on 2026-08-28 with RSI(14) at 18.6, retracing the entire 2026-06-10 beat-and-raise and leaving the $2.95 52-week low as the next reference. The… Special situation · Consumer discretionary rotation · Small-cap value rotation catalyst · SG Sweetgreen, Inc. LOW The turnaround guide was retracted on 2026-08-06 and no desk has re-rated since DA Davidson's 2026-08-10 cut to $5.50. What has carried the shares to $6.84 on 2026-09-04 is menu press — Fall Harvest returned nationwide 09-04 — while short… Retail squeeze · Consumer discretionary rotation · Squeeze & momentum setups catalyst · SHOO Steven Madden, Ltd. LOW Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted… Special situation · Consumer discretionary rotation · Cyclical industrials catalyst · SID Companhia Siderurgica Nacional S.A. (CSN) LOW New-CEO deleveraging story: Fabio Schvartsman replaced 24-year CEO Benjamin Steinbruch on 2026-09-03 and the ADR ran from $1.13 (09-01) to $1.22 (09-04) with RSI at 79.2, while R$42.1bn net debt and 3.49x leverage are untouched until a… Special situation · Critical materials & rare earths · Cyclical industrials analysed · SITM SiTime Corporation LOW MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close… Cyclical recovery · AI datacenter infrastructure · Networking & optical catalyst · SKWD Skyward Specialty Insurance Group, Inc. LOW Post-print fade extends: the 2026-08-04 beat (op EPS $1.30 vs $1.17, 89.5% combined, 19% operating ROE) and four target raises to $65–$75 have been met by a lower tape — $58.29 on 2026-08-28, 11.2% under the $65.63 high, RSI 36.5 versus… Defensive · Managed care & health services · Small-cap value rotation catalyst · SLS SELLAS Life Sciences Group, Inc. LOW Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short… Retail squeeze · Oncology & immunology · Binary-catalyst biotech catalyst · SMTC Semtech Corporation LOW The mix-purification leg has lost its price leg: the August bounce round-tripped from a $140.35 close on 2026-08-14 to $124.09 on 2026-08-21, under the 2026-07-17 flush close. The binary moved forward — Q2 FY27 prints 2026-08-25 after the… Cyclical recovery · Analog semiconductors · AI datacenter infrastructure catalyst · SNDR Schneider National, Inc. LOW The 2026-07-30 beat-and-raise (adj EPS $0.29 vs $0.23 consensus; FY26 guide lifted to $0.90–$1.10) has been fully given back — the 2026-08-28 close of $34.44 is 10.9% under the 2026-06-08 high and sits 1.3% above the $34 shelf. The… Defensive · Freight & logistics · Cyclical industrials catalyst · SPRB Spruce Biosciences, Inc. LOW Ultra-rare ERT filing story cooling: after the 2026-08-24 pre-BLA clearance the news flow stopped, and the shares drifted from the 2026-08-28 close of $60.78 to $57.93 on 2026-09-04 with RSI(14) back to 58.1 from 77.6. Nothing… Earnings inflection · Precision biotech & therapeutics · Rare disease & gene therapy analysed · SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… Earnings inflection · Precision biotech & therapeutics analysed · SRAD Sportradar Group AG LOW Scope expanded, revenue did not: the 2026-08-27 Polymarket deal widened to 20+ leagues and ~300,000 matches a year, and the 2026-08-26 Euroleague renewal runs to 2031, yet the 2026-08-28 close of $12.94 sits below the $13.82 of two weeks… Cyclical recovery · Prediction markets & betting · AI datacenter infrastructure catalyst · STAA STAAR Surgical Company LOW The re-rating leg failed and has not been re-bid: after the 2026-08-21 weekly close at $23.14 broke the $23.50 shelf, ten sessions produced only $23.47 on 2026-09-04 and a 2026-09-02 CTO appointment the tape ignored. What is left is a… Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · STM STMicroelectronics N.V. LOW The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA… Earnings inflection · Analog semiconductors · AI datacenter infrastructure catalyst · STRL Sterling Infrastructure, Inc. LOW The published $500 break condition fired: last close $486.49 on 2026-09-04, 51.0% under the 2026-06-04 high, RSI(14) 23.1, and no analyst action at all since D.A. Davidson's $700 initiation on 2026-08-24. Q2 (2026-08-03) delivered revenue… Cyclical recovery · AI datacenter infrastructure · Industrial power & grid catalyst · STRO Sutro Biopharma, Inc. LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · STUB StubHub Holdings, Inc. LOW June's busted-IPO recovery leg has fully reversed. D.C.'s RESALE Act (10% resale-markup cap, effective 2027-01-01) plus a Texas AG probe into undelivered World Cup tickets broke the experience-economy narrative; at ~$8.60 STUB trades below… Special situation · Consumer discretionary rotation · Travel & leisure catalyst · SUPV Grupo Supervielle S.A. LOW Q2 beat, tape ignored it: adjusted EPS $0.29 vs $0.13 consensus on 2026-08-10, NIM +253bps to 20.3% — yet SUPV closed $8.05 on 2026-08-14 at RSI 24, with bank ADRs leading the Merval lower and country risk back to 479bps. The company… Compounder · Emerging markets catalyst · SVV Savers Value Village, Inc. LOW Busted-IPO thrift retailer's June recovery has stalled and rolled back toward its ~$9 base as the June 27 Russell-deletion passive-bid loss bites; the July 30 Q2 print is now an imminent, FX-exposed binary rather than a five-weeks-away… Defensive · Consumer discretionary rotation catalyst · SWVL Swvl Holdings Corp Class A LOW Post-SPAC MENA transit operator still extending on the ~$14.5M Sawiris-backed Coefficient round (2026-08-25/26): the 2026-09-04 close was $4.93 against a $1.446 issue price, with a new 52-week high of $5.52 and RSI(14) at 83.0. The… Retail squeeze · EV & autonomous mobility · Small-cap value rotation catalyst · SXC Suncoke Energy Inc LOW Coal-policy sympathy trade is fully dead: SXC has gone nowhere for three weeks, $8.39 on 2026-06-27 to $8.37 on 2026-07-17, pinned to the $8 shelf with no narrative velocity. The only live variable is the Q2 print, pulled forward to… Special situation · Cyclical industrials · Critical materials & rare earths analysed · TAL TAL Education Group LOW Legacy-pivot re-rating still intact on fundamentals — Q1 FY2027 revenue +31.9% to $758.4M with selling and marketing down 5% — but the post-print impulse has largely round-tripped: $12.16 on 2026-08-11 to $11.32 on 2026-08-21, RSI 37.2,… Special situation · Semi foundry & equipment · Cyclical industrials analysed · TASK TaskUs, Inc. LOW Mix-shift re-rating: AI Services hit $66.1M (+25.8%) in Q2 CY2026 on 2026-08-05 — seventh straight quarter above 25% — and is guided above 30% YoY in Q4 on AV/robotics work, against a 25%-of-revenue Trust & Safety book the market assumes… Special situation · AI datacenter infrastructure · Physical AI & robotics analysed · TDOC Teladoc Health, Inc. LOW The pivot re-rating is dead; what is left is a balance-sheet floor — $774.3M cash at 2026-06-30, an unchanged $130–170M FY free-cash-flow guide — that must hold the $6.00 shelf through an empty calendar into the unconfirmed late-October Q3… Special situation · Managed care & health services analysed · TDUP ThredUp Inc. LOW The tariff/de-minimis re-rate is fully unwound: the 2026-08-05 FY2026 cut broke the growth leg, and the $2.80 weekly shelf flagged in prior coverage went on the 2026-08-28 close of $2.72. RSI(14) 28.2 with buyers +21% YoY and $57.4M cash… Retail squeeze · Consumer discretionary rotation · Small-cap value rotation analysed · TENB Tenable Holdings, Inc. LOW The S&P SmallCap 600 bid expired on schedule — after the ~12% move on 2026-08-27 and the $37.67 close on 2026-08-28, the 2026-09-04 close of $34.25 has handed most of the index gap back, and the 2026-09-03 OpenAI CyberAgents announcement… Special situation · Cybersecurity · AI enterprise software analysed · TENX Tenax Therapeutics, Inc. LOW Post-failure rebuild, not a rescue: the 2026-08-29 ESC late-breaker put the prespecified sub-median-6MWD subgroup (n=119) at +26.3m vs placebo (nominal p=0.0112), and Adar1 disclosed buying 1m+ shares at an average $1.77 on 2026-08-25,… Earnings inflection · Binary-catalyst biotech · Precision biotech & therapeutics analysed · TER Teradyne, Inc. LOW Parabolic AI-test leg broke hard: $483.84 closing ATH (2026-06-30) to $322.36 (2026-07-17), −33% in twelve sessions on a memory-glut scare, with the whole $446–$550 analyst band now stranded above spot. Company guided Q2 revenue DOWN… Cyclical recovery · Semi foundry & equipment · AI chips & memory catalyst · TGTX TG Therapeutics, Inc. LOW The catalyst leg is spent; what is left is whether the $46–48 shelf holds through a two-month news vacuum into year-end subcutaneous Phase 3 topline. Compounder · Oncology & immunology · Precision biotech & therapeutics analysed · TH Target Hospitality Corp. LOW The AI-datacenter-landlord re-rate has stalled: TH peaked at $20.85 and has given back ~21% to $16.36 (2026-07-17) as TDR Capital affiliates distribute shares in-kind to partners, losing the $17 secondary clearing shelf while Oppenheimer… Special situation · AI datacenter infrastructure · Cyclical industrials catalyst · THC Tenet Healthcare Corporation New LOW Hospital margin-expansion re-rating stalled at the 2026-08-21 high of $280.77 and gave back 5.0% into the 2026-08-28 close of $266.8, with RSI(14) cooling from 77.3 to 56.8, no confirmed new sell-side number since 2026-08-14 and no company… Special situation · Managed care & health services catalyst · TIC TIC Solutions, Inc LOW Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5%… Special situation · M&A & special situations · AI datacenter infrastructure catalyst · TLN Talen Energy Corporation LOW Contracted-floor re-rating has stopped paying: the 2026-08-05 Q2 raised FY26 Adj EBITDA guidance to $2,025–2,225M and PJM's 2028/29 auction cleared >10 GW at the $325/MW-day cap, yet the stock closed $347.71 on 2026-08-07, 22% below the… Theme leader · Industrial power & grid · AI datacenter infrastructure analysed · TLRY Tilray Brands, Inc. LOW Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20… Earnings inflection · Cannabis reclassification · Consumer discretionary rotation analysed · TMC TMC the metals company Inc. LOW The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is… Earnings inflection · Critical materials & rare earths · Bitcoin miners catalyst · TNDM Tandem Diabetes Care, Inc. LOW Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi ("Toby") 510(k) — planned for a Q2 filing but still unconfirmed after the quarter closed 2026-06-30 — plus margins scaling toward a ~60% Q4 exit. Shares… Special situation · Medtech & diagnostics catalyst · TORO Toro Corp. LOW Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true… Retail squeeze · Freight & logistics · M&A & special situations catalyst · TRIP TripAdvisor, Inc. LOW The prior $10 weekly-close condition fired: the week ending 2026-08-28 closed at $9.87, through JP Morgan's 2026-08-07 Underweight target, with metasearch revenue -21% YoY. What remains is a residual-value question — $700M of contracted… Special situation · Travel & leisure · M&A & special situations analysed · TSAT Telesat Corporation Class A Common Shares and Class B Variable Voting Shares LOW Legacy GEO operator re-rating on a funded LEO pivot: 2026-08-04 C$2.3B, 15-year Canadian Arctic Mil-Ka contract expands Lightspeed 156→225 satellites and lifts the 2032 revenue target to US$4.9B from US$3.2B. Price closed at the 52-week… Special situation · Space economy · Defense & aerospace analysed · TSHA Taysha Gene Therapies, Inc. LOW De-risking is behind the stock and the calendar in front of it is empty: after the clean 2026-06-22 data and the $6.00 June raise, no company-dated event lands before the ~November Q3 update, and the tape has drifted to a $5.60 close on… Earnings inflection · Rare disease & gene therapy · Precision biotech & therapeutics analysed · TXN Texas Instruments Incorporated LOW The post-print shelf broke — $258.64 on 2026-08-28 versus $279.58 on 2026-08-14, RSI 31.1, 21.8% under the $330.59 high — and it broke in the same week ADI printed a record Q3 and raised (2026-08-19). The analog/data-center cycle is… Theme leader · Analog semiconductors · AI datacenter infrastructure catalyst · UCTT Ultra Clean Holdings, Inc. LOW WFE upcycle intact fundamentally but the tape broke: -35% from the $142.59 all-time close (2026-06-30) back under the ~$95 breakout shelf on sector-wide selling with no company news. Failed breakout, no support to $80.55, binary Q2 print… Cyclical recovery · Semi foundry & equipment · AI chips & memory analysed · UFPT UFP Technologies, Inc. LOW The $300 shelf broke: the 2026-09-04 close of $288.79 sits 13.8% under the $334.84 high with RSI(14) at 15.8, the lowest reading in the series, and the entire post-Q2 re-rate is now overhead. Six insiders filed sales between 2026-08-06 and… Cyclical recovery · Medtech & diagnostics analysed · UHAL U-Haul Holding Company LOW The post-print re-rating has unwound: after a 52-week high at $75.27 in mid-August, UHAL closed 2026-08-28 at $68.59 with RSI(14) at 19.8, sitting on the $68.25 shelf that was July's ceiling. No company news since the 2026-08-24 8-K and… Special situation · Housing, homebuilders & proptech · AI chips & memory analysed · UI Ubiquiti Inc. LOW Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,… Earnings inflection · Networking & optical · Squeeze & momentum setups catalyst · UNIT Uniti Group Inc. LOW Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above… Special situation · AI datacenter infrastructure · M&A & special situations catalyst · URGN UroGen Pharma Ltd. LOW The 2026-08-17 UGN-103 NDA submission landed six weeks ahead of the Q3 target and emptied the calendar — nothing company-dated until the ~2026-11-04 Q3 print. Price set a $50.29 52-week high after 2026-08-14, then gave back 13.3% into the… Compounder · Precision biotech & therapeutics · Oncology & immunology catalyst · VAC Marriott Vacations Worldwide Corporation LOW Post-Q2 re-rating is giving back: the 2026-08-28 close of $110.09 is 9.0% under the 2026-08-14 close of $120.99, MarketBeat consensus sits at $101.45 (2026-08-29), and 10%-owner Impactive Capital sold 750,000 shares at $111.49 on… Special situation · Travel & leisure · Consumer discretionary rotation analysed · VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · VERI Veritone, Inc. LOW The growth story broke on the 2026-08-13 guide cut to $100–115M from $130–145M; what trades now is $45.6M of 1.75% converts maturing 2026-11-15 against $12.7M of cash at 2026-06-30 and disclosed going-concern doubt. The stock bounced from… Earnings inflection · AI enterprise software · Defense & aerospace catalyst · VERU Veru Inc. LOW The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding — the company will now sell stock… Retail squeeze · Precision biotech & therapeutics · Small-cap value rotation catalyst · VIR Vir Biotechnology, Inc. LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… Earnings inflection · Binary-catalyst biotech · Oncology & immunology catalyst · VKTX Viking Therapeutics, Inc. LOW The stock has round-tripped its ECO move — $32.16 on 2026-08-28, 23.7% below the $42.13 high, the ~$34 line gone since 2026-08-14. The only company-guided 2026 event left is the VK2735 maintenance readout, a Phase 1 whose weight endpoint… Earnings inflection · Precision biotech & therapeutics catalyst · VOYG Voyager Technologies, Inc. LOW The order-flow re-rating leg has stalled: the entire post-Q2 advance was handed back between 2026-08-21 ($38.40) and the 2026-08-28 close of $34.29 with no company release in that window, RSI(14) at 20.7. Backlog of $335.5M and the… Compounder · Space economy catalyst · VPG Vishay Precision Group, Inc. LOW The AI-precision re-rate broke at the print: Q2 (2026-08-05) missed on revenue ($83.936M vs $84.646M) and adjusted EPS ($0.04 vs $0.19), Q3 guide midpoint sits below consensus, and the stock gapped -26.95% to $73.78 and has since made… Theme leader · Analog semiconductors · AI datacenter infrastructure analysed · VSXY Victorias Secret & Co. LOW Turnaround re-accelerated with no new number: the July mid-$70s range broke, a $99.97 52-week high printed, then 11% came back into the 2026-09-03 Q2 report. Consensus target $91.40 sits ~3% over the $89.02 close on 2026-08-14, so the… Special situation · Consumer discretionary rotation catalyst · W Wayfair Inc. LOW Margin-inflection turnaround has stalled: after the June Evercore-driven pop, W has faded ~10% back to the ~$84–85 recovery base ahead of the binary Aug 4 Q2 print. Wedbush's Jul 16 Neutral/$104 initiation and a ~$100-capped consensus mark… Special situation · Consumer discretionary rotation · Housing, homebuilders & proptech catalyst · WGS GeneDx Holdings Corp. LOW Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the… Earnings inflection · Medtech & diagnostics · Oncology & immunology catalyst · WHD Cactus, Inc. LOW International wellhead order narrative from the 2026-07-29 Q2 beat is intact, but the re-rating leg is largely spent: Citigroup cut to Neutral on 2026-08-20 while raising its target to $75, and the shares closed $69.43 on 2026-08-21, 5.8%… Cyclical recovery · Oil, energy & geopolitical · AI datacenter infrastructure catalyst · WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… Earnings inflection · Consumer discretionary rotation · Precision biotech & therapeutics catalyst · WLFC Willis Lease Finance Corporation LOW Engine-leasing supercycle still printing records (Q1 rev +23%, EPS $4.03 vs $3.02 est), but the theme is maturing and the stock has faded ~18% off its 2026-07-06 ATH into the now-completed 3-for-1 split. The event stack has collapsed to… Cyclical recovery · Small-cap value rotation · M&A & special situations catalyst · WPP WPP PLC LOW The flow leg is settled and it went the wrong way: the 2026-09-02 FTSE review promoted easyJet and Ithaca Energy, not WPP, and RSI(14) has unwound from 76.8 on 2026-08-21 to 46.6 at the 2026-09-04 close of $25.32. What remains is a purely… Special situation · Consumer discretionary rotation · AI enterprise software analysed · WRLD World Acceptance Corporation LOW Three-month price change decayed from +27.1% to +12.3% in two weeks, leaving a maturing narrative with no company-dated binary before the 2026-10-22 Q2 print and $181 as the gap-fill line. Special situation · Fintech & consumer credit · Small-cap value rotation catalyst · WSC WillScot Holdings Corporation LOW Cyclical modular-space leasing recovery with a small data-center kicker and an activist/M&A floor, but range-bound and digesting: shares drifted to ~$26 under the $31.88 high after the 2026-06-27 Russell growth-index removal. The confirmed… Theme leader · AI datacenter infrastructure · Industrial power & grid catalyst · WSM Williams-Sonoma, Inc. LOW Q2 on 2026-08-26 resolved the binary bullish — comp +6.2%, non-GAAP EPS $2.10 vs $2.08 est., FY comp guide raised to +4.0%–+6.5% and margin guide to 17.8%–18.2% — and seven desks moved targets into a $240–$270 band. The 2026-08-28 close of… Defensive · Consumer discretionary rotation · Cybersecurity analysed · WTTR Select Water Solutions, Inc. LOW Contracted produced-water midstream re-rate is intact on fundamentals — the 2026-08-18 amendment extended the Northern Delaware agreement 12 years across ~875,000 acres and JP Morgan initiated Overweight at $24 on 2026-08-21 — but shares… Special situation · Oil, energy & geopolitical · Critical materials & rare earths analysed · XENE Xenon Pharmaceuticals Inc. LOW The $62 consolidation shelf failed at the 2026-08-28 weekly close of $59.99, and two dated events now sit inside 30 days: the EEC oral presentation of X-TOLE2 on 2026-09-07 and the guided Q3 FOS NDA submission by 2026-09-30. Neither is an… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · XHG XChange TEC.INC LOW The 2026-08-13 non-binding First Cycle LOI re-rated XHG ~4x, and the leg has since stalled: no company disclosure in 16 sessions, the 2026-08-28 close of $3.41 sits 26.2% under the $4.62 high, and a registered $100.0M discretionary ADS… Retail squeeze · M&A & special situations · AI datacenter infrastructure analysed · XOS Xos, Inc. LOW First-ever U.S. Air Force award (prototype OTA for the Xos Hub mobile BESS, announced 2026-08-17, terms not disclosed) took the stock ~100% on 2026-08-18 and put a defense-pivot narrative on a going-concern EV maker that just missed Q2… Retail squeeze · Defense & aerospace · EV & autonomous mobility analysed · XRAY DENTSPLY SIRONA Inc. LOW The turnaround re-rating leg resolved at the 2026-08-06 Q2 print and then reversed: $13.78 pre-print, $13.19 on the print session, $11.12 by 2026-08-28 with RSI(14) at 34.3. Barclays kept Underweight on 2026-08-24 while lifting its target… Special situation · Medtech & diagnostics · Semi foundry & equipment catalyst · XRX Xerox Holdings Corporation LOW Distressed-deleveraging special situation that round-tripped its June activist pop into a binary 2026-07-30 Q2 print. At ~$2.60 it sits below the $2.75 Hold consensus and inside the $2.25–$2.50 target band; anchor buyer STARTEEPO (8.8M sh,… Special situation · M&A & special situations · Cyclical industrials catalyst · XTLB XTL Biopharmaceuticals Ltd. LOW The compliance-cure leg is spent and the $2.70 private-placement shelf broke — $2.47 on 2026-08-28 — even as the psychedelics complex got its loudest policy headline of the year on 2026-08-18 (University of Miami's 1994 ibogaine IND handed… Special situation · Precision biotech & therapeutics · M&A & special situations analysed · YAAS Youxin Technology Ltd LOW Prior coverage's $2.50 break level is gone — the 2026-08-28 close was $2.14. The 2026-08-27 H1 print delivered the first real revenue line in this name (+444% to $1.88M, 41% gross margin) and no bid followed it; cash halved to $4.55M… Retail squeeze · Semi foundry & equipment · Crypto exchanges & financials analysed · ZENA ZenaTech, Inc. LOW The Section 232 leg is spent for ZENA: the 2026-08-13/14 policy advance round-tripped to a 2026-08-28 close of $1.71, breaking the $1.95 weekly shelf and the $2.12 May unit price, and the company's own 2026-08-17 advantage release carried… Retail squeeze · Defense & aerospace · Cyclical industrials catalyst · ZS Zscaler, Inc. LOW The binary resolved against the recovery frame: Q4 FY26 beat every guided line on 2026-09-03 (ARR $3,771M above the $3.749B top end, net new ARR $246M vs $166M), but the first formal FY27 guide of 16.6–17.5% growth ratified the May reset,… Compounder · Cybersecurity · AI enterprise software analysed · ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now… Earnings inflection · Rare disease & gene therapy · Binary-catalyst biotech catalyst · DHT DHT HOLDINGS, INC. fresh NONE Freight & logistics analysed · DSX Diana Shipping, Inc. fresh NONE Freight & logistics analysed · FRO Frontline Plc fresh NONE Freight & logistics analysed · GPRK Geopark Limited fresh NONE Oil, energy & geopolitical analysed · HAFN Hafnia Limited fresh NONE Freight & logistics analysed · PBR PETROLEO BRASILEIRO S.A.-PETROBRAS ADS (REP 1 COMMON SHARE) fresh NONE Oil, energy & geopolitical analysed · SM SM Energy Company fresh NONE Oil, energy & geopolitical analysed · SSL Sasol Limited fresh NONE Oil, energy & geopolitical analysed · TK Teekay Corporation Ltd. fresh NONE Freight & logistics analysed · TNK Teekay Tankers Ltd. fresh NONE Freight & logistics analysed · TRMD TORM plc fresh NONE Freight & logistics analysed ·

Common questions

What is a FrontierPicks dossier?

A per-ticker research note written by a frontier language model: the current thesis, the archetype the name is trading as, the next dated catalyst, and an explicit kill line — the price level or event that would prove the pick wrong. Every dossier is dated and rewritten as the facts change.

How many stocks does FrontierPicks cover?

929 US tickers have a dossier right now. 917 of the 929 published dossiers carry the full shape — a dated thesis and the exact level that ends it. The other 12 are listed rather than hidden: 11 are waiting on a first read, and 1 publishes no kill line. Coverage is earned rather than fixed: a name gets a dossier when the model has something to say about it beyond the price trend. The 56 names the model holds, has just exited, or that sit in a theme it is currently calling accelerating are re-read every trading day — every one of them was read in the current session. The wider 873-name coverage universe cycles behind them: its median name was last read 3 sessions ago, and no dossier is more than 8 sessions old.

Is AI-generated stock research reliable?

It should be judged the way any research is judged — on whether its stated confidence holds up against outcomes. FrontierPicks is built to make that measurable: every pick publishes a kill line before the outcome is known and is graded mechanically against it, and the resulting calibration record is recomputable from the published data rather than asserted. It is research to evaluate, not advice; no performance claim is made.

How often are the dossiers updated?

On a rolling cycle, not uniformly. The 56 names the model holds, has just exited, or that sit in a theme it is currently calling accelerating are re-read every trading day — every one of them was read in the current session. The wider 873-name coverage universe cycles behind them: its median name was last read 3 sessions ago, and no dossier is more than 8 sessions old. The model re-reads a covered name against fresh price, filing and news data and rewrites the dossier when the facts move; each page shows its own last-updated date rather than a sitewide timestamp, so the cadence is checkable name by name.